Inhibition of the fracture healing process in smokers: deregulation of cellular and molecular milieu in tibial fracture micro-environment by Sloan, Andrew
Inhibition of The Fracture Healing Process in Smokers: 
Deregulation of Cellular and Molecular Milieu in Tibial 
Fracture Micro-Environment 
 
By 
Andrew Sloan BSc. (Hons), MRes., PgD. 
 
         
 
 
 
 
School of Life Sciences 
University of Lincoln 
Lincoln, U.K. 
 
Supervisors: 
Dr. Mohamed El-Sheemy 
Professor Oleg Eremin 
Professor Mohammad Maqsood 
Dr. Carol Rea 
 
 
Thesis submitted to The University of Lincoln in part fulfilment for the degree of 
Doctor of Philosophy (Ph.D.) 
December 2013
 i 
TABLE OF CONTENTS 
  
LIST OF FIGURES .............................................................................................. xi 
LIST OF TABLES .............................................................................................. xiv 
ABSTRACT ......................................................................................................... xv 
ACKNOWLEDGEMENTS ............................................................................. xviii 
DECLARATION ................................................................................................. xx 
RESEARCH PUBLICATIONS ........................................................................ xxi 
ABBREVIATIONS .......................................................................................... xxiv 
CHAPTER 1 .......................................................................................................... 1 
1 GENERAL INTRODUCTION .................................................................... 2 
1.1 OVERVIEW OF OSTEOLOGY ................................................................................... 5 
1.1.1 Bone Physiology ....................................................................................................... 5 
Table 1: Function of Bone ....................................................................................................... 5 
Table 2:  Structure of Bone ..................................................................................................... 6 
Figure 1:  Anatomy of a Long Bone ....................................................................................... 7 
1.1.2 Histology of Bone ..................................................................................................... 8 
Figure 2: Cross Section of Compact Bone .............................................................................. 8 
Table 3: Histology of Bone ..................................................................................................... 9 
1.1.3 Bone Cytology:  Osteoblasts ................................................................................... 10 
Figure 3: Osteoblast and Osteoid in a Section of Bone ......................................................... 10 
1.1.4 Bone Cytology:  Osteocytes ................................................................................... 11 
Figure 4: Osteocytes in Cancellous Bone .............................................................................. 11 
1.1.5 Bone Cytology:  Osteoclasts ................................................................................... 12 
Figure 5: Osteoclasts ............................................................................................................. 12 
ii 
1.2 OVERVIEW OF FRACTURE HEALING .................................................................. 13 
1.2.1 Types of Fracture .................................................................................................... 15 
1.2.2 Types of Fracture in the Study ................................................................................ 16 
Figure 6:  Comminuted Fracture ........................................................................................... 16 
Figure 7:  Spiral Fracture ...................................................................................................... 16 
Figure 8: Impacted fracture ................................................................................................... 17 
Figure 9:  Pott’s Fracture ....................................................................................................... 17 
1.2.3 The Extracellular Matrix ......................................................................................... 18 
Figure 10: Biochemical Cell-to-ECM Interactions ............................................................... 19 
1.2.4 Regulatory Hormones in Fracture Healing ............................................................. 20 
1.2.4.1 Parathyroid Hormone, Calcitriol and Calcitonin .............................................................. 20 
1.2.4.2 Oestrogen and Osteoporosis ............................................................................................ 22 
1.2.4.3 Vitamin D (Cholecalciferol) ............................................................................................ 23 
1.3 THE PHASES OF FRACTURE HEALING ................................................................ 25 
1.3.1 Inflammatory Phase ................................................................................................ 25 
1.3.1.1 Chemotaxis ...................................................................................................................... 27 
1.3.1.2 Neutrophils and Macrophages ......................................................................................... 28 
1.3.2 Reparative Phase ..................................................................................................... 29 
1.3.2.1 Mesenchymal Stem Cells ................................................................................................. 33 
Table 4:  A Summary of Mesenchymal Stem Cell Biochemical Markers ............................ 35 
1.3.3 Maturation or Remodelling Phase .......................................................................... 36 
1.3.3.1 Bone Remodelling ........................................................................................................... 37 
Figure 11: Bone Remodelling Cycle ..................................................................................... 37 
1.3.3.2 Mineralisation of Bone .................................................................................................... 39 
Figure 12: Mineralisation of bone ......................................................................................... 39 
1.3.4 A Summary of the Phases of Fracture Healing Illustrated ...................................... 40 
Figure 13: Stages of the Fracture Healing Process. ............................................................... 40 
Figure 14:  The Process of Fracture Healing; Radiology ...................................................... 41 
1.4 MODES OF OSSIFICATION IN FRACTURE REPAIR ........................................................... 42 
1.4.1 Direct (Primary) Fracture Healing .......................................................................... 42 
Figure 15.  Primary Fracture Healing. ................................................................................... 43 
iii 
1.4.2 Indirect (Secondary) Fracture Healing .................................................................... 44 
1.4.2.1 Endochondral Ossification in Indirect Fracture Healing .................................................. 45 
1.4.2.2 Intramembranous Ossification in Indirect Fracture Healing ............................................ 46 
1.5 MOLECULAR ASPECTS OF FRACTURE HEALING ............................................. 48 
1.5.1 Proinflammatory Cytokines .................................................................................... 49 
Table 5:  Inflammatory Interleukins 1to10 (IL-1 to IL-10) in Fracture Repair ..................... 51 
1.5.2 Transforming Growth Factor Beta (TGF-) ........................................................... 52 
1.5.3 TGF-Cell Signalling Pathway.............................................................................. 52 
Figure 16:  TGF-Cell Signalling Pathway.......................................................................... 53 
1.5.4 Subtypes of Transforming Growth Factoreta (TGF-) .................................... 54 
1.5.5 Bone Morphogenetic Proteins (BMPs) ................................................................... 55 
Table 6: Temporal and Functional Characteristics of TGF-in fracture healing ................. 56 
1.5.6 Metalloproteinases and Angiogenesis ..................................................................... 57 
1.5.7 Growth Factors ....................................................................................................... 57 
Table 7: Growth Factors of the Immune System................................................................... 59 
1.5.8 Platelet-Derived Growth Factor (PDGF) ................................................................ 60 
1.5.9 Fibroblast Growth Factor (FGF) ............................................................................. 60 
1.5.10 Insulin-Like Growth Factors (IGFs) ....................................................................... 61 
1.5.11 Colony Stimulating Factor (CSF) ........................................................................... 61 
1.5.12 Chemokines ............................................................................................................ 61 
1.5.13 Lymphokines and Monokines ................................................................................. 62 
1.5.14 Eicosanoids ............................................................................................................. 62 
1.5.15 Prostaglandins ......................................................................................................... 64 
1.5.16 Lipoxins .................................................................................................................. 64 
1.5.17 Interferon (IFN) ...................................................................................................... 65 
1.6 INHIBITORY MOLECULES INVOLVED IN FRACTURE HEALING .................. 66 
1.6.1 Extracellular Matrix Inhibition ............................................................................... 66 
1.6.2 Noggin .................................................................................................................... 67 
1.6.3 Chordin ................................................................................................................... 68 
1.6.4 Gremlin ................................................................................................................... 68 
iv 
1.6.5 Sclerostin ................................................................................................................ 69 
1.6.6 Follistatin ................................................................................................................ 70 
1.6.7 Anti-Inflammatory Effects of BMP-3 ..................................................................... 70 
1.6.8 Inhibition at the Cell Receptor Level ...................................................................... 70 
1.6.9 Inhibition of Intracellular Processes ....................................................................... 71 
Table 8: Intracellular Inhibitors ............................................................................................. 71 
1.6.10 Clinical Applications in Trauma ............................................................................. 72 
1.7 THE TOXICOLOGICAL ASPECTS OF TOBACCO SMOKING ............................. 73 
1.7.1 The Constituents of Cigarette Smoke ..................................................................... 74 
Figure 17: The Chemical Structures of Nicotine, Anatabine and Anabasine ........................ 75 
1.7.2 Nicotine .................................................................................................................. 75 
1.7.3 Carbon Monoxide ................................................................................................... 76 
1.7.4 Cigarette Smoking and Cellular Damage................................................................ 77 
1.8 CIGARETTE SMOKING AND FRACTURE HEALING .......................................... 80 
1.9 SUMMARY OF INTRODUCTION ............................................................................ 84 
1.10 AIMS AND OBJECTIVES ................................................................................................. 85 
Figure 18: Proposal for Outline of Study .............................................................................. 86 
2 CHAPTER 2 ................................................................................................ 87 
MATERIALS AND METHODS ........................................................................ 87 
2.1 METHODS I: CELLULAR ASPECTS ....................................................................... 88 
2.2 SPECIMEN PROCESSING ........................................................................................ 89 
2.2.1 Patient Handling ..................................................................................................... 89 
Table 9: Sample Information................................................................................................. 89 
2.2.2 Extraction and Isolation of Haematoma Cells (HCs) .............................................. 91 
2.2.3 Tissue Collection and Processing ........................................................................... 93 
2.2.4 Isolation of Haematoma Cells (HCs) via Subculture .............................................. 95 
Figure 19: Schematic Diagram of Methods Involved in Extraction and Isolation of 
Haematoma Cells (HCs) ....................................................................................................... 97 
Figure 20: Fracture Haematoma Processing ......................................................................... 98 
v 
2.2.5 Cell Counting Using Flow Cytometry .................................................................... 99 
2.3 CHARACTERISATION OF HAEMATOMA CELLS ............................................. 100 
2.3.1 Immunofluorescence Assay .................................................................................. 100 
2.3.2 Immunophenotyping Assay .................................................................................. 102 
2.3.3 Generation of Cigarette Smoke Extract (CSE) ..................................................... 103 
Figure 21:  Apparatus set-up for the generation of Cigarette Smoke Extract (CSE) ........... 103 
2.3.4 Nitric Oxide (NO) Analysis in CSE-Treated MSCs ............................................. 105 
Figure 22: The Seivers 180i NOA Nitric Oxide (NO) Analyser (Analytix, Durham). ....... 105 
2.3.5 Nitric Oxide (NO) Analytical Assay in CSE-Treated MSCs ................................ 106 
2.3.6 Cell Necrosis Assay .............................................................................................. 107 
2.3.7 MSC Recovery Assay ........................................................................................... 108 
2.3.8 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) Assay:  In 
Vitro Effect of BMP-2 on Cell Viability Enhancement ...................................................... 109 
2.3.8.1 Cell Preparation – MTT Assay ...................................................................................... 110 
2.3.9 Cryopreservation of MSCs ................................................................................... 112 
2.4 METHODS II:  MOLECULAR ASPECTS ............................................................... 113 
2.4.1 Serum Protein Determination Using SDS-PAGE ................................................. 114 
2.4.2 SDS-PAGE Gel Production: ................................................................................. 119 
2.4.3 Analysis of SDS-PAGE GELS via Mass Spectrometry ....................................... 121 
2.4.4 TGF- and IL-6; Intracellular Markers in MSCs .................................................. 124 
2.4.5 VEGF and IL-6 Quantitation via ELISA in Haematoma Serum and Lysed Fracture 
MSCs:  A Preliminary Study ............................................................................................... 126 
2.4.6 Bone Alkaline Phosphatase (b-ALP) Quantitation in Fracture Serum.................. 129 
2.4.7 Albumin Quantitation in Fracture Serum ............................................................. 134 
2.4.8 Total Protein Quantitation in Fracture Serum ....................................................... 139 
2.4.9 Statistical Data Analysis ....................................................................................... 144 
2.4.9.1 The Mann-Whitney U-test ............................................................................................. 144 
2.4.9.2 Student’s t-Test .............................................................................................................. 145 
2.4.9.3 Analysis of Variance (ANOVA) .................................................................................... 146 
 
vi 
3 CHAPTER 3 .............................................................................................. 147 
RESULTS ........................................................................................................... 147 
3.1 CLINICAL OBSERVATIONS ................................................................................. 148 
3.1.1 Nonunion of fracture in a smoking patient ........................................................... 148 
Figure 23 (a):  2 days post presentation, plaster of Paris immobilisation in a smoking patient  
  .............................................................................................................................. 148 
Figure 23 (b): 6 weeks post injury after external fixation (unilateral frame) ...................... 148 
Figure 23 (c):  Nonunion of fracture, 6 months post-reduction ........................................... 149 
3.1.2 Malunion Due to Obesity ...................................................................................... 150 
Figure 24 (a):  Obese patient 3 days post-injury ................................................................. 150 
Figure 24 (b):   Obese patient 6 months post surgery at follow up ..................................... 150 
3.1.3 Patient with Osteopenia ........................................................................................ 151 
Figures 25 (a) and (b):  Oblique x-ray images of osteopenic patient .................................. 151 
3.1.4 Patient with a History of Compartment Syndrome ............................................... 152 
Figures 26 (a) and (b):  Images of patient with compartment syndrome ............................. 152 
3.1.5 Patient with Crohn’s Disease ................................................................................ 153 
Figures 27 (a) and (b):  Patient with Crohn’s Disease ......................................................... 153 
3.2 FRACTURE HAEMATOMA CELL CULTURES .................................................. 154 
Figures 28-34:  Fracture Haematoma Cells in Culture ........................................................ 154 
3.2.1 Mesenchymal Stem Cell Control Slide ................................................................. 157 
3.3 CHARACTERISATION OF HAEMATOMA CELLS USING QUALITATIVE 
IMMUNOCYTOCHEMICAL ANALYSES ........................................................................... 158 
3.3.1 Immunofluorescence via Fluorescent Microscopy ............................................... 158 
Figure 35: CD29. ................................................................................................................. 158 
Figure 36:  CD44. ................................................................................................................ 159 
Figure 37:  CD105. .............................................................................................................. 159 
Figure 38:  CD166. .............................................................................................................. 160 
Figure 39:  CD34. ................................................................................................................ 160 
Figure 40: Control Slide. ..................................................................................................... 161 
vii 
Figure 41: Control Slide. ..................................................................................................... 161 
3.4 CELL ANALYSES USING FLOW CYTOMETRY ................................................ 162 
3.4.1 Cellular Immunophenotyping via Flow Cytometry .............................................. 163 
Figure 42:  Immunophenotyping CD29 .............................................................................. 163 
Figure43:  Immunophenotyping CD44 ............................................................................... 163 
Figure 44:  Immunophenotyping CD73. ............................................................................. 164 
Figure 45:  Immunophenotyping CD105 ............................................................................ 164 
Figure 46:  Immunophenotyping CD166 ............................................................................ 165 
Figure 47:  Immunophenotyping CD34 .............................................................................. 165 
Figure 48:  Immunophenotyping Control ............................................................................ 166 
Table 10:  Summary of Mesenchymal Stem Cell Markers Over 10 Passages .................... 167 
3.5 CELL POPULATION COUNTING USING FLOW CYTOMETRY (FACS) ............................ 168 
Figure 49:  Example of data acquisition from flow cytometer ............................................ 168 
3.5.1 Flow Cytometry Cell Gating ................................................................................. 169 
Figure 50:  Flow Cytometry Gating .................................................................................... 169 
3.6 ABSOLUTE CELL COUNTING (FACS)................................................................. 170 
3.6.1 Mesenchymal Stem Cell Proliferation (Smokers vs. Non-Smokers) .................... 170 
Figure 51:  Cell Proliferation .............................................................................................. 170 
3.6.2 Mesenchymal Stem Cell Proliferation (CSE-Treated vs. Untreated) .................... 171 
Figure 52: Effect of CSE on Proliferation ........................................................................... 171 
3.6.3 Cell Necrosis Comparison (CSE-Treated vs. Untreated) ...................................... 172 
Figure 53: Effect of CSE on Necrosis ................................................................................. 172 
3.6.4 Nitric Oxide Levels in Lysed Cells (CSE Treated vs. Untreated) ........................ 173 
Figure 54:  Effect of CSE on Nitric Oxide .......................................................................... 173 
3.6.5 Recovery of MSCs Subjected to CSE Infusion .................................................... 174 
Figure 55 a) Cells before CSE Infusion (d7 of culture) ...................................................... 174 
Figure 55 b) Cells after CSE Infusion (2.5%) (d21) ........................................................... 174 
Figure 55 c) Cell recovery after withdrawal of CSE (d35) ................................................. 174 
3.6.6 MSC Cell Recovery Assay ................................................................................... 176 
Figure 56:  MSC Recovery Assay ....................................................................................... 176 
viii 
3.6.7 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) Assay:  In 
Vitro Effect of BMP-2 on Cell Viability Enhancement ...................................................... 177 
Figure 57:  BMP-2 Infusion in MSCS in Normal Environment. ......................................... 177 
Figure 58.  BMP-2 Infusion in CSE Environment. ............................................................. 178 
3.7 MOLECULAR STUDIES ......................................................................................... 179 
3.7.1 SDS-PAGE – Fracture Haematoma Serum .......................................................... 179 
3.7.2 SDS-PAGE of Fracture Haematoma Serum: Coomassie Blue Stain .................... 180 
Figure 59:  Electrophoresis of Haematoma Serum Proteins (Coomassie Blue). ................. 180 
3.7.3 SDS-PAGE of Fracture Haematoma: Silver Nitrate Stain .................................... 181 
Figure 60.  Electrophoresis of Haematoma Serum Proteins (Silver Nitrate)....................... 181 
3.7.4 Peptide Mass Fingerprint (PMF) for Haemoglobin Alpha (Hb  ....................... 182 
Figure 61:  Mass Spectrometry (Hb ). .............................................................................. 182 
3.7.5 Peptide Mass Fingerprint (PMF) for Haemoglobin Beta (Hb  .......................... 183 
Figure 62:  Mass Spectrometry (Hb ). ............................................................................... 183 
3.7.6 Peptide Mass Fingerprint (PMF) for Haptoglobin (Hp) ....................................... 184 
Figure 63:  Mass Spectrometry (Hp). .................................................................................. 184 
3.7.7 Intracellular Labelling of MSCs Using IL-6 and TGF-A Preliminary Study .. 185 
Figure 64.  Flow cytometry histogram showing intracellular expression of IL-6 in MSCs 
extracted from a smoking patient. ....................................................................................... 185 
Figure 65.  Flow cytometry histogram showing intracellular expression of IL-6 in MSCs 
extracted from a non-smoking patient. ................................................................................ 185 
Figure 66.  Flow cytometry histogram showing intracellular expression of TGF- in MSCs 
extracted from a smoking patient. ....................................................................................... 186 
Figure 67.  Flow cytometry histogram showing intracellular expression of TGF- in MSCs 
extracted from a non-smoking patient. ................................................................................ 186 
Table 11:  Intracellular IL-6 and TGF- ........................................................................... 187 
3.7.8 Quantitation of VEGF-A via ELISA in Fracture Haematoma Serum (Smokers vs. 
Non-Smokers): A Preliminary Study .................................................................................. 188 
Figure 68: ELISA (VEGF-A) .............................................................................................. 188 
ix 
3.7.9 Quantitation of IL-6 via ELISA in Lysed MSCs (Smokers vs. Non-Smokers): A 
Preliminary Study ............................................................................................................... 189 
Figure 69: ELISA (IL-6) ..................................................................................................... 189 
3.8 BIOCHEMICAL STUDIES ...................................................................................... 190 
3.8.1 Comparison of bone-Alkaline Phosphatase (b-ALP) in Fracture Haematoma Serum 
in Smokers vs. Non-Smokers .............................................................................................. 190 
Figure 70: b-ALP Levels in Serum ..................................................................................... 190 
3.8.2 Serum Albumin Biochemical Quantitation in Fracture Haematoma Serum (Smokers 
vs. Non-Smokers) ................................................................................................................ 191 
Figure 71:  Serum Albumin Levels ..................................................................................... 191 
3.8.3 Comparison of Total Protein in Fracture Haematoma Serum (Smokers vs. Non-
Smokers) ............................................................................................................................. 192 
Figure 72: Total Protein Levels ........................................................................................... 192 
CHAPTER 4 ...................................................................................................... 193 
4 DISCUSSION ............................................................................................. 194 
4.1.1 Clinical Findings from Patient Histories ............................................................... 195 
4.1.1.1 Smoking-Related Nonunion of Fracture ........................................................................ 195 
4.1.1.2 Obesity ........................................................................................................................... 197 
4.1.1.3 Osteopenia and Fracture ................................................................................................ 198 
4.1.1.4 Compartment Syndrome in Fracture Healing ................................................................ 199 
4.1.1.5 Crohn’s Disease ............................................................................................................. 201 
4.1.2 Sample Collection for In Vitro Studies ................................................................. 202 
4.2 CELLULAR ANALYSIS OF FRACTURE HEALING........................................................... 203 
4.2.1 Cell Explantation .................................................................................................. 204 
4.2.2 Adherent Properties of Fracture Cells in Culture .................................................. 205 
4.2.3 Characterisation of the Haematoma Cells ............................................................. 207 
4.2.4 Cell Counting ........................................................................................................ 210 
4.2.5 The Infusion of Cigarette Smoke Extract (CSE) into MSC Cultures.................... 212 
4.2.6 Cellular Nitric Oxide (NO) Quantitation .............................................................. 213 
x 
4.2.7 Cellular Necrosis in MSC Cultures....................................................................... 217 
4.2.8 Cell Recovery Assay ............................................................................................. 219 
4.2.9 In Vitro Effect of Bone Morphogenetic Protein-2 (BMP-2) on Cell Viability via the 
MTT Assay ......................................................................................................................... 220 
4.3 THE MOLECULAR ASPECTS OF FRACTURE HEALING ................................. 225 
4.3.1 SDS-PAGE Assay for Protein Separation ............................................................ 225 
4.3.2 Intracellular Growth Factors ................................................................................. 228 
4.3.3 ELISA: VEGF and IL-6 ........................................................................................ 229 
4.1 BIOCHEMICAL ANALYSIS OF THE FRACTURE HAEMATOMA SERUM ........................... 230 
4.1.1 Bone-Specific Alkaline Phosphatase (b-ALP) ...................................................... 231 
4.1.2 Albumin and Total Protein ................................................................................... 232 
4.2 CONCLUSIONS ............................................................................................................ 234 
5 FUTURE STUDIES .................................................................................. 236 
5.1 FUTURE STUDIES ........................................................................................................ 237 
CHAPTER 6 ...................................................................................................... 242 
6 REFERENCES .......................................................................................... 243 
CHAPTER 7 ...................................................................................................... 293 
7 APPENDICES ........................................................................................... 294 
7.1.1 Letter from Minister of Public Health .................................................................. 295 
7.1.2 SICOT Conference Attendance ............................................................................ 296 
7.1.3 Ethical Approval Documentation ......................................................................... 298 
7.1.4 Copyright Permissions .......................................................................................... 299 
7.1.5 Patient Information Sheet and Consent Form ....................................................... 306 
7.1.6 Flow Cytometry Data ........................................................................................... 309 
 
 
xi 
LIST OF FIGURES 
 
Figure 1 (Pg.7):  Anatomy of a Long Bone 
Figure 2 (Pg.8):  Cross Section of Compact Bone 
Figure 3 (Pg.10):  Osteoblast and Osteoid 
Figure 4 (Pg.11):  Osteocytes in Cancellous Bone 
Figure 5 (Pg.12):  Osteoclasts 
Figure 6 (Pg.16):  Comminuted Fracture 
Figure 7 (Pg.16):  Spiral Fracture 
Figure 8 (Pg.17):  Impacted fracture 
Figure 9 (Pg.17):  Pott’s Fracture  
Figure 10 (Pg.19):  Biochemical Cell-to-ECM Interactions 
Figure 11 (Pg.37):  Bone Remodelling Cycle 
Figure 12 (Pg.39): Mineralisation of bone  
Figure 13 (Pg.40):  Stages of the fracture healing process 
Figure 14 (Pg.41):  The Process of Fracture Healing; Radiology  
Figures 15 (Pg.43):  Primary fracture healing.   
Figure 16 (Pg.53):  TGF-Cell Signalling Pathway 
Figure 17 (Pg.75): The Chemical Structures of Nicotine, Anatabine and 
Anabasine  
Figure 18 (Pg.87):  Proposal for Outline of Study 
Figure 19 (Pg.98):  Schematic Diagram of Methods Involved in Extraction 
and Isolation of Haematoma Cells (HCs) 
Figure 20 (a-d) (Pg.99):  Fracture Haematoma Processing 
xii 
Figure 21 (Pg.104):  Apparatus set-up for the generation of Cigarette Smoke 
Extract (CSE) 
Figure 22 (Pg.106):  The Seivers 180i NOA nitric oxide (NO) Analyser 
Figure 23 (a-c) (Pg.148-149):  Nonunion of fracture in a smoking patient 
Figure 24 (a-b) (Pg.150):  Malunion Due to Obesity 
Figure 25 (a-c) (Pg.151):  Patient with Osteopenia  
Figure 26 (a-b) (Pg.152):  Patient with a History of Compartment Syndrome   
Figure 27 (a-b) (Pg.153):  Patient with Crohn’s Disease 
Figure 28-33 (Pg.154-157):  Haematoma Cells in Culture   
Figure 34 (Pg.157):  Mesenchymal Stem Cell Control Slide 
Figure 35 (Pg.158):  Immunofluorescent labelling CD29 
Figure 36 (Pg.159):  Immunofluorescent labelling CD44 
Figure 37 (Pg.159):  Immunofluorescent labelling CD105 
Figure 38 (Pg.160):  Immunofluorescent labelling CD166 
Figure 39 (Pg.160):  Immunofluorescent labelling CD34 
Figure 40-41 (Pg.161):  Control Slides for Immunofluorescent labelling 
Figure 42 (Pg.163):  Immunophenotyping CD29  
Figure 43 (Pg.163):  Immunophenotyping CD44 
Figure 44 (Pg.164):  Immunophenotyping CD73 
Figure 45 (Pg.164):  Immunophenotyping CD105 
Figure 46 (Pg.165):  Immunophenotyping CD166 
Figure 47 (Pg.165):  Immunophenotyping CD34 
Figure 48 (Pg.166):  Immunophenotyping Control 
Figure 49 (Pg.168):  Example of data acquisition on flow cytometry 
Figure 50 (Pg.169):  Flow Cytometry Gating 
xiii 
Figure 51 (Pg.170):  Cell Proliferation 
Figure 52 (Pg.171):  Effect of CSE on Proliferation 
Figure 53 (Pg.172):  Effect of CSE on Necrosis  
Figure 54 (Pg.173):  Effect of CSE on Nitric Oxide   
Figure 55 a) (Pg.174):  Cells before CSE Infusion (d7 of culture) 
Figure 55 b) (Pg.174):  Cells after CSE Infusion (d21) 
Figure 55 c) (Pg.174):  Cell recovery after withdrawal of CSE (d35) 
Figure 56 (Pg.176):  MSC Recovery Assay 
Figure 57 (Pg.177):  BMP-2 Infusion in Normal Environment 
Figure 58 (Pg.178):  BMP-2 Infusion in CSE Environment 
Figure 59 (Pg.180):  Electrophoresis of Serum Proteins (Coomassie Blue)  
Figure 60 (Pg.181): Electrophoresis of Serum Proteins (Silver Nitrate)  
Figure 61 (Pg.182):  Mass Spectrometry (Hb )   
Figure 62 (Pg.183):  Mass Spectrometry (Hb )   
Figure 63 (Pg.184):  Mass Spectrometry (Hp)   
Figure 64 (Pg.185):  Intracellular IL-6 in MSCs (Smoking Patient) 
Figure 65 (Pg.185):  Intracellular IL-6 in MSCs (Non-Smoking Patient) 
Figure 66 (Pg.186):  Intracellular TGF-in MSCs (Smoking Patient) 
Figure 67 (Pg.186):  Intracellular TGF- in MSCs (Non-Smoking Patient) 
Figure 68 (Pg.188):  ELISA (VEGF-A)  
Figure 69 (Pg.189):  ELISA (IL-6)  
Figure 70 (Pg.190):  Bone-Alkaline Phosphatase (b-ALP) in Serum 
Figure 71 (Pg.191):  Serum Albumin in Serum 
Figure 72 (Pg.192):  Total Protein in Serum 
xiv 
LIST OF TABLES 
 
Table 1 (Pg.5):  Function of Bone 
Table 2 (Pg6):  Structure of Bone 
Table 3 (Pg.9):  Histology of Bone 
Table 4 (Pg.35):  A Summary of Mesenchymal Stem Cell Biochemical 
Markers 
Table 5 (Pg.51):  Inflammatory Interleukins 1to10 (IL-1 to IL-10) in Fracture 
Repair 
Table 6 (Pg.56):  Temporal and Functional Characteristics of TGF- in 
fracture healing  
Table 7 (Pg.59):  Growth Factors of the Immune System that are involved in 
Wound Healing 
Table 8 (Pg.71):  Intracellular Inhibitors 
Table 9 (Pg.91):  Sample Information 
Table 10 (Pg.167):  Summary of Mesenchymal Stem Cell Markers Over 10 
Passages 
Table 11 (Pg.187):  Intracellular IL-6 and TGF-beta TGF-  
 
 
 
xv 
ABSTRACT 
 
 
Introduction:  Tobacco smoking has been shown to have a detrimental impact on 
fracture healing and is often implicated in the non- and delayed-union of bone.  
Whilst numerous studies have concentrated on the demographic and clinical 
manifestations of fracture healing and smoking, very little analyses have been 
undertaken at the biochemical level.  Aims:  This research project will assess the 
impact of smoking on the cellular and molecular mechanisms of bone healing by 
analysing human tibial fracture haematomas using a variety of laboratory 
techniques.  Materials and methods:  Cell culture: Fracture haematomas (~2 
mL) were collected from anaesthetised patients (n=48), who had sustained a 
fracture of the tibia.  The semisolid material was explanted into 25 cm
2
 non-
coated tissue culture flasks and allowed to clot.  Complete culture media was 
prepared and pipetted into the vessels, which were then placed in an incubator 
(37˚C; humidified 5% CO2).  After characterisation via immunocytochemistry 
(using antigen-specific markers to CD29, CD44, CD73, CD105, CD166 and 
CD34), isolated cells were counted using flow cytometry and proliferation rates 
were compared between non-smokers and smokers.  Cigarette smoke extract 
(CSE) was manufactured based on the methods of Bernhard et al. (2004), in order 
to synthesise an in vitro smoking environment.  Cells harvested from non-smokers 
(n=10) were cultured and infused with the CSE (2.5%) and proliferation and cell 
recovery rates were compared between the treated and untreated groups.  Cellular 
nitric oxide levels and necrosis rates (using propidium iodide for the latter) were 
also compared in a similar way.  An MTT assay was conducted to assess response 
to various concentrations of BMP-2 (10, 100 and 500 ng mL
-1
) infusion in cell 
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cultures.  Molecular assays: Serum was extracted from the haematomas and 
resolved on 16% acrylamide gels before staining with either Coomassie blue or 
silver nitrate.  The resolved gels were photographed using a Kodak gel imaging 
system and unknown bands were identified using MALDI-TOF.  Intracellular 
TGF- and IL-6 were probed using antibodies, which were then analysed via flow 
cytometry in order to confirm the presence of these acute-phase proteins.  In 
additional experiments, the ELISA was undertaken to quantify and compare the 
amounts of VEGF and IL-6 in haematoma serum and lysed fracture cells 
respectively.  Biochemical testing on serum for b-ALP, albumin and total protein 
amounts in fracture serum was carried out, comparing smoker (n=10) and non-
smoker (n=10) levels.  Results:  Cell culture:  Spindle-shaped, fibroblast-like 
cells were visible in the primary culture, which were expanded through at least 10 
further passages.  The immunostaining of cells suggested a mesenchymal stem 
cell (MSC) lineage (CD29+, CD44+, CD73+, CD105+, CD166+, CD34-).  
Absolute cell counting using flow cytometry revealed marked proliferation of 
cells after 3 passages of culture.  There was a reduction in the rate of proliferation 
of MSCs in smokers over 2 passages compared with non-smokers (-20%).  A 5-
day proliferation study in the CSE-treated vs. untreated cells showed a reduction 
in the rate of doubling in the treated group (-40% p<0.05).  Cells showed a 
recovery response after CSE was withdrawn from culture, but was not significant.  
Cell necrosis analysis of CSE-treated vs. untreated cells showed that the CSE-
treated cultures had a higher rate of necrosis than the untreated cells (CSE-treated 
14.37% vs. untreated 7.98% p<0.05).  Nitric oxide levels were lower in the CSE-
treated cells (CSE-treated 3.0 M vs. untreated 3.6 M; p<0.05).  MTT assay; 
BMP-2 infusions all improved cell viability compared to the non-infused cells, 
xvii 
with a BMP-2 concentration of 10 ng mL
-1
 increasing cell viability the most, 
though not significantly (+23%; p>0.05).  Molecular assay:  After staining, SDS-
PAGE gels showed numerous bands of serum proteins and the haematoma serum 
lanes displayed  unknown proteins which were later found to be haptoglobin (~20 
kDa) and haemoglobin (~14 kDa) chains via mass spectrometry (MALDI-TOF). 
Cells were strongly positive (>96%) for the intracellular protein markers TGF- 
and IL-6. The VEGF-A (serum) and IL-6 (cells) preliminary data from the ELISA 
revealed a reduction of these acute-phase proteins in patients who were smokers 
(VEGF-A -10%; IL-6 -15%). In the biochemical assays, albumin was reduced in 
smokers’ serum (-13%, p<0.05), whereas b-ALP was raised (+20%; p>0.05 n.s.) 
and total protein lowered (-12%; p<0.01). Conclusions:  The haematoma cultures 
produced colonies of adherent fibroblast-like cells that were of a MSC lineage.  
With the exception of a residual haemolysis-derived haptoglobin band, SDS-
PAGE did not appear to show an over-expression of acute phase proteins, 
although it was useful for the characterisation of the fracture milieu, in that it was 
suggestive of a consistently haemolysed haematoma.  The effect of smoking on 
bone fracture healing, therefore, appears to contribute to the inhibition of MSC 
proliferation, angiogenesis and the acute phase stress response.  Cigarette smoke 
was also shown to cause excessive necrosis and reduce the amount of NO in those 
MSC cultures treated with CSE, which may indicate reduced vasodilatation to the 
fracture site.  Bone alkaline phosphatase (b-ALP) was raised in the fracture serum 
of smokers, suggesting abnormally-high bone turnover, whilst the reduction of 
total protein and serum albumin likely indicates a lowered capacity for acute-
phase protein synthesis and calcium transport in these patients.  Exogenous BMP 
may be indicated for rectification of malunion in smokers.  
xviii 
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1 GENERAL INTRODUCTION 
 
Tobacco smoking was first shown to have a deleterious effect on tissue healing in 
1977 by Mosely and Finseth, who reported an impaired digital blood-flow in the 
hand wound of a smoker.  Indeed, the association of smoking and delayed wound 
healing, particularly in the field of orthopaedics, is now a well recognised caveat 
in clinical practice (Adams et al., 2001; Patel et al., 2013).  Following the work of 
Mosley and Finseth, similar observations have been made in various other tissues 
including skin, bone, mouth and peptic ulcers (Silverstein, 1992; McRobert, 2013; 
Takamiya et al., 2013).  Despite this interest, the specific biochemical relationship 
of smoking and wound healing has not yet been fully elucidated (Whiteford, 
2003).  This is most likely the result of hospitalisation and immobility, which 
usually prevent continuation of smoking during the early recovery period 
following the trauma, thereby disallowing substantial viable human tissue 
procurement (Silverstein, 1992).  One study reported that elective surgery patients 
were more likely to quit smoking if the advice came from their general 
practitioner rather than if the advice came from an anaesthetist, nurse or hospital 
literature (Webb et al., 2013).  The cost to the NHS of treating smoking-related 
disease is estimated to be approximately £5.2 billion per year (Callum et al., 
2010). 
 
There are >4000 reported toxins in tobacco cigarette smoke, yet most research 
addressing the effects of smoking on tissue healing has emphasised the activity of 
the addictive component,  nicotine (Siana et al., 1989; Al-Hadithy et al., 2012; 
Takamiya et al., 2013).  The pharmacokinetics of nicotine are considered to be a 
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causative factor in healing impairment due to both a capacity to prevent adequate 
vascular function, a consequence of nicotine’s vasoconstrictive properties and an 
inhibitory action on macrophage and fibroblast proliferation (Silverstein, 1992; 
Tomek et al., 1994; Tipton and Dabbous, 1995; Wong and Martins-Green, 2004).  
The process of tissue formation and development is essential in fracture healing 
and, therefore, requires adequate mesenchymal stem cell (MSC) production, as 
well as the migration and deposition of acute-phase proteins into the extracellular 
matrix (ECM) (Hynes, 1986; Dimitriou and Giannoudis, 2013).  Thus, high 
plasma levels of nicotine and tobacco-associated toxins are likely to disrupt the 
bone healing process, because the rate of mesenchymal stem cell proliferation is 
reduced (Villarreal et al., 1999; Patel et al., 2013).   
 
The process of fracture healing involves a cascade of complex, integrated, 
inflammatory and biomolecular processes that are initiated in response to injury.    
Bone tissue is repaired, regenerated and reformed during the classical three-phase, 
overlapping series of key biological processes termed inflammatory phase, 
reparative phase and maturation phase, or bone remodelling.  The repair pathway 
consists of embryonic developments, with precisely co-ordinated participation 
from several cell types (Ferrara and Davis-Smyth, 1997; Dimitriou et al., 2005).   
Importantly, there are specific adhesive interactions between cells and the 
extracellular matrix (ECM) in their immediate microenvironment (Ettinger and 
Doljanski, 1992; Raghow, 1994; Bainbridge, 2013). 
 
There are many similarities shared between fracture healing and embryogenesis.  
Wound healing following an acute injury such as fracture, regardless of the 
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mechanism, recapitulates the events associated with the development of the 
zygote in utero and there is a heightened biosynthetic activity at the site of repair 
(Tranquillo and Murray, 1992; Dimitriou et al., 2011).  Aside from their role as 
crucial mechanisms in healing, cell adhesion and migration are integral factors in 
organogenesis during embryonic and neural development, tumour metastases and 
post-inflammatory tissue repair (Howell, 1992; McGowan, 1992; Yost, 1992; Le 
Bras et al., 2012).   
 
This introduction will briefly focus upon the basic anatomy and physiology of 
bone and fracture, including the hormonal aspects, before analysing the cellular 
and molecular features of fracture healing and how tobacco smoking elicits such a 
detrimental impact on the events that are associated with the repair processes.  It 
will describe the cytokine involvement that mediates the regeneration of injured 
limbs and how they adeptly switch on and switch off vital cellular actions.  The 
information available in the literature concerning the effects of smoking has been 
sourced to convey the main issues associated with malunion that is hampering 
patients’ recovery after sustaining a fractured limb.  
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1.1 OVERVIEW OF OSTEOLOGY 
1.1.1 Bone Physiology 
Bone is made up of several different tissue types comprising of osseous tissue, 
cartilage, dense connective tissue, epithelium, adipose tissue and nervous tissue 
(as summarised in Table 1).  Each bone in the skeleton is classed as an individual 
organ on account that all these different tissue types work together, each being 
dynamic and highly complex.  The process of bone remodelling, or turnover, is 
continual throughout life and concerns all the different types of bone cells (Clarke, 
2008). 
Table 1: Function of Bone 
 
 
Function 
 
 
Description 
Support: Supports the tissues of the body by providing a 
structural framework on which muscle, tendons 
and ligaments are attached. 
Protection:   Many internal organs are protected from injury 
by bone.  Ribs protect visceral organs such as 
the heart, lungs, spleen and most of the liver; the 
cranium houses the brain.  
Assistance in movement: Bones are vital in movement since they are 
attached to muscles.  
Mineral homeostasis: Calcium (Ca
+2
) and phosphorous (P) are stored 
in bone and released into the blood on demand 
to maintain critical mineral balances. Ca
+2
 and P 
form hydroxyapatite (Ca10(PO4)6(OH)2) crystals; 
also present in the amorphous form. 
Blood cell production: Haematopoiesis takes place in the red bone 
marrow; mainly pelvis, ribs, breastbone, 
vertebrae, femur and skull.  Red bone marrow 
consists of reticulocytes, adipocytes, fibroblasts 
and macrophages within a network of reticular 
fibres. 
Triglyceride storage: Triglycerides are stored in yellow bone marrow 
as a chemical energy reserve. Adipose cells store 
triglycerides and blood cells.   
 
(Tortora and Grabowski, 2003) 
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Table 2:  Structure of Bone 
 
 
Structure 
 
 
Description 
 
The diaphysis:   
The long cylindrical shaft that forms the main 
portion of the bone. 
The epiphyses:   The distal and proximal ends of the bone. 
 
The metaphyses:   
The regions where the diaphysis joins the 
epiphyses and includes an epiphysial plate in 
growing bones.  This allows for growth in 
length and is replaced by a structure known as 
the epiphysial line on cessation of growth. 
 
Articular cartilage: 
 A thin layer of hyaline cartilage covering the 
epiphyses where the bone forms an articulation 
point with another bone.  Its purpose is to 
reduce friction and absorb shock at freely 
moveable joints.  Repair of the cartilage is 
restricted because there is no perichondrium. 
 
The periosteum: 
A hard sheet of dense irregular connective tissue 
that covers the bone surface where it is not 
covered by articular cartilage.  This type of 
tissue contains the bone forming cells that 
enable the bone to grow in diameter and 
thickness, but not in length.  The periosteum 
assists in fracture repair, nourishment of bone 
and serves as an attachment point for ligaments 
and tendons. 
 
The medullary cavity:   
The space within the diaphysis that houses the 
yellow bone marrow that contains the 
triglyceride fats storage. 
 
The endosteum:   
The thin membrane lining the medullary cavity 
that contains osteoclasts and a small amount of 
connective tissue. 
 
(Tortora and Grabowski, 2003) 
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Figure 1:  Anatomy of a Long Bone 
 
The following diagram (Figure 1) is a schematic representation of the femur, 
displaying epiphyses, diaphysis, articular cartilage, medullary cavity, periosteum 
and cancellous and compact bone:- 
 
 
 
 
 
 
Figure 1: Diagram of a long bone  
Image reproduced with permission of Elsevier.  
(Young and Heath, 2003, Pg. 176) 
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1.1.2 Histology of Bone 
 
Types of histological bone tissue can be classified in several ways and is based on 
texture.  The following diagram (Figure 2) illustrates a section of compact bone 
and the various systems in place. 
 
Figure 2: Cross Section of Compact Bone 
 
 
Figure 2: Cross section of compact bone  
Image reproduced with permission of Elsevier  
(Young and Heath, 2003, Pg.177) 
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Table 3: Histology of Bone 
 
Histological feature Description 
Compact bone:   Ivory-like bone, dense in texture and without 
cavities. Forms the shell of many bones and 
surrounds the trabecular bone in the centre. 
Consists mainly of Haversian systems or 
secondary osteons, which are neurovascular 
channels interconnected via the obliquely 
piercing Volkmann’s canals.  The parallel bony 
columns are arranged along the lines of stress 
exerted on the bone. 
Spongy bone: Spongy bone has numerous cavities and is 
located within the medullary cavity.  It consists 
of extensively connected bony trabeculae 
oriented along the lines of stress.  Includes 
trabecular bone, cancellous bone.  In contrast to 
compact bone, complete osteons are normally 
absent due to the thinness of the trabeculae.  
Sponge bone is more metabolically active than 
compact bone due to its much larger surface 
area for remodelling. 
Lamellar bone or secondary bone tissue: Lamellar bone is mature bone with collagen 
fibres arranged in lamellae.  In spongy bone, 
lamellae are arranged parallel to each other, 
whereas in compact bone, they are 
concentrically organised around a vascular 
canal, termed a Haversian canal. 
Woven bone or primary bone tissue:   Woven bone is immature bone with collagen 
fibres arranged in irregular random arrays and 
contains smaller amounts of minerals but a 
higher proportion of osteocytes than lamellar 
bone. Woven bone is temporary and is 
eventually converted to lamellar bone.  It is 
pathologic tissue in adults except in a few 
places such as the areas near sutures of the flat 
bones of the skull, tooth sockets and the 
insertion sites of some tendons. 
Immature bone or primary bone tissue:   Immature bone is woven bone. 
Mature bone or secondary bone tissue:   Mature bone is lamellar bone and almost all 
bones in adults are lamellar bones. 
Intramembranous bone or mesenchymal bone:   Intramembranous bone develops from a direct 
transformation of condensed mesenchyme and 
flat bones are formed in this way. 
Intracartilaginous bone, cartilage bone or 
endochondral bone: 
Intracartilaginous bone is shaped by replacing a 
reformed cartilage model.    Long bones grow 
in a longitudinal direction, acting on the 
epiphyseal growth plate.  
(Kobayashi et al., 2003; Clarke, 2008) 
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1.1.3 Bone Cytology:  Osteoblasts  
Osteoblasts are located on the surface of bone (osteoid) and are responsible for 
synthesising the organic components of bone matrix (see Figure 3), including type 
I collagen, proteoglycans and glycoproteins.  Osteoblasts also synthesise the 
enzyme alkaline phosphatase, which is needed locally for the mineralisation of 
osteoid (Rivera et al., 2013).  Active osteoblasts are of cuboidal or columnar 
shape with eccentrically located nuclei and a perinuclear cytoplasmic halo.  
Inactive osteoblasts are flattened with low alkaline phosphatase activity.  
Osteoblasts contact their neighbouring osteoblasts cytoplasmically and do not 
divide but rather mature into osteocytes.  They remain as osteoblasts or return to 
the state of osteoprogenitor cells from which they are derived (Kobayashi et al., 
2003; Clarke, 2008). 
 
Figure 3: Osteoblast and Osteoid in a Section of Bone   
Image reproduced with permission of Elsevier  
(Young and Heath, 2003, Pg.181) 
 
 
Osteoblasts 
 
Osteoid 
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1.1.4 Bone Cytology:  Osteocytes  
Osteoblasts undergo maturity into osteocytes when encased by the self-
synthesised osteoid matrix.  Lacuna and canaliculi form around osteocytes and 
their cytoplasmic processes.  Osteocytes lie in their own lacuna and contact 
neighbouring osteocytes cytoplasmically through the canaliculi.  Adjacent cells 
make contact via gap junctions, maintaining the strength of osteocytes by passing 
nutrients and metabolites between blood vessels and distant osteocytes.  This 
process regulates ion homeostasis and transmits electrical signals in bone.  
Although osteocytes have a reduced synthetic activity and are not capable of 
mitotic division, they are actively involved with the maintenance of bony matrix.  
Some of the osteocytes die during remodelling but most return to the state of 
osteoprogenitor cell or persist as osteocytes in the long term (Clarke, 2008). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Osteocytes in Cancellous Bone  
 
Image reproduced with permission of Elsevier  
 
(Young and Heath, 2003, Pg.182) 
 
 
Osteocytes 
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1.1.5 Bone Cytology:  Osteoclasts 
Osteoclasts are derived from a monocytic-macrophage system and are responsible 
for bone resorption.  They are multinucleated cells with fine finger-like 
cytoplasmic processes and are rich in lysosomes containing tartrate-resistant acid 
phosphatase (TRAP).  Osteoclasts lie in resorption craters known as Howship 
lacunae on bone surfaces or in deep resorption cavities known as cutting cones. 
They can only resorb mineralised bone matrix (Reddy, 2004). 
Osteoclast activity always predominates over that of osteoblasts because they are 
three times more efficient at bone resorption than osteoblasts are at bone 
deposition.  On balance, osteoclasts have a much shorter life span than 
osteoblasts.  Osteoclasts are rarely seen in routine histological sections of normal 
bone.  An increased number of osteoclasts are characteristic of disease associated 
with increased bone turnover, such as osteoporosis.  Osteoclasts do not have 
receptors for parathyroid hormone but do have receptors for calcitonin and the 
hormonal signal is mediated by osteoblasts (see later) (Martin and Sims, 2005). 
 
Figure 5: Osteoclasts 
Image reproduced with permission of Elsevier  
 
(Young and Heath, 2003, Pg.181)  
Osteocytes 
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1.2 OVERVIEW OF FRACTURE HEALING  
A fracture is simply defined as any break in a bone.  Despite a generous blood 
supply, fractures can take a considerable amount of time to heal and one study 
reported an average time to union of six months (Marcacci et al., 2007).  This is 
due to the fact that calcium and phosphorous, necessary to strengthen and harden 
new bone, are deposited very gradually during the process.  In severely fractured 
bones, the temporary disruption in the blood supply accounts for elongated 
healing times (Dimitriou et al., 2005). 
 
Fracture healing comprises a complex series of sequential interrelated 
biomolecular processes that involve both intracellular and extracellular signalling 
processes during the repair and regeneration of damaged bone.  This procedure 
follows a chain of events that are specifically orientated to temporal and spatial 
sequences (Sandberg et al., 1993; Reddi, 2001; Lee et al., 2004; Marsell and 
Einhorn, 2011; Dimitriou and Giannoudis, 2013).  The molecular mechanisms 
responsible for mediating embryonic development are replicated in skeletal tissue 
formation during fracture healing.  Bone, therefore, has the unique ability to 
regenerate without the permanent formation of a scar, a process that is seen in the 
repair of tissues in the developing mammalian foetus and is achieved via complex 
overlapping phases of healing.  Indeed, fibrous scars compromise the mechanical 
integrity and strength of the skeleton.  A healed bone will often be stronger than it 
was before the fracture; a phenomenon known as ‘Wolff’s Law’, which is named 
after the German surgeon Julius Wolff (1836-1902).  Wolff observed that long 
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bones change shape to accommodate stresses placed on them (Prendergast and 
Huiskes, 1995; Kanczler and Oreffo, 2008; Wolff, 2010).   
 
Despite some reported variations on the theme, there exists a multi-phased 
fracture repair pattern, or classical ‘three-phase dogma’, consisting of an 
inflammatory phase, a reparative phase and maturation, or remodelling phase, 
which have been historically well characterised in the literature (Schilling, 1976; 
Howell, 1992; Marcacci et al., 2007).  There is a shared heuristic regulatory 
similarity that includes the extra-cellular matrix (ECM), cytokines, receptors, 
signalling molecules and transcription factors (Yu et al., 2002; Takayanagi, 2005).   
 
There are four separate tissue components involved in long bone fractures; the 
cortex, the periosteum, the bone marrow and the external soft tissues.  The extent 
of involvement of each component is dependent upon the following factors 
present at the site of injury; 
 
 Level of growth factors 
 Hormones 
 Nutrients 
 pH of the microenvironment 
 Oxygen tension of the microenvironment 
 Electrical environment 
 Mechanical stability of the fracture itself 
 
(Riedel and Valentin-Opran, 1999) 
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1.2.1 Types of Fracture 
There are several types of fracture, named depending on severity, the position or 
after the surgeon who originally described them.  The most common long-bone 
fractures are as follows: 
 
 Open or compound fracture: The fractured portion of the bone protrudes 
through the skin. 
 Comminuted fracture (Figure 6): The bone splinters and fragments at the 
location of impact and pieces of bone lie in situ of the fracture. 
 Greenstick fracture: A partial fracture that occurs in children, where one 
side of the bone is broken and the contralateral side is bent. 
 Spiral Fracture (Figure 7):  Sustained due to a twisting force on the bone. 
 Impacted fracture (Figure 8):  One end of the fracture is driven into the 
interior of another 
 Pott’s fracture (Figure 9):  A fracture of the distal and lateral portion of 
the lower leg, resulting in serious injury of the distal tibial articulation. 
 Colle’s fracture: A fracture of the distal radius bone of the forearm, in 
which the distal fragment is displaced posteriorly. 
 
(Tortora and Grabowski, 2003) 
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1.2.2 Types of Fracture in the Study 
 
The following radiographs, sourced from participants, illustrate the most common 
types of tibial fracture presented by patients involved in this study: 
 
 
 
Figure 6:  Comminuted Fracture 
 
 
 
 
 
Figure 7:  Spiral Fracture 
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Figure 8: Impacted fracture 
 
 
 
 
 
Figure 9:  Pott’s Fracture 
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1.2.3 The Extracellular Matrix 
The ECM has an intimate involvement with all aspects of bone repair and 
remodelling, especially in callus development and post-inflammatory 
regeneration.  The dynamically-modulated key stages involved in healing are 
accomplished through a unique capability of the ECM to generate vast arrays of 
structures, offering support in an injured environment.  The matrix has the 
capacity  to orchestrate cellular processes, bind specific growth factors and 
cytokines and organise the geometric framework that can assist in cell migration 
as well as numerous cell-to-cell interactions (Raghow, 1994; Pankov and Yamada, 
2002; Hidalgo-Bastida and Cartmell, 2010). 
 
The specialised adhesive cell-to-cell interactions are enabled by the substantial 
range and abilities of cell surface receptors and integrins; the latter being 
generated by various combinatorial associations amongst the constituent  and  
integrin chains, the receptors that mediate the attachment of a cell to the 
surrounding tissues around it (normally other cells and the ECM scaffold itself).  
The dynamic cell-to-ECM interactions are continuously modified by a range of 
potent cytokines and are subject to feedback regulation mediated by 
transcriptional, post-transcriptional, translational and post-translational 
mechanisms elaborated during fracture repair.  The mediators involved in cell-to-
ECM relationships include mesenchymal stem cells (MSCs), fibroblasts, 
endothelial and epithelial cells, as well as cells of the immune system (Raghow, 
1994; Pankov and Yamada, 2002).  
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Figure 10: Biochemical Cell-to-ECM Interactions 
 
 
 
 
 
Figure 10.  The cell-extracellular matrix relationship elicits many key mechanisms involved in 
post-inflammatory fracture healing and bone modelling. The ECM is a source of a variety of 
mediators, which impact on cellular processes in a dynamic reciprocity.  Examples of these 
mediators include collagens, fibronectin, laminin, fibrinogen, vitronectin, thrombospondin, 
tenascin and proteoglycans.  Cells often alter the quality and quantity of various ECM components 
they synthesise and are subsequently expressed into the interstitial fluid within the fracture micro-
environment (Pankov and Yamada, 2002; Hidalgo-Bastida and Cartmell, 2010). 
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1.2.4 Regulatory Hormones in Fracture Healing 
Bone is the body’s largest reservoir of calcium (Ca2+), with 99% being stored in 
the skeleton.  Calcium blood levels are regulated by controlling resorption from 
bone to blood and its deposition from blood into bone.  Many homeostatic 
processes, as well as haemostasis and enzymatic reactions, depend on stable Ca
2+
 
levels within extracellular fluid, which are typically 9-11 g mL-1 (2.2-2.5 mmol 
L
-1
) in blood plasma (Tortora and Grabowski, 2003).  Bone therefore acts as a 
buffer in calcium homeostasis, a process that is regulated by hormones (Fleet and 
Schoch, 2010). 
 
1.2.4.1 Parathyroid Hormone, Calcitriol and Calcitonin 
 
The most important hormone in Ca
2+
 regulation is parathyroid hormone (PTH), 
which is secreted by the parathyroid glands.  Secretion of PTH operates via a 
negative feedback system, i.e. if a stimulus should trigger Ca
2+
 levels to fall, as is 
the case in early fracture, parathyroid gland cell receptors detect this change and 
increase their production of cyclic adenosine monophosphate (cAMP).  The 
increased production of cAMP causes an increase in PTH synthesis, via the gene 
for this hormone in the nucleus of the parathyroid gland, releasing more PTH into 
the blood.  The occurrence of higher levels of the circulating hormone stimulate 
osteoclastic activity, speeding up the rate of bone resorption which gives rise to 
elevated levels of Ca
2+
 in the blood.  Hence, blood calcium levels return to normal 
due to its release from the bone (Jilka, 2007; Paskalev and Goranov, 2012; 
Aspenberg, 2013). 
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Calcium levels may not necessarily be low following fracture in certain patients.  
Serum parathyroid hormone and calcium levels were measured in elderly hip 
fracture patients (n=20) in a study conducted by Sato et al. (2001).  At one week 
following injury, parathyroid hormone was found to be depressed, whilst Ca
2+
 
levels were increased.  It was shown that both these analytes returned to normal 
after three months post-injury.  The group found that increased bone resorption 
and decreased bone formation with hypercalcaemia are present by one week 
following the hip fracture and some heightened resorption continues for at least 3 
months.  This quandary could explain why elderly patients are of high risk of 
sustaining another hip fracture  (Sato et al., 2001).  
 
Parathyroid hormone also acts upon the kidneys to slow down the rate of Ca
2+
 loss 
in the urine, in order that more is retained in the blood.  In addition, it promotes 
synthesis of calcitriol, a hormone that stimulates absorption of calcium from the 
gastrointestinal tract, thus assisting in elevating Ca
2+
 levels further.  The hormone 
calcitonin (CT) also contributes to the homeostasis of Ca
2+
 in the blood in that it 
has the opposing effect of PTH.  In the event that blood calcium levels become 
raised, parafollicular cells of the thyroid gland secrete CT, which inhibits 
osteoclastic activity, thereby accelerating Ca
2+
 deposition into bone.  Calcitonin 
consequently promotes bone formation and reduces blood Ca
2+
 levels (Tortora 
and Grabowski, 2003; Fleet and Schoch, 2010). 
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1.2.4.2 Oestrogen and Osteoporosis 
 
Osteoporosis is a bone disease that is epitomised by increased porosity of the 
skeleton due to a reduction in bone mass.  The associated structural changes in 
bone architecture give rise to a heightened risk of fracture.  The condition may be 
localised to a single bone or region, as in disuse osteoporosis of a limb, or may 
involve the entire skeleton, as a manifestation of a metabolic bone disease 
(McNamara, 2010). 
 
In the ten years following menopause, which is characterised by a reduction in the 
production of oestrogen, yearly reductions in bone mass can reach 2% of cortical 
bone and 9% of cancellous bone.  Within the 30-40 years following menopause, 
women can lose up to 35% of cortical bone and 50% of their trabecular bone.  It is 
for this reason that postmenopausal women are at an extremely high risk of 
sustaining an osteoporotic fracture than men.  Postmenopausal osteoporosis can be 
described as a hormone-dependent acceleration of bone loss due to oestrogen 
deficiency.  Indeed, oestrogen replacement at menopause is protective against 
such bone depletion.  The effect of this hormone on bone mass is mediated by 
cytokines and decreased oestrogen levels give rise to increased secretion of IL-1, 
IL-6 and TNF- by blood monocytes and cells of the bone marrow.  Such 
cytokines are potent stimulators of osteoclast activity and recruitment.  A degree 
of compensatory osteoblastic activity does occur, but fails to keep up with the 
osteoclasts, resulting to what can be described as a high turnover form of 
osteoporosis (Raisz, 2005; D'Amelio et al., 2008; Faienza et al., 2013). 
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1.2.4.3 Vitamin D (Cholecalciferol) 
 
Vitamin D, also known as cholecalciferol, is synthesised by natural sunlight 
exposure to the skin and is responsible for the evolution of a healthy calcified 
skeleton; it is a hormone that elicits a wide range of biological processes.  The 
ultraviolet B radiation (UVB) in sunlight converts 7-dehydrocholesterol to pre-
vitamin D3 which rapidly becomes isomerised to vitamin D3.  Once synthesised, it 
is metabolised in the liver to 25-hydroxyvitamin D3 and in the kidneys to its active 
form 1,25-dihydroxyvitamin D3.  1,25-dihydroxyvitamin D3 interrelates with its 
vitamin D receptor in Ca
2+
-mediating tissues to regulate calcium metabolism and 
bone health.  It is known that the majority of cells in the body have a vitamin D 
receptor and are capable of producing 1,25-dihydroxyvitamin D3.  1,25-
dihydroxyvitamin D regulates a wide array of genes that have essential functions 
in modulating cellular development, immune processes and cardiovascular 
homeostasis.  Vitamin D deficiency is associated with a heightened risk of chronic 
conditions including autoimmune and cardiovascular disease, cancer and type II 
diabetes amongst others.  Deficiency and insufficiency have been characterised as 
a 25-hydroxyvitamin D level of <20 ng mL
-1
 and 21-29 ng mL
-1
 respectively.  
Adults require 2000 IU of vitamin D a day to meet the body's vitamin D 
requirement.  It is estimated that 1 billion people are vitamin D deficient or 
insufficient worldwide (Holick, 2011).   
 
Fu et al. (2009) studied the efficacy of exogenous 1,25-dihydroxy vitamin D3 on 
osteoporotic fracture healing, employing an in vivo rat model to evaluate its 
histomorphometric effects on bone repair.  Six month old oopherectomised female 
Sprague Dawley rats (n=40) were randomised into two groups and a bilateral 
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midshaft femoral osteotomy was performed on each of the animals.  Treatment in 
the groups commenced at the second day after fracture and was continued until 
sacrifice at 6 and 16 weeks post-osteotomy.  The experimental group (n=20) was 
given 1,25-dihydroxy vitamin D3, 0.1 g kg
-1
 day
-1
 and the control group (n=20) 
was given a vehicle of middle chain triglyceride (MCT), both by oral gavage.  
Fracture callus in the rats was evaluated via a range of imaging techniques (x-ray 
and micro-computed tomography (micro-CT)) as well as histological testing.  
Biomechanical testing was also performed.  At 6 weeks post-fracture, x-ray 
revealed a less pronounced fracture line in the 1,25-dihydroxy vitamin D3 group 
compared with the MCT-vehicle group.  However, the fracture line was not 
visible in both groups after 16 weeks.  Micro-CT showed that the total volume of 
callus was 23% higher in the experimental group than that in the control group 
(p<0.001) after 6 weeks.  Histology showed improved remodelling of 
the fracture callus in the 1,25-dihydroxy vitamin D3 compared to the control 
group.  Biomechanical performance was also superior in the rats that were given 
1,25-dihydroxy vitamin D3  (data not shown).  Fu and co-workers concluded that 
exogenous 1,25-dihydroxy vitamin D3 could enhance fracture healing by 
improving the histomorphometric parameters and mechanical strength of the 
fracture callus, giving rise to increased transformation of woven bone into 
lamellar bone (Kellum et al., 2009). 
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1.3 THE PHASES OF FRACTURE HEALING 
There are essentially three phases of fracture repair, the inflammatory phase, the 
reparative phase and the maturation, or remodelling phase.  An overview of these 
phases is discussed as follows. 
 
1.3.1 Inflammatory Phase 
Immediately following the fracture, a haematoma is formed at the site of injury 
and the inflammatory phase is initiated.  The haematoma results from traumatic 
damage to the vasculature, associated with musculoskeletal damage, acute 
necrosis and hypoxia of the surrounding tissues (Glowacki, 1998).  The activation 
of the thrombotic factors within the coagulation cascade leads to the development 
of the haematoma at the site of the fracture.  The early trauma period is 
characterised by the presence of certain mediators within the haematoma 
microenvironment, which includes platelets, cytokines, fibroblasts and 
mesenchymal stem cells (MSCs) associated with growing capillaries (Marsell and 
Einhorn, 2011).   
 
Platelets are mobilised by thrombin and subendothelial collagen, ultimately 
expressing PDGF and TGF-, factors that are actively involved with the initiation 
of fracture repair (Connor and Evans, 1982).  There is marked proliferation and 
differentiation of mesenchymal cells (of osteogenic and chondrogenic lineage) 
over the subsequent days, during which time angiogenesis takes place, which is 
essential for the progression to the next stage; the reparative phase (Yu et al., 
2002).   
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The preliminary inflammatory step in bone healing is blood clotting, or 
haemostasis, which follows an initial momentary period of vasodilatation and 
increased vascular permeability immediately after the injury has taken place.  The 
inflammatory phase can last up to 4 days from the onset of the fracture.   
Haemostasis provides the foundation from which the proceeding elements of the 
cascade can follow.  Bleeding is rapidly controlled by acute vasoconstriction of 
the damaged vessel, prompting the endothelium and neighbouring platelets to 
trigger the intrinsic coagulation pathway.  During this process, a fibrin clot, 
known as a haematoma, is formed; this contains collagen, platelets, thrombin and 
fibronectin.  This haematoma is able to release various cytokines and growth 
factors into the ECM to act as inflammatory promoters.  The early phase in trauma 
is known as the acute-phase response or acute-phase reaction, which triggers a 
systemic feedback cascade, involving the release of acute-phase proteins by the 
liver (Witte and Barbul, 1997; Broughton et al., 2006). 
 
The haematoma is able to provide a network of intricate scaffolding, which can be 
utilised by migrating leukocytes such as neutrophils, monocytes and fibroblasts 
and also endothelial cells during the acute-phase response.  The liver plays an 
important role by regulating the amount of recruited cytokines and growth factors 
at the site of injury, which, if up or down-regulated by at least 25% during the 
inflammatory process, are termed acute-phase proteins.  Those which are under-
produced are termed negative acute phase proteins (e.g., serum albumin); those 
which are overproduced, (e.g., IL-6), are known as positive acute-phase proteins.  
Any deficiencies in those factors that are required for clot-formation (e.g., factor 
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XIII) give rise to impaired wound healing  (Kurkinen et al., 1980; Hollenbeck, 
1996; Wong and Martins-Green, 2004). 
 
1.3.1.1 Chemotaxis 
 
As soon as the haematoma is formed, cellular signalling will elicit a neutrophil 
response.  In addition, inflammatory mediators accumulate, prostaglandins (PGs) 
are activated and localised vasodilatation occurs, which facilitates cellular 
migration to the site of injury.  The neutrophils are mobilised by various 
cytokines, including IL-1, TNF- and TGF-.  Bacteria-produced 
lipopolysaccharides (LPS) are also capable of evoking similar responses  
(Bevilacqua et al., 1985; Pohlman et al., 1986; Gerstenfeld et al., 2003; Dimitriou 
et al., 2011).   In addition to neutrophils, monocytes are activated and migrate to 
the wounded area, where they are transformed into macrophages.  This is a crucial 
process for the transition to the early reparative phase of wound healing and 
usually occurs around 48-96 hours post-injury.   An activated macrophage will 
then initiate angiogenesis by synthesising VEGF, FGF and TNF-.  The 
formation of fibrous tissue, or fibroplasia, occurs as a result of TGF-, endothelial 
growth factor (EGF), PDGF, IL-1 and TNF-synthesis.  Indeed, IL-1 and TNF- 
are accountable for the synthesis of nitric oxide (NO) through the activation of 
inducible nitric oxide synthase (iNOS), thus affording the initiation of 
vasodilatation (Witte and Barbul, 2002; Marsell and Einhorn, 2011). 
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1.3.1.2 Neutrophils and Macrophages 
 
Neutrophils migrating to the wound site clear the area of residual bacteria and 
cellular debris.  The neutrophils release proteolytic enzymes and proteases that 
digest bacteria and other debris and are therefore vital components of the fracture 
healing process.  Proteases are categorised according to their specific target, 
whether it is proteins, amino acids or metal ions within enzymes.  Serine 
proteases, for example, have a broad specificity, whereas metalloproteinases 
(which contain zinc ions) have a limited specificity dissolving both collagen and 
the ECM.  Proteases break down the matrix at the wound site, as protease 
inhibitors (normally found in undamaged tissue) are overwhelmed and 
compromised during the inflammatory process due to the substantial release of the 
proteases (Yager and Nwomeh, 1999; Tsiridis et al., 2007).  
 
Neutrophils are also capable of generating reactive oxygen free radicals via a 
myeloperoxidase pathway, which are combined with chlorine to form a very 
effective sterilising agent and this is able to control the pathogen levels within the 
wound milieu (Yager and Nwomeh, 1999).  There is widespread neutrophil 
apoptosis, which are subsequently replaced by macrophages, although the 
stimulus for this enhanced cell death is unknown.  The macrophages phagocytose 
the dead neutrophils, clearing them from the injury site.   Macrophages continue 
to destroy residual bacteria because they are able to produce large quantities of 
NO, a process stimulated by TNF and IL-1.  A higher yield of NO can be further 
generated by a reaction between TNF and IL-1 and peroxide ion oxygen radicals 
to produce very toxic peroxynitrite and hydroxyl radicals (Goldman, 2004).  The 
impaired ECM is cleared of any remaining inflammatory debris by matrix 
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metalloproteinase (MMP), an enzyme that is expressed by keratinocytes, 
fibroblasts, monocytes and macrophages in the presence of TNF-(Abraham et 
al., 2000).   
 
The inflammatory phase is a well organised and coordinated process, mediated by 
a series of reactions that eventually give rise to stop signals, which are also known 
as checkpoint controllers of inflammation (Nathan, 2002; Serhan and Chiang, 
2004).  The major mediators involved in the regulation of inflammation are the 
various eicosanoids (e.g. PGE2, PGI2, PGF2, TxA2).  The enzyme lipoxygenase, 
involved in the synthesis of eicosanoids, has a pivotal role in the synthesis of 
lipoxins.  Lipoxins and aspirin-triggered lipoxins, are the stop signal for 
inflammation and are formed by platelets and leukocytes through transcellular 
biosynthesis (Broughton et al., 2006).  When platelets and neutrophils adhere to 
one another, the latter produces leukotriene A4 (via 5-lipoxygenase), which is 
conveyed to the platelet and transformed into lipoxin A4 and B4 (Serhan and 
Chiang, 2004) and these are discussed in more detail later.   
 
1.3.2 Reparative Phase 
 
The second stage of fracture healing, occurring from day 4 to 14 from the injury, 
known as the reparative phase, involves angiogenesis, epithelialisation and 
provisional ECM formation.  The initial stage in the reparative phase is 
synonymous with healing seen in other tissues, for example, skin and soft tissue. 
Activated platelets produce EGF and TGF-; cytokines which stimulate 
chemotaxis and epithelial proliferation (Grotendorst et al., 1989; Marsell and 
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Einhorn, 2011).  This is relevant in fracture healing where there is simultaneous 
epithelial damage to surrounding tissue, especially in compound fractures.  In this 
case, epithelialisation actually occurs immediately after injury and is initially 
stimulated by inflammatory messengers via the up-regulation of keratinocyte 
growth factors (KGFs) by IL-1 and TNF-.  Fibroblasts synthesise and secrete 
KGF-1, KGF-2 and IL-6, which stimulate neighbouring keratinocytes to migrate 
to the wounded area, where they proliferate and differentiate in the epidermis .  It 
would appear that KGF-2 has a substantial influence in orchestrating this process 
(Jimenez and Rampy, 1999; Sorg et al., 2009). 
 
During the reparative phase of fracture healing, it is both the MSCs and 
endothelial cells that are the most proliferative.  Endothelial cells residing in 
venules are recruited by VEGF for the redevelopment of capillary tubes.  The 
VEGF is secreted mainly by keratinocytes, but also by macrophages, fibroblasts, 
platelets and other endothelial cells.  Keratinocytes are able to express VEGF 
through stimulation by IL-1, TNF-, TGF-1 and KGF.  Endothelial nitric oxide 
synthase (eNOS) is derived from endothelial cells in response to hypoxia, a 
process which further increases the production of VEGF.  Raised levels of NO 
initiate vasodilatation and, thus, can protect the new tissue from the toxic effects 
of ischaemia and reperfusion injury at the fracture site (Witte and Barbul, 2002; 
Goldman, 2004).    
 
Although the haematoma is a well organised structure, it does not have a 
significant mechanical role in the immobilisation of the fracture, but instead acts 
principally as a fibrin scaffold over which repair cells perform their function.  
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During this phase, the microenvironment of the fracture becomes acidic, which 
provides an additional stimulus to cellular activity during the early period of 
fracture healing.  However, later in the repair process, the pH gradually reverts to 
neutral and then corrects to a slightly alkaline level, typically 7.4 (Keramaris et 
al., 2008). 
The cells directly involved in fracture repair are of mesenchymal origin, are 
pluripotent and are thought to originate from cartilage and bone of the fracture 
periphery.  Some cells originate from the cambium layer within the periosteum, 
forming the earliest bone, which is particularly active and important in children.  
Cells derived from the endosteum also participate.  Small variations in the fracture 
microenvironment and the stresses to which they are subjected to, likely 
determines their fate in terms of cell type differentiation.  Surviving osteocytes are 
not involved in the repair process, as they are destroyed during 
resorption.  However, the majority of cells that are engaged in fracture healing 
enter the milieu with the granulation tissue, which is composed of new connective 
tissue and tiny blood vessels, which infiltrates the region from surrounding vessels 
and is associated with the ingress of capillary buds (Kitaori et al., 2009).  
The vascular bed of an extremity undergoes expansion following a fracture, but 
the osteogenic response is, in the main, confined to the area surrounding the 
fracture site.  Under normal circumstances, it is the periosteal vessels that donate 
the majority of capillary buds, with the nutrient medullary artery having a more 
important role later in the healing process.  During operative reduction and 
fixation of the fracture, the surgeon may obstruct this natural process, either by 
excessively stripping the periosteum, or by destroying the intramedullary system 
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via the use of nails, screws and plates.  In this case, the repair must continue with 
vessels derived from the surviving tissue (Fayaz et al., 2011). 
Mesenchymal stem cells invade the haematoma and begin to rapidly synthesise 
the soft callus, which is chiefly composed of fibrous tissue and cartilage. This 
quickly envelopes the fractured bone ends and gives rise to a steady increase in 
stability of any loose bone fragments.  Deviations in oxygen tension lead to the 
formation of either bone or cartilage, with cartilage being formed in areas in 
which oxygen tensions are relatively low and vice versa for bone; the ensuing 
process dependant on the distance of the cell from its blood supply. The 
developing bridging callus is regulated by FGF and angiopoietins 1 and 2 initially, 
with VEGF occurring later, during endochondral bone formation (Lieberman et 
al., 2002; Gerstenfeld et al., 2003; Marsell and Einhorn, 2011).    
The cartilage produced is ultimately resorbed by a process similar to endochondral 
bone formation (discussed later), but is one which is less organised.  Bone will be 
formed, through primam intentionem, by cells that receive sufficient oxygen and 
those which are subjected to the appropriate mechanical stimuli.  In early fracture, 
cartilage formation prevails and glycosaminoglycans exist in elevated 
concentrations.  In the latter stages, the formation of bone becomes more apparent, 
during which time biochemical events continue with an accumulation of calcium 
hydroxyapatite crystals.  The collagen content returns to a normal level after 
mineralisation has taken place (Gerstenfeld et al., 2006). 
Mineralised tissues are highly organised in their internal structure as a result of 
specialised cellular activity.  The initial step of mineralisation is the formation of 
                                                                                                               Introduction 
33 
tropocollagen by osteoblasts, which moves from inside the cells to outside, before 
polymerising to develop collagen fibrils.  The collagen fibrils possess their own 
internal structures, known as hole zones, which are located within the core of the 
fibrils.  They are organised in a regular fashion as a result of the internal structure 
of the collagen molecules.  The initial deposition of mineral occurs in this region 
due to interactions between metastable solutions of calcium and phosphate and 
groups of specific amino acid side chains within the holes.  This arises due to a 
series of ordered collagen fibrils, around which there are clustered crystals of 
calcium hydroxyapatite (Dimitriou et al., 2005; Marsell and Einhorn, 2011; 
Dimitriou and Giannoudis, 2013). 
At this stage, the fractured bone ends gradually become encased in a fusiform 
mass of callus composed of increasing amounts of bone.  Immobilisation of the 
fragments is more rigid because of the internal and external callus production and 
clinical union is said to have taken place.  However, complete union does not exist 
at this point, since the remodelling phase begins in the middle of the reparative 
phase, with resorption of excess or inefficient fragments of the callus and the 
laying down of trabecular bone along lines of stress (Gerstenfeld et al., 2006; 
Marsell and Einhorn, 2011). 
 
1.3.2.1 Mesenchymal Stem Cells 
 
Mesenchymal stem cells are non-haematopoietic stromal cells that are fibroblast-
like and spindle-shaped in their morphology; these are the essential ‘orchestrators’ 
of mammalian healing.  They are key producers of cytokines that are instrumental 
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in the inflammatory response and have an important role in the formation of 
granulation tissue. Chemokines, for example, which are vital in attracting 
neutrophils and other leukocytes to the wound area, are secreted by these cells 
(Wong and Martins-Green, 2004).  They also have the capacity to become 
differentiated into chondrocytes, osteoblasts and ultimately osteocytes, which are 
crucial for the regeneration of bone in the fracture healing process.  A study found 
that fibroblast-like, mesenchymal cells isolated from human tibial fracture 
haematomas could be differentiated into osteocytes, chondrocytes and adipocytes 
in vitro, thus, having progenitor capabilities (Oe et al., 2007).   
 
Mesenchymal stem cells are identified by their immunophenotype, or expression 
of various cell surface antigens, which include, amongst others, CD29, CD 44, 
CD73, CD105 and CD166 in adult humans (for summary, see Table 4) 
(Haynesworth et al., 1992; Conget and Minguell, 1999; Le Blanc et al., 2003; 
Sordi et al., 2005).  They lack expression of the haematopoietic stem cell markers 
CD34, CD45 and CD14 (Chamberlain et al., 2007).  The ability of MSCs to self-
renew and differentiate into a wide range of cell types, notably bone, adipose and 
cartilage, renders them suitable for use in tissue bio-engineering (Pittenger et al., 
1999; Lee et al., 2009; Cartmell et al., 2011).  The cells have a migratory 
capability and systemically-transplanted cells have been shown to migrate to the 
injury site, conveniently homing to tissues that are inflamed or damaged (Barbash 
et al., 2003). 
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Table 4:  A Summary of Mesenchymal Stem Cell Biochemical Markers 
 
 
MSC Marker 
 
Alternative Nomenclature 
 
Function 
 
CD29 Integrin 1 Cell adhesion molecule 
(Haynesworth et al., 1992). 
CD44 HCELL Cell adhesion, migration, 
‘bone homing receptor’ 
(Haynesworth et al., 1992). 
CD54 Inter-cellular Adhesion Molecule1 
(ICAM-1) 
Cell adhesion and migration 
(Pittenger et al., 1999). 
CD71 Transferrin receptor Maintains cellular iron 
homeostasis (Pittenger et al., 
1999). 
CD73 5’-nucleotidase, ecto (NT5E) Marker of lymphocyte 
differentiation (Sordi et al., 
2005).  
CD90 
 
Thy-1 
 
Cell adhesion, extravasation & 
migration (Sordi et al., 2005). 
CD105 Endoglin Part of TGF- receptor 
complex.  Involved in 
cytoskeletal organisation, cell 
morphology and migration 
(Pittenger et al., 1999). 
CD106 Vascular Cell Adhesion Molecule-
1 (VCAM-1) 
Cell adhesion molecule 
(Conget and Minguell, 1999). 
CD166 Activated Leukocyte Cell 
Adhesion Molecule (ALCAM) 
Tissue growth and cell 
migration (Conget and 
Minguell, 1999). 
Stro-1                         - Adherence and cell 
proliferation.  Identifies bone 
marrow stromal cell precursors 
(Galmiche et al., 1993). 
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1.3.3 Maturation or Remodelling Phase 
Regarded as a key phase clinically and the most long-lasting, the maturation and 
remodelling stage of fracture healing occurs from around day 8 and can continue 
for up to a year and beyond, depending on the severity of the injury and the 
healing abilities of the patient.  The main aspect of this element is the deposition 
of collagen and calcium, providing a strong, well-coordinated framework.  The 
strength of a wound may be notably compromised if patients have mineral 
deposition problems due to malnutrition, disease, alcoholism and other lifestyle 
factors.  Indeed, problems can also arise as a result of tobacco smoking and this is 
discussed later  (Sloan et al., 2010; Patel et al., 2013). 
 
Fracture repair is completed during the maturation phase, when the healing bone 
is restored to its original shape, structure and mechanical strength.  Remodelling 
of the bone takes place gradually during several months and years and is a process 
enabled due to mechanical stresses being placed upon the bone.  As the fracture 
site is exposed to an axial loading force, bone is generally laid down where it is 
needed and resorbed from where it is not.  Sufficient strength is typically achieved 
in 3 to 6 months and then undergoes normal skeletal remodelling thereafter 
(Dimitriou et al., 2011). 
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1.3.3.1 Bone Remodelling 
The following schematic diagram (Figure 11) illustrates the various stages of the 
biochemical pathway of the bone remodelling cycle.    
  
Figure 11: Bone Remodelling Cycle 
Image adapted from Jones (2013)  
Available from:  http://graduatehistology.blogspot.co.uk/ 
 
The biochemical resorption and formation of bone occurs simultaneously at 
different points along the groove or tunnel (Figure 11) (Jones, 2013).  
Multinucleated osteoclasts resorb bone at the groove's apex in response to 
increased RANK-L (ligand for receptor activator of nuclear factor kappa B) and 
M-CSF (macrophage colony stimulating factor) and reduced osteoprotegerin from 
adjacent osteoblasts.  Activation is effected by hormones, cytokines or by 
osteocytes under mechanical strain.  Macrophages appear in the osteoclasts' wake, 
clear apoptotic cells and prepare the resorbed bone surface as a 'cement line'.  
~3 Weeks 
~3 Months 
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Growth factors released from the bone stimulate differentiation of local stem cells 
to osteoblasts that form new bone, completing the cycle.  The growth factors TNF 
(tumour necrosis factor), TGF- (transforming growth factor-beta) and various 
cytokines (interleukins IL-1, 3, 6, 11) are also involved in this process (Dimitriou 
et al., 2005). 
 
Osteocytes communicate mechanical strain to osteoblasts on the bone surface via 
cytoplasmic projections.  The osteoblasts respond to this or to other signals such 
as parathyroid hormone (PTH), dihydroxy-vitamin D3, cytokines and growth 
factors by increasing RANK-L and M-CSF and reducing osteoprotegerin.  
Osteoclast formation ensues from circulating monocyte precursors, responsible for 
the direction of osteoclasts to the area of bone to be resorbed.  Inhibitory signals 
limit osteoclast recruitment and activity.  Macrophages remove apoptotic 
osteoclasts and prepare the resorbed surface.  Growth factors drive osteoblast 
formation from local stem cells (coupling of resorption and formation), producing 
osteoid, which is mineralised to form new bone.  On completing the cycle (about 
120 days), remodelling is balanced if there has been no net change in the amount 
of bone (Dimitriou et al., 2005). 
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1.3.3.2 Mineralisation of Bone 
 
The schematic diagram below (Figure 12) portrays events involved in the 
mineralisation of osteoid to form mineralised bone.  Active cuboidal osteoblasts 
secrete osteoid collagen and matrix vesicles.  The matrix vesicles are targets for 
the deposition of hydroxyapatite crystals; the first step in mineralisation.  
Confluent mineralisation of osteoid collagen supports the glycosaminoglycan 
matrix (Young and Heath, 2003). 
Figure 12: Mineralisation of bone 
 
Figure 12: Mineralisation of bone; the matrix vesicles are rich in the enzyme alkaline phosphatase 
and pyrophosphatase, both of which can produce phosphate ions from an assortment of molecules.  
The phosphate ions accumulate in the matrix vesicles with calcium ions and together they form 
hydroxyapatite (Young and Heath, 2003, Pg.183). Image reproduced with permission of Elsevier. 
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1.3.4 A Summary of the Phases of Fracture Healing Illustrated 
 
 
 
 
Figure 13: Stages of the Fracture Healing Process. 
Figure 13:  The diagrammatical stages of fracture healing, from the formation of the fracture 
haematoma in the inflammatory phase (1), the development of the soft callus (2) to the bony callus 
(3) in the reparative phase before bone remodelling (4) in the final maturation phase (Tortora and 
Grabowski, 2003, Pg.176).  Image reproduced with permission of John Wiley & Sons, Inc. 
 
 
 
                                                                                                               Introduction 
41 
Figure 14:  The Process of Fracture Healing; Radiology 
Pre-fixation 
(<24hrs 
post injury) 
Post 
Fixation 
(+4 months) 
Post Fixation 
(+13 months) 
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Figure 14 (previous page): The radiographs show the healing progress of a tibia and fibula 
fracture in the right leg of a 55 year old non-smoking female, who consented to take part in this 
study.  The images were acquired pre- and post-fixation and represent a time-frame of 13 months 
from the time of injury.  The formation of the callus during secondary fracture healing can be 
observed in the images as endochondral ossification takes place.  The patient’s healing progress 
was satisfactory in this particular case. 
 
1.4 Modes of Ossification in Fracture Repair 
The basic biology of fracture repair is divided into two parts; direct (primary) and 
indirect (secondary) fracture healing.   
1.4.1 Direct (Primary) Fracture Healing 
 
There are two types of direct or primary healing; gap healing and contact healing 
(see Figure 15).  Gap healing takes place after micrometric clinical anatomical 
reduction and rigid fixation, which is usually internal.  In the first phase, there is a 
disruption of the blood supply and necrosis at each of the fracture ends, affecting 
the bone cellular components, but not necessarily the humoral elements.  Even 
fractures that have been very well surgically reduced have irregular surfaces that 
can create gaps between fragments.  Direct bone formation has the potential to fill 
gaps of up to 1.0 mm in width and, therefore, removes the requirement for 
connective tissue and fibrocartilage production prior to bone formation.  In the 
second phase of gap healing, the immature woven bone is longitudinally 
reconstructed through a process known as Haversian remodelling.  Despite 
effective rigid internal fixation, any gaps greater than l.0 mm are partially filled 
with fibrous tissue, which is later replaced by bone (Gullihorn et al., 2005). 
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Contact healing occurs when the fracture fragments are in direct apposition, also 
known as a ‘hairline’ fracture, resulting in union through the ingrowth of 
Haversian systems at the injury site; there is no callus formation in this case 
(Marshall et al., 2004).  Osteoclasts form ‘cutting cones’ that advance across the 
fracture line and construct resorption cavities; a process aimed at restoring 
mechanical continuity.  This is followed by the growth of a capillary loop down 
the centre of the hollow.  Mesenchymal stem cells accompany the capillaries and 
become differentiated into osteoblasts and produce osteoid closing cones.  These 
bone forming units are conical in shape, due to the relative speed of the cutting 
and closing cones.  Osteoclasts are approximately 10 times faster at resorbing 
bone than the osteoblasts are at its formation and this has important implications 
on the timing of bone regeneration (Dimitriou et al., 2005) . 
 
 
 
 
Figure 15.  Primary Fracture Healing.  Radiograph of a fracture of the 5
th
 metatarsal that will 
likely unify via primary fracture healing.  The anterior portion of the fracture is in direct 
apposition, so will undergo contact healing, whilst the posterior aspect shows a small gap of 
approximately 1.0 mm, whereby gap healing is applicable.  Image obtained from a consenting 
patient in this study. 
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1.4.2 Indirect (Secondary) Fracture Healing 
Most fractures heal by indirect or secondary fracture healing, which results in the 
formation of a bridging callus through either endochondral (involving cartilage) or 
intramembranous ossification (not involving cartilage) (discussed later).  Bone 
does not ‘evolve’ from previously formed cartilage (where applicable), but is 
instead directly formed via intramembranous ossification.   The early phase of 
secondary fracture healing involves MSCs and provides an early bridging callus, 
histologically characterised as a soft callus.  The function of the soft callus is to 
stabilise the fracture fragments following injury (Dimitriou et al., 2005).  
Secondary fracture healing, therefore, involves a contribution from the bone 
marrow during the early phase, when endothelial cells transform into polymorphic 
cells, expressing an ‘osteoblastic phenotype’ (Claffey et al., 2001; Marsell and 
Einhorn, 2011). 
The process of secondary fracture healing was first described by McKibbin in 
1978 as a five-stage process; haematoma formation, inflammation, soft then hard 
callus production and finally remodelling (McKibbin, 1978).  The stages of 
fracture healing (applicable in endochondral ossification as discussed later) are 
now more comprehensively described as an initial haematoma formation with 
inflammation, angiogenesis and production of cartilage, cartilage calcification, 
cartilage removal, bone generation and bone remodelling.  During the final stage, 
cartilage becomes calcified and replaced by bone.  This developmental process 
can be seen in the x-ray images as depicted in Figure 14.  It is a process enhanced 
by micromotion, but one which is inhibited by rigid fixation (Marshall et al., 
2004; Dimitriou et al., 2005).  
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1.4.2.1 Endochondral Ossification in Indirect Fracture Healing 
 
This type of bone formation is more common than intramembranous ossification, 
as it occurs in a mechanically less-stable fracture environment, normally 
associated with long bone fractures that have been stabilised with plaster of Paris 
(Ford et al., 2004).  The process takes place predominantly adjacent to the fracture 
site periosteum and is assisted by the soft tissues surrounding the fracture site.  
Mesenchymal stem cells are recruited to the fracture milieu and subsequently 
proliferate.  They then differentiate into chondroblasts in a process known as 
chondrogenesis, forming the soft, fibrocartilaginous callus.  New chondrocytes 
synthesise and secrete a cartilage-specific matrix, composed of type II collagen 
and proteoglycans.  After mechanical stability has been achieved, the cartilage 
matrix is subjected to hypertrophic activity and mineralisation in a spatially 
organised manner (Gerstenfeld et al., 2003).  Following this repair process, 
vascularisation of the new bone occurs, the calcifying hypertrophic chondrocytes 
are removed via chondroclastic activity and the formation of woven bone takes 
place.  Apoptosis of chondrocytes follows ossification of the callus as the former 
is replaced by the woven marrow-filled bone.   Substantial remodelling takes 
place in order for the newly-formed bone to become stable and able to weight-
bear (Dimitriou et al., 2005; Marsell and Einhorn, 2011). 
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1.4.2.2 Intramembranous Ossification in Indirect Fracture Healing 
 
Intramembranous ossification takes place where fractures have been surgically 
reduced and stabilised using metal plates and screws and involves the laying down 
of bone into the mesenchyme. The sources of the cells that are relevant in 
intramembranous formation of bone are provided by the following; 
 
 Underlying cortical bone 
 Proximal periosteum 
 Bone marrow  
             
Twenty four hours following the onset of the fracture, local MSCs migrating from 
the bone marrow become differentiated into an osteoblastic phenotype.  Seventy 
two hours following fracture, cortical osteoblasts and osteoprogenitors (the latter 
derived from periosteal cambium) divide and differentiate, forming a hard callus, 
or woven bone that envelopes the fracture site.  The proliferation of these cells 
peaks at between 7 and 10 days and, despite continued activity, is substantially 
decreased after 14 days (Gerstenfeld et al., 2003). 
 
Intramembranous ossification is the simpler method of bone formation and differs 
from endochondral ossification in that cartilage is not present in this process.  The 
flat bones of the skull and mandible are formed via intramembranous ossification 
during foetal development.  During this type of bone development in bone 
healing, mesenchymal stem cells cluster at the site of the fracture and differentiate 
into osteogenic cells and then into osteoblasts.  The site of the cluster is known as 
the ‘centre of ossification’, where osteoblasts secrete the organic matrix of the 
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bone until they become surrounded by it.  There then follows a calcification stage, 
when the secretion of the matrix ceases and the cells become osteocytes.  After 
several days, Ca
2+
 is deposited and the matrix becomes calcified and hardens.  As 
the bone matrix forms, it develops into trabeculae and blood vessels grow along 
the spaces between this spongy bone and mesenchyme along the surfaces of the 
newly formed bone.  The connective tissue that is associated with vascularisation 
differentiates into bone marrow.  The development of periosteum then ensues, 
which occurs at the periphery of the bone from the condensed trabeculae.  A thin 
layer of compact bone then forms, which covers the surface layers of spongy bone 
prior to remodelling (Tortora and Grabowski, 2003). 
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1.5 MOLECULAR ASPECTS OF FRACTURE HEALING 
As with all repair processes, fracture healing is initiated and regulated by the 
immune system.  There is an established association between the immune system 
and the skeleton; this has been well recognised since the 1970s, when several 
seminal studies were published (Horton et al., 1972; Mundy et al., 1974; 
Horowitz et al., 1984; Dewhirst et al., 1985).  Current evidence also indicates that 
there is a close interrelationship between the biology of bone and host defences, 
giving rise to the term osteoimmunology.  This represents a research area that 
focuses on the biomolecular interactions of both the cellular and molecular 
components (Arron and Choi, 2000; Dimitriou et al., 2005).   
 
The inflammatory and anti-inflammatory molecular mediators are those soluble 
factors of the immune system that are expressed in and secreted by cells, platelets 
and leukocytes in order to control damage and maintain an efficient repair 
process.  There are three categories of promoter molecules involved in early 
fracture healing; (i) the pro-inflammatory cytokines, (ii) the TGF- superfamily 
and (iii) the metalloproteinases and angiogenic factors (Gerstenfeld et al., 2003).  
The other significant mediators involved in healing are growth factors, 
chemokines, lymphokines and monokines, eicosanoids, prostaglandins, lipoxins, 
kinins and cellular metabolites (Oberyszyn, 2007).  These humoral intermediaries 
of fracture healing and associated immune response are discussed here. 
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1.5.1 Proinflammatory Cytokines 
Cytokines are a group of intracellular and extracellular proteins and peptides that 
are used in organisms as chemical signalling agents, allowing cells to 
communicate with each other.  The cytokine family consists of small water-
soluble proteins and glycoproteins with a mass typically between 5 and 30 
kilodaltons (kDa).  Cytokines are clinically important in both innate and adaptive 
immune responses.  Due to their central role in the immune system, cytokines 
participate in a variety of immunological, inflammatory and infectious diseases; 
they are also involved in several developmental processes during embryogenesis.  
Cytokines can be subcategorised as chemokines, lymphokines, monokines, 
interleukins, colony-stimulating factors and interferons (Mlodzikowska-Albrecht 
et al., 2007). 
 
The cytokines interleukin-1, IL-6 and TNF- have a key role in initiating the 
healing process of fractured bones (Gerstenfeld et al., 2003).  They are referred to 
as positive acute-phase proteins and are secreted by macrophages, inflammatory 
cells and also cells of mesenchymal origin that are found in the periosteum.  Their 
function is to promote chemotaxis, thereby attracting other inflammatory cells to 
the site of injury.  This mechanism stimulates extracellular matrix synthesis, 
angiogenesis and the recruitment of endogenous fibrogenic cells to the affected 
area.  There is peak concentration of these proteins within the first 24 hours of the 
fracture occurring, followed by a drop in levels during the period of cartilage 
formation.  Cytokine quantities are later restored and become markedly increased 
again during the remodelling phase (Gerstenfeld et al., 2003).   
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The formation and remodelling of endochondral bone is also regulated by 
cytokines (Gerstenfeld et al., 2003).  For example, TNF- stimulates the 
migration of MSCs, evoking apoptosis of hypertrophic chondrocytes and 
stimulating osteoclastic activity.  Indeed, absence of TNF- causes delayed 
resorption of mineralised cartilage, thereby inhibiting bone formation.  Levels of 
IL-1, IL-6 and TNF- are increased again during callus reshaping in the latter 
stages of fracture healing and remodelling (Uchida et al., 2003; Dimitriou et al., 
2005).  Importantly, there are temporal aspects associated with the activity of 
growth factors.  For example, IL-1 and IL-6 peak at 24 hours post-fracture, but are 
barely detectable after three days (Lee et al., 2004).  The table overleaf 
summarises the interleukins (IL-1-IL-10) that are involved in the inflammation 
stage of fracture healing. 
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Table 5:  Inflammatory Interleukins 1to10 (IL-1 to IL-10) in Fracture Repair 
 
INTERLEUKIN ROLE SOURCE 
IL-1 Induces fever, ACTH release, enhances 
TNF-, IFN-; activates granulocytes, 
endothelial cells, stimulates 
haematopoiesis. 
Macrophages, mast cells, 
keratinocytes, lymphocytes. 
IL-2 Activates macrophages, T lymphocytes, 
NK cells, stimulates differentiation of B 
lymphocyte; induces fever. 
Macrophages, mast cells, 
keratinocytes, 
T lymphocytes. 
IL-3 Stimulates bone marrow stem cells T lymphocyte 
IL-4 Early: Stimulates fibroblast proliferation; 
Late: Downregulates cytokine expression 
Mast cells. 
IL-5 B-cell differentiation, eosinophil and IgA 
production 
TH2 lymphocytes 
IL-6 Released in response to IL-1; induces 
fever; enhances release of acute-phase 
reactants by the liver; inhibits ECM 
breakdown during proliferation. 
Macrophages, mast cells, 
keratinocytes, lymphocytes. 
(pro-inflammatory mediator) 
IL-7 Lymphocyte maturation Stromal cells of red bone 
marrow and thymus 
IL-8 Enhances neutrophil adherence, 
chemotaxis and granule release; enhances 
epithelialisation.  
Macrophages, mast cells, 
keratinocytes, lymphocytes. 
IL-9 Stimulate mast cells T lymphocytes 
IL-10 Downregulates cytokine expression in 
latter stages (anti-inflammatory). 
Mesenchymal stem cell. 
 
(Cross and Mustoe, 2003) 
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1.5.2 Transforming Growth Factor Beta (TGF-) 
 
There are many members of the TGF- superfamily, consisting of numerous 
growth and differentiation factors.  More than 30 TGF- superfamily members 
have been identified in the human genome and include the BMPs, growth 
differentiation factors (GDFs), activins, inhibins, the Mullerian inhibiting 
substance, in addition to the various numerical subtypes (i.e., TGF-1, TGF-2 
and TGF-3) in humans (Tardif et al., 2004).  Transforming growth factor 
derivatives are produced by the activity of proteolytic enzymes on large proteins 
(Shimasaki and Ling, 1991) and act upon serine/threonine kinase receptors (Type 
I and Type II) in target cells (Lind et al., 1991).  The ligand-receptor interaction 
initiates an intracellular signalling pathway that influences gene expression within 
the nucleus of the cell it is bound to.  This then initiates and promotes the various 
stages of intramembranous and endochondral bone ossification associated with 
fracture healing (Lee et al., 2004).   
 
1.5.3 TGF-Cell Signalling Pathway 
The TGF-β ligand initiates signalling by binding to and bringing together type I 
and II receptor serine/threonine kinases located on the cell surface.  Receptor II is 
then allowed to phosphorylate receptor I kinase domain, which then disseminates 
the signal via phosphorylation of the Smad proteins (Figure 16).  There are eight 
different Smad isoforms, constituting three functional classes; the receptor-
regulated Smad (R-Smad), the Co-mediator Smad (Co-Smad) and the Inhibitory 
Smad (I-Smad).  R-Smads (Smad1, 2, 3, 5 and 8) are phosphorylated and 
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activated directly by the type I receptor kinases and undergo homotrimerisation 
and formation of heteromeric complexes with the Co-Smad, Smad4.  The 
activated Smad complexes are translocated into the nucleus and, in combination 
with other nuclear cofactors, control the transcription of target genes.  The I-
Smad, Smad6 and Smad7, negatively regulate TGF-β signalling by competing 
with the R-Smads for receptor or Co-Smad interaction and by targeting the 
receptors for degradation (Shi and Massague, 2003). 
Figure 16:  TGF-Cell Signalling Pathway 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16:  TGF-β signalling from cell membrane to the nucleus.  The arrows demonstrate signal 
flow.  Orange arrows represents ligand and receptor activation; grey represents Smad and receptor 
inactivation; green arrows, Smad activation and formation of a transcriptional complex; blue 
arrows, Smad nucleocytoplasmic shuttling.  Also depicted are phosphate groups (green circles) 
and ubiquitin (red circles) (Shi and Massague, 2003).  Image reproduced with permission of 
Elsevier. 
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1.5.4 Subtypes of Transforming Growth Factoreta (TGF-) 
In mammalian subjects, there are three subtypes of TGF- that are involved in 
healing; TGF-1, TGF-2 and TGF-3.  These are released by platelets during the 
inflammatory phase of fracture healing; they are also secreted by macrophages, 
monocytes and lymphocytes in normal, non-traumatised tissues.  The TGF-s are 
believed to be involved in the early stages of callus formation (Connor and Evans, 
1982; Kingsley, 1994; Bostrom, 1998).  In addition to platelets and leukocytes, 
TGF- is produced by osteoblasts and chondrocytes and is stored in the bone 
matrix (Lieberman et al., 2002).  It is a ligand that binds to a kinase receptor, 
activating intracellular pathways (Simonsson et al., 2005).  This growth factor is a 
large cytokine that is capable of mobilising acute phase proteins via chemotaxis 
and therefore promotes the proliferation of MSCs, pre-osteoblasts, chondrocytes 
and osteoblasts (Lieberman et al., 2002).  There is an additional influence on the 
production of extracellular proteins such as collagen, proteoglycans, osteopontin, 
osteonectin and alkaline phosphatase (Sandberg et al., 1993; Zimmermann et al., 
2007).   
 
It has been suggested that TGF-2 and TGF-3 have more important roles than 
TGF-1 in fracture healing, as expression of isoforms two and three tend to peak 
during chondrogenesis.  There is a high basal level of TGF-1 in healthy 
diaphyseal bone that remains unchanged in the event of a fracture, possibly 
rendering this type less significant than TGF-2 and TGF-3(Lee et al., 2004).  
Moreover, there is controversy regarding the therapeutic potential for exogenous 
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TGF- in terms of enhancing bone repair (Lieberman et al., 2002; Zimmermann 
et al., 2007). 
 
1.5.5 Bone Morphogenetic Proteins (BMPs) 
Bone morphogenic proteins are pleiotropic morphogens that are capable of 
regulating growth, differentiation and apoptosis of osteoblasts, chondroblasts, 
neural cells and epithelial cells (Sakou, 1998).  The production of BMPs involves 
various ECM-based factors and includes osteoprogenitors, mesenchymal stem 
cells, osteoblasts and chondrocytes; BMPs are essential in fracture healing 
because they elicit a series of events relevant to chondro-osteogenesis.  This 
typically features chemotaxis, mesenchymal (and osteoprogenitor) cell 
proliferation and differentiation (Sammons et al., 2004), angiogenesis and ECM 
synthesis (Prisell et al., 1993; Yu et al., 2010).   There are four subtypes of BMPs, 
categorised according to their primary amino acid sequence and members are 
categorised into groups as follows; 
 
 Group 1: BMP-2, BMP-4, 
 Group 2: BMP-5, BMP-6, BMP-7, 
 Group 3: GDF-5 (BMP-14), GDF-6 (BMP-13), GDF-7 (BMP-12), 
 Group 4: BMP-3 (osteogenin), GDF-10 (BMP-3b)  
 
(Dimitriou et al., 2005) 
 
There is a structural and functional similarity amongst BMPs, although each 
subtype has a unique role within fracture healing.  The BMPs also have an ability 
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to stimulate the synthesis and secretion of other bone repair factors such as 
insulin-like growth factor (IGF) and VEGF (Deckers et al., 2002; Keramaris et 
al., 2008).  It may be worth noting that BMP-1 is not a member of the TGF- 
superfamily.  It is classified as a metalloproteinase that is capable of cleaving the 
BMP-2 antagonist chordin and is involved in the direction of bone and cartilage 
formation in vivo.  It is for this reason that the protein was first thought to behave 
like other BMPs (Nelson et al., 1994; Bond and Beynon, 1995; Wozney, 2002; 
Hartigan et al., 2003).   
Table 6: Temporal and Functional Characteristics of TGF-in fracture 
healing  
 
(Russell et al., 1980; Dong and Canalis, 1995; Cho et al., 2002; Devlin et al., 
2003; Aspenberg, 2013) 
 
TGF- member 
 
Time of expression (from 
point of injury) 
 
Function 
 
 
GDF-8 
 
Day 1 only 
Negative regulator of skeletal 
muscle growth 
 
BMP-2 
 
Day 1 to 21 
Recruitment of MSCs, 
chondrogenesis, role in 
fracture healing cascade, 
regulates expression of BMPs; 
differentiation of MSCs 
 
BMP-3, 8 
 
Day 14 to 21 
 
Regulation in osteogenesis 
 
BMP-4 
 
Day 14 to 21 
Involvement in early stage of 
callus formation 
 
BMP-7 
 
Day 14 to 21 
 
Regulation of ossification 
 
GDF-10 
BMP-5, 6 
 
Day 3 to 21 
Regulation in ossification, 
BMP-6 initiates chondrocytes 
maturation 
 
GDF-5, 1 
 
Day 7 to 14 
GDF-5 involved in 
chondrogenesis; Stimulation of 
MSC aggregation, 
angiogenesis, chemotaxis, 
degradation of matrix proteins 
TGF-1 
TGF-2 
TGF-3 
Day 1 to 21 
Day 3 to 14 
Day 3 to 21 
Chemotactic for bone forming 
cells and macrophages; 
proliferation of MSC, 
osteoblasts, chondrocytes 
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1.5.6 Metalloproteinases and Angiogenesis 
 
Successful bone repair requires sufficient blood flow to the injury site.  In the final 
phases of bone healing, there is endochondral ossification and bone remodelling.  
During this remodelling phase, matrix metalloproteinases degrade cartilage and 
bone, allowing for the permeation of blood vessels.  The VEGF-dependent and 
angiopoietin-dependent pathways are believed to be mediators in angiogenesis 
and are, therefore, highly active in the fracture repair process (Gerstenfeld et al., 
2003).  There are two forms of angiopoietin; angiopoietin I and II, both of which 
are regulatory vascular morphogenic molecules related to the formation of larger 
vessels and development of collateral branches of existing vessels.  Exogenous 
administration of VEGF has been shown to improve fracture repair (Street et al., 
2002; Keramaris et al., 2008). 
 
1.5.7 Growth Factors 
The term ‘growth factor’ applies to a group of proteins, weighing between 4 and 
60 kDa that are capable of stimulating cellular proliferation and cellular 
differentiation.  Growth factors are vital for regulating a variety of cellular 
processes and act as cell signalling molecules.  Examples are cytokines and 
hormones that bind to specific receptors on the surface of their target cells.  They 
promote cell differentiation and maturation, which varies between different 
growth factors.  For example, bone morphogenetic protein (BMP) stimulates bone 
cell differentiation, while vascular endothelial growth factor (VEGF) stimulates 
blood vessel formation and differentiation.  For the circulatory system and bone 
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marrow in which cells are free and unbound, it is preferable for them to 
communicate by soluble, circulating protein molecules (Cross and Mustoe, 2003).   
While ‘growth factor’ implies a positive effect on cell size, ‘cytokine’ is perhaps a 
neutral term with reference to whether a molecule affects proliferation.  In this 
sense, some cytokines can be growth factors, such as granulocyte colony 
stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor 
(GM-CSF).  However, some cytokines have an inhibitory effect on cell growth or 
proliferation.  Yet others, such as Fas ligand, are used as ‘death’ signals, as they 
cause target cells to undergo apoptosis.  Cytokines can affect cellular function 
through endocrine, paracrine, autocrine and intracrine mechanisms (Cross and 
Mustoe, 2003; Goldman, 2004). 
Individual growth factor proteins tend to be derivatives of members of larger 
families of structurally and evolutionary-related proteins.  There are many growth 
factor families, e.g.,  VEGF, transforming growth factor-beta (TGF-) (of which 
BMP is a member), neurotrophins (nerve growth factor (NGF), brain-derived 
neurotrophic factor (BDNF) and neurotrophin3 (NT3)) and fibroblast growth factor 
(FGF) (Shimasaki and Ling, 1991; Beer et al., 2000; Cross and Mustoe, 2003). 
Most growth factors are derived from larger proteins that have been the focus of 
post-translational modification before being expressed in an active state.  Growth 
factor receptors are transmembrane glycoproteins that are activated through 
tyrosine kinase enzyme and phosphorylation reactions, as illustrated in Figure 16 
(Bennett and Schultz, 1993; Shi and Massague, 2003). 
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Table 7: Growth Factors of the Immune System 
 
 
 
 
.   
 
GROWTH FACTOR 
 
 
FUNCTION 
Vascular Endothelial Growth 
Factor (VEGF) 
Mitogen for vascular endothelial cells in angiogenesis (Petreaca 
et al., 2008). 
Transforming growth factor 
beta (TGF-)  
Mitogenic or antiproliferative depending on cell type; regulates 
ECM formation.  Anti-inflammatory effect in healing 
(Frangogiannis, 2008). 
Granulocyte-colony 
stimulating factor (G-CSF)  
Proliferation/differentiation stimulator in neutrophils and 
granulocytes (Seshadri et al., 2008).  
Granulocyte-macrophage 
colony stimulating factor 
(GM-CSF) 
Pleiotropic stimulator and activator of granulocyte and 
monocyte proliferation (Sugano et al., 2005). 
Nerve growth factor (NGF)  Differentiation of sensory, cholinergic and sympathetic neurons 
(Madduri et al., 2009). 
Neurotrophins (NT-3, 4, 5 & 
6)  
Differentiation/survival of sensory neurons (Madduri et al., 
2009). 
Platelet-derived growth 
factor (PDGF)  
Mitogenic and differentiating activity in endothelial cells and 
neurons (Lin et al., 2009). 
Erythropoietin (EPO)  Stimulates proliferation of erythroid progenitors; induces 
haemoglobin production (Sorg et al., 2009). 
Thrombopoietin (TPO)  Promotes megakaryocyte development (Huang et al., 2009). 
Transforming growth factor 
alpha (TGF-) 
Mediator of bone resorption and wound healing (Leker et al., 
2009). 
Epidermal growth factor  Mitogenic and differentiating in many cell types (Borisov et al., 
2009) 
Basic fibroblast growth 
factor (bFGF or FGF2)  
Mitogenic activity in embryonic and adult tissues and tumour 
cells (Sun et al., 2009). 
Insulin-like growth factor  Mediator of growth hormone activity and cell development 
(Steigen et al., 2009). 
Hepatocyte growth factor 
(HGF) 
Mitogenic activity in hepatocytes.  Stimulator of motility and 
matrix invasion of epithelial cells (Liu et al., 2006). 
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1.5.8 Platelet-Derived Growth Factor (PDGF) 
Platelet derived growth factor (PDGF) is a dimeric polypeptide composed of  
and  chains; it is a ligand of the tyrosine kinase receptor and its binding is 
affected by IL-1, TNF- and TGF-1 (Solheim, 1998).  It is chemotactic for 
MSCs and is synthesised by platelets, monocytes, macrophages, endothelial cells 
and osteoblasts (Andrew et al., 1993).  There are potentially beneficial clinical 
implications for PDGF and Nash et al., (1994) showed that PDGF increased callus 
density and volume in the tibial fractures of rabbits (Nash et al., 1994; Tsiridis et 
al., 2007). 
 
1.5.9 Fibroblast Growth Factor (FGF) 
 
There are nine structurally-related polypeptides of the FGF family, which are 
bound to the tyrosine kinase receptor.  In normal adult tissue, FGFs are both 
acidic and basic in nature and there are varying degrees of potency between 
members.  In fracture healing, FGFs are synthesised by monocytes, macrophages, 
MSCs, osteoblasts and chondrocytes.  The growth and differentiation of all of 
these factors are further promoted by FGFs (Zimmermann et al., 2007; Jemal et 
al., 2008).   
 
Fibroblast growth factors are active in the initial period of bone repair and are 
therefore crucial in angiogenesis and MSC mobilisation.  There is also an 
instrumental involvement in chondrocyte proliferation and maturation and 
evidence suggests that FGF can have an advantageous influence on callus size 
(Matzuk et al., 1995; Lieberman et al., 2002; Gerstenfeld et al., 2006).  
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1.5.10 Insulin-Like Growth Factors (IGFs) 
 
Also known as somatomedin-C, IGF-I and IGF-II originate from endothelial cells, 
osteoblasts and chondrocytes.  Serum concentrations of these growth factors are 
chiefly regulated by growth hormone and their biologic actions are controlled via 
the cellular mechanisms of IGF binding proteins (IGFBPs) (Shimasaki and Ling, 
1991; Solheim, 1998; Lieberman et al., 2002).  Insulin-like growth factor 
encourages bone matrix formation by mature osteoblasts and is more potent than 
the IGF-II isomer.  The latter becomes active at a later stage of endochondral bone 
formation and promotes type I collagen production, cartilage synthesis and cell 
proliferation (Prisell et al., 1993; Gerstenfeld et al., 2003). 
 
1.5.11 Colony Stimulating Factor (CSF) 
 
Colony stimulating factor (CSF) is a member of a group of cytokines that 
stimulate wound-healing.  Macrophages secrete CSF-1, an autocrine mediator, in 
order to ‘reproduce’ itself in an act of ‘self-preservation’.  The macrophage 
releases granulocyte-macrophage CSF, which has chemotactic, as well as cellular 
proliferation and activation abilities (Tsiridis et al., 2007).   
 
1.5.12 Chemokines 
Chemokines represent a subdivision of cytokines that are soluble proinflammatory 
mediators capable of attracting and activating leukocytes.  They are subdivided 
into four families depending on their specific amino acid formation at the first two 
cysteine residues closest to the N terminus.  This factor is important in that the 
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different cysteine patterns are chemoattractive to different classes of leukocytes 
(Luster, 1998; Broughton et al., 2006; Heo et al., 2011).  
 
1.5.13 Lymphokines and Monokines 
 
Lymphokines are a subset of cytokines that are produced by activated T 
lymphocytes.  Monokines are produced by mononuclear phagocytes.  Interleukins 
represent a group of cytokines that were thought to be secreted by one type of 
leukocyte that acts upon a different type of leukocyte.  All of these cytokines are 
expressed by non-haematopoietic cells, or MSCs, providing a range of biological 
functions.  The interleukin (IL) numbering system was devised in 1978 and ranges 
from IL-1 to IL-36 (Oppmann et al., 2000; Kleiner et al., 2013).   
 
1.5.14 Eicosanoids 
 Eicosanoids are signalling molecules that originate from omega-3 (ω-3) and 
omega-6 (ω-6) essential fatty acids.  They exert important control of inflammation 
and immunity and are also cell messengers of the central nervous system (CNS).  
They are a superfamily of biologically active compounds derived from the 
oxygenation of arachidonic acid.  Specific (and non-specific) stimuli, such as 
cellular damage, free radicals or osmotic stress, cause the release of phospholipase 
A2 (PLA2) (Boyer et al., 1995; Thoroed et al., 1997).  At the cell membrane, PLA2 
hydrolyzes arachidonic acid (generally phosphatidylcholine) to produce 
arachidonate metabolites.  Following this specialised cleavage step, arachidonic 
acid is swiftly re-esterified into membrane lipids or is bound by intracellular 
proteins, rendering it unavailable for additional metabolism (Raikin et al., 1998).  
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In the event that arachidonic acid avoids re-esterification, it becomes freely 
available as a substrate for further enzymatic conversion.   The reaction results in 
the addition of oxygen atoms at varying sites of the fatty acid backbone, giving 
rise to biologically active eicosanoids (Fitzpatrick and Soberman, 2001; Kalish et 
al., 2013). 
 
There are four families of eicosanoids; prostaglandins, prostacyclins, 
thromboxanes and leukotrienes (Soberman and Christmas, 2003).  The 
prostaglandins (PGs) are mediated by cyclooxygenase 1 and 2 (COX-1 and COX-
2) and exist as a series of isoforms; PGD, PGE, PGF, PGG and PGH, with a 
subscripted numeral that designates the number of double bonds within the 
compound (Smith, 2013).  The PGs most relevant in inflammation are the 
prostacyclins PGE2, PDG2, PGF2-, PGI2 and thromboxane A2 (TxA2); each is 
formed by the activity of a specific enzyme.  Thromboxane A2 is the major 
product formed by platelets and is both an effective platelet-aggregating agent and 
vasoconstrictor; it is unstable and is rapidly converted to its inactive form, 
thromboxane B2 (TxB2), a metabolite and not involved in platelet aggregation 
(Mayer et al., 2005).   Prostacyclin synthase, which can be located in the 
endothelium, is able to assist with the formation of PGI2 and the more robust 
isoform, PGF1-.  Prostacyclin is a vasodilator that inhibits the aggregation of 
platelets; it is also capable of increasing the chemotactic capacity of other 
inflammatory mediators (Tilley et al., 2001; Kalish et al., 2013). 
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1.5.15 Prostaglandins 
The prostaglandins contribute to the pathogenesis of inflammatory pain (dolor), 
redness (rubor) and fever (calor).  Prostoglandin E2 (also known as dinoprostone) 
causes hyperalgesia of the skin, due to suboptimal concentrations of intradermal 
histamine and bradykinin.  It causes softening of the cervix and stimulates uterine 
contraction during labour and is also known to motivate the release of certain 
factors by osteoblasts, which in turn promote bone resorption by osteoclasts.   
There is a febrile cytokine interaction with PGE2 to promote fever in the event of 
infection.  The prostaglandins PGE2, PGD2 and PGF2 are the primary metabolites 
of the cyclooxygenase pathway in mast cells, causing vasodilatation and oedema 
formation (Dray, 1995; Nelson et al., 2013). 
 
1.5.16 Lipoxins 
 
First described by Serhan et al (1984), lipoxins are anti-inflammatory lipid 
mediators generated from arachidonic acid; transcellular biosynthesis involving 
platelets and leukocytes is essential for their formation (Serhan et al., 1984).  
Platelets can form lipoxins from neutrophil-derived intermediates.  For example, 
lipoxins A4 and B4 (LXA4, LXB4) are formed by the action of platelet 12-
lipoxygenase on leukotriene A4 (LTA4) in neutrophils (Kilfeather, 2002).  Lipoxin 
production is inhibited by blocking cellular adhesion, but augmented by intricate 
cell-to-cell contact.  This eicosanoid is capable of evoking both pro-inflammatory 
and anti-inflammatory processes.  There is a tendency of lipoxins to inhibit 
chemotaxis and adhesion in neutrophils, but to cause cellular adhesion in 
monocytes (Maddox et al., 1998; Chinthamani et al., 2012).  
                                                                                                               Introduction 
65 
1.5.17 Interferon (IFN) 
The interferon (IFN) group is made up of three subtypes; IFN-, IFN- and IFN-
.  Each group is named according to their capability to ‘interfere’ with viral 
proliferation and survival.  Interferon-alpha, for example, is mainly produced by 
monocytes, macrophages, B lymphocytes and natural killer (NK) cells.  It is 
capable of limiting viral replication within virus-infected cells, preventing 
contamination of uninfected cells and stimulates anti-viral immunity from 
cytotoxic lymphocytes and NK cells.  Also stimulated are antigen-presentation, 
cytokine production by monocytes as well as monocyte effector functions such as 
adherence, phagocytosis and nitric oxide (NO) production.  There is a net 
accumulation of macrophages, in addition to an increase in the destruction of 
intracellular pathogens.  Interferon-gamma also promotes killing by activating NK 
cells and neutrophils and by stimulating the adherence of granulocytes to 
endothelial cells via the recruitment of intracellular adhesion molecules, an action 
that is also undertaken by IL-1 and tumour necrosis factor-alpha (TNF-)  (Farrar 
and Schreiber, 1993; Franceschetti et al., 2009).  
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1.6 INHIBITORY MOLECULES INVOLVED IN FRACTURE 
HEALING 
There are various inhibitory molecules that are capable of regulating certain 
biochemical pathways involved in bone regeneration, maintenance of adult tissues 
and embryonic development.  The inhibition of cellular processes incorporates 
negative feedback loops and crosstalk that will decrease the exposure of cells to 
signalling molecules, thus affecting their behaviour.  Inhibition can take place at 
any stage of the cascade, whether in the ECM or at the cellular level in the cell 
membrane, the cytosol or in the nucleus.  The fact that inhibition can feature at 
any stage of the cascade reflects the complexity of signalling regulation that is 
involved in fracture healing (Dimitriou et al., 2005).  Signalling molecules 
regulate the progression of endochondral and intramembranous bone regeneration 
and achieve this by recruiting undifferentiated MSCs and osteoprogenitor cells 
before inducing their differentiation and subsequent proliferation into osteoblasts 
(Dimitriou and Giannoudis, 2013).  
 
1.6.1 Extracellular Matrix Inhibition 
At the ECM level, various molecular inhibitors target BMPs and therefore are 
termed ‘BMP antagonists’.  The antagonists that exist in the extracellular 
compartment become specifically bound to BMPs, altering certain developmental 
and cellular processes.  Specific antagonistic molecules are released into the ECM 
by osteoblasts, the stimulation of which is increased on exposure to BMPs.  This 
is due to the presence of local autoregulatory feedback mechanisms that occur 
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during injury, involving the rapid appearance of BMPs at the fracture site (Tsiridis 
et al., 2007).   
1.6.2 Noggin 
The secreted protein noggin binds exclusively to BMP-2, -4, -5, -6 and -7 and also 
GDF-5 and -6.  The binding of noggin prevents the bound BMPs interacting with 
their respective cellular receptors (Gazzerro et al., 1998; Aspenberg, 2013).   
Osteoblasts express noggin in response to high levels of BMP in the ECM, 
reducing the effects of BMPs on osteoblastic differentiation and function 
(Gazzerro et al., 1998; Devlin et al., 2003).  The exogenous administration of 
BMP-2 counteracts this process by inhibiting the actions of noggin, thus 
increasing osteoblastogenesis and optimising the regulation of callus formation.  
Experimentally, the addition of noggin antibody (and ultimately its inhibition) can 
also promote osteoblastogenesis.  Indeed, the balance of noggin and another BMP 
subtype, BMP-4, is important in the regulation of the callus formation in fracture 
repair and is vital in certain other adult biological processes, including the 
formation of joints (Russell et al., 1980; Yoshimura et al., 2001; Tsiridis et al., 
2007).    
 
Mammalian in vivo studies, concerning the role of noggin in terms of skeletal 
function, found that transgenic mice over-expressing the noggin gene (NOG, 
locus 17q22) were susceptible to fractures in the developmental stages following 
birth.  This was consistent with a low bone mass, osteopenia and abnormal 
osteoblastic function.  Humans with NOG mutations can present frank skeletal 
and joint impairment, whilst NOG knockout mice die shortly after birth and have 
dense, deformed long bones, implicating the mediatory role of noggin  (Brunet et 
                                                                                                               Introduction 
68 
al., 1998; Devlin et al., 2003).  The rare genetic bone disease fibrodysplasia 
ossificans progressiva (FOP) is characterised by abnormal hallux development 
and progressive heterotopic endochondral ossification of the muscles.  This 
disorder is due to a lack of expression of the NOG gene (Fontaine et al., 2005). 
1.6.3 Chordin 
The antagonist chordin (Chd) binds with BMP-2, BMP-4 and BMP-7 in a similar 
way to noggin, thereby antagonising the actions of BMP by blocking the binding 
action to its receptors.  Chordin also has a role in embryonic development, 
especially in skeletogenesis, as high levels are expressed in cartilage and in the 
epiphyseal regions of developing long bones (Bostrom, 1998; Balemans and Van 
Hul, 2002; Yang et al., 2013).  Expression of Chd in vitro has been found to be 
inversely related to chondrocyte maturation and differentiation due to BMP 
inhibition and is considered to be a negative regulator of endochondral 
ossification.  The secreted protein twisted gastrulation (TSG) is a cofactor that 
attaches to Chd, thus facilitating the inhibition of BMPs by sensitising binding.  
Twisted gastrulation can also act as an independent inhibitor and levels are 
highest in the early stages of osteoblast differentiation (the preosteoblast stage) 
(Oelgeschlager et al., 2003; Petryk et al., 2005).  
 
1.6.4 Gremlin 
Gremlin (GREM1, locus 15q11-13; GREM2 locus 1q43), another BMP 
antagonist, behaves in a similar way to chordin and noggin in that it directly binds 
to BMP-2, BMP-4 and BMP-7, blocking their receptor interactions.  It is a 
member of the ‘differential screening-selected gene aberration in neuroblastoma’ 
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(DAN) protein family.  These proteins have an important role in skeletal function 
(Balemans and Van Hul, 2002).  Gremlin has an effect on bone remodelling.  In 
vivo studies involving transgenic mice over-expressing this protein exhibited a 
decreased body size, spontaneous bone fractures, modelling defects of long bones 
and severe osteopenia.  A non-expression of the gremlin gene (known as a 
homozygous null mutation) in mice resulted in high BMP activity, which was 
shown to cause profound limb deformity in growing long bones.  In in vitro 
studies, gremlin has been shown to inhibit BMP-induced osteoblastic 
differentiation (Le Blanc et al., 2003; Gazzerro et al., 2005).    
 
1.6.5 Sclerostin 
Sclerostin (SOST, 17q12-21) is a novel member of the DAN family that is 
specifically expressed by osteocytes and competes with BMP-2, -4, -6 and -7 in 
binding to their receptors (Kusu et al., 2003).  The inhibitory actions of sclerostin 
decrease the activity of osteoblasts, MSC proliferation and osteoprogenitor 
differentiation.  It also has a role as a mediator of osteoblast survival and provides 
a significant level of regulation of bone formation by stimulating apoptosis, 
remodelling and repair (Sutherland et al., 2004).   Genetic mutations in the 
sclerostin gene give rise to a disorder known as sclerosteosis, which is 
characterised by serious lifelong bone overgrowth (Balemans and Van Hul, 2004).   
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1.6.6      Follistatin 
Follistatin (FST 5q11.2) has a high affinity in binding BMP-7, but also binds 
BMP-2, -4 and -15, forming trimeric complexes (Fainsod et al., 1997; Otsuka et 
al., 2001).   It has potent inhibitory mechanisms during embryogenesis and 
knockout mice devoid of this gene die soon after birth and display skeletal 
abnormalities (Matzuk et al., 1995).  Along with gremlin, follistatin is upregulated 
in osteoarthritic (OA) chondrocytes, implicating their pathologic involvement 
within this disease (Tardif et al., 2004).    
 
1.6.7       Anti-Inflammatory Effects of BMP-3 
Bone morphogenetic protein 3 is the most abundant BMP found in adult bone and 
is a known antagonist of osteogenic BMPs, specifically BMP-2.  It has been 
shown to induce osteogenic differentiation in vitro and to negatively regulate bone 
density in vivo (Daluiski et al., 2001).  Mutations in the gene for BMP-3 (BMP3 
4q21.1 – 4q21.23) are associated with FOP (Schmitt et al., 1999; Le Blanc et al., 
2003).   
 
1.6.8 Inhibition at the Cell Receptor Level 
The antagonistic mechanisms concerning inhibition at the receptor level involves 
targeting the signalling pathway of the members of the BMP and TGF- 
superfamily, including activin.  The pseudo-receptor BAMBI (BMP and activin 
membrane bound inhibitor) is structurally related to BMP receptors in the 
extracellular domain, but not the intracellular domain, preventing further 
signalling within the cells (Onichtchouk et al., 1999; Le Blanc et al., 2003). 
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1.6.9 Inhibition of Intracellular Processes 
The following table summarises some of the proteins that are considered to be 
intracellular inhibitors that regulate various signalling pathways in respect of 
fracture healing. 
 
Table 8: Intracellular Inhibitors 
 
 
Inhibitor 
 
 
Types 
 
Actions 
Inhibitory I-Smad 
 
SMAD-6, SMAD 7 Inhibition through activation 
of type-I BMP receptors, 
reduces transcriptional activity 
Smurfs (smad ubiquitin 
regulatory factor) 
 
Smurf-1, Smurf-2 Inhibits BMP by degrading 
receptor molecules in 
signalling pathway 
Tob 
 
_ Anti-proliferative protein 
 
CIZ 
 
_ Inhibits BMP/Smad signalling 
pathway 
Cytokines 
 
Osteoprotegrin (OPG) 
Il-1 receptor antagonist (IL-
1Ra) 
Inhibits biological effects of 
specific cytokines.  OPG 
inhibits bone resorption and 
induces apoptosis.  IL-1Ra 
inhibits biological activity of 
IL-1. 
Insulin-like growth factor 
binding proteins (IGFBPs) 
ILGFBP-(1 – 6) Modulates availability and 
stability of IGF through 
binding (receptor inhibition)  
 
(Hata et al., 1998; Schmidmaier et al., 2000; Itoh et al., 2001; Murakami et al., 
2003; Kwan Tat et al., 2004) 
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1.6.10 Clinical Applications in Trauma 
Statistics from the United States report that, in 1992, between 5-10% of the 6.2 
million fractures resulted in either delayed healing or nonunion.  Research has 
focused on several biological treatments for bone regeneration and fracture repair, 
highlighting, in particular, the usefulness of BMP on open tibial fractures (Riedel 
and Valentin-Opran, 1999).  Indeed, the work carried out by Govender et al. 
(2002) demonstrated effective reliability of the recombinant (rh) BMP-2 in 
fractures, reporting a higher union rate, accelerated time to union, improved 
wound healing and reduced infection rate (Govender et al., 2002).  Other studies 
have found similar robustness with BMP-7 (Geesink et al., 1999; Friedlaender et 
al., 2001); both are now available as treatments for delayed healing, 
demonstrating the excellent osteoinductive properties of this growth factor 
(Dimitriou et al., 2005). 
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1.7 THE TOXICOLOGICAL ASPECTS OF TOBACCO SMOKING 
There are thought to be around 1.3 billion smokers globally and it is estimated that 
this results in 6 million deaths worldwide annually.  Cigarette smoking has 
become the single most avoidable cause of morbidity and mortality and it is 
expected that 1 billion people will die as a result of smoking in the 21
st
 century  
(Wipfli and Samet, 2009).  In the United Kingdom in 2004, 25% of adults 
smoked, according to the Office for National Statistics (Gruer et al., 2009).  
Orthopaedic surgeons have long known about the complications of smoking that 
can harmfully influence the dynamics of bone healing  (Porter and Hanley, 2001).  
The damaging effects of tobacco smoke are dose-related and as such are perhaps 
reversible by cessation.  However, the habit is very addictive and many people 
who take up smoking before they reach twenty years of age continue to smoke for 
many years, often up until death (Bartecchi et al., 1994).  The musculoskeletal 
effects may become more apparent as treatments for smoking-related conditions 
become more effective and individuals survive longer (Capewell et al., 2009). 
 
The adverse effect of smoking on healing has been the basis of numerous clinical 
studies since Mosely and Finseth found that cigarette smoking had a deleterious 
effect on the healing of hand wounds in 1977 and there is a strong association 
with cardiovascular and respiratory diseases (Mosely and Finseth, 1977; Rees et 
al., 1984; Riefkohl et al., 1986; Kroll, 1994).  Research findings have suggested 
that nicotine and related chemicals in cigarette smoke can also impair the 
regeneration of healing wounds and soft tissue in limbs following fracture injury, 
thereby decreasing the quality of postoperative outcomes and prolonging healing 
times (Nolan et al., 1985; Netscher and Clamon, 1994; Pitts et al., 1999).   
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1.7.1 The Constituents of Cigarette Smoke 
Two types of cigarette smoke exist, ‘mainstream’ smoke and ‘sidestream’ smoke.  
The former is inhaled by the smoker from the filter-tip end of the cigarette; the 
latter is the smoke that is released into the local environment from the burning end 
of the cigarette.  The mainstream smoke is rich in reactive oxygen species (ROS) 
and reactive nitrogen species (RNS), termed ‘free radicals’, both of which can 
cause cellular damage (and/or death) via oxidative stress processes (Pryor, 1997; 
Comhair and Erzurum, 2002).  Approximately 2-3 mg of nicotine and 20-30 mL 
of carbon monoxide are inhaled from each cigarette, depending on the brand and 
tar content (Sherwin and Gastwirth, 1990).  The toxins that are implicated in the 
cardiovascular morbidity found in cigarette smokers are also responsible for the 
damage inflicted on the musculoskeletal system (Toyooka and Ibuki, 2009). 
 
Both types of cigarette smoke consist of volatile acids, known as the volatile 
phase and also complex compounds of particulate matter, known as the 
particulate phase.  The volatile phase is larger and accounts for 95% of the 
cigarette smoke; in this phase, approximately 500 different gases are released, 
including nitrogen (N2), carbon monoxide (CO), carbon dioxide (CO2), ammonia 
(NH3), hydrogen cyanide (HCN) and benzene (C6H6).  Around 3500 chemicals are 
produced during the particulate phase and include nicotine (C10H14N2), anatabine 
(C10H12N2) and anabasine (C10H14N2) (Figure 17) (Hoffmann and Hoffmann, 
1997).  The tar, which is produced when the particulate matter loses water, 
contains the carcinogens in cigarette smoke (Zevin et al., 1998). Hydrogen 
cyanide is a noxious gas that is found  in the bloodstream of smokers; its primary 
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effect is at the cellular level, disrupting enzymatic oxidative metabolism 
(Whiteford, 2003). 
 
Figure 17: The Chemical Structures of Nicotine, Anatabine and Anabasine 
 
            
 
 
      Nicotine (C10H14N2)              Anatabine (C10H12N2)   Anabasine (C10H14N2) 
 
(Hukkanen et al., 2005) 
1.7.2 Nicotine 
Regarded as the addictive component in tobacco, nicotine has been shown to 
increase platelet aggregation, decrease microvascular prostacyclin levels and 
inhibit the biological function of fibroblasts, red blood cells and macrophages.  It 
is a toxic alkaloid that becomes bound to nicotinic acetylcholine (ACh) receptors.  
The mechanism of action is complex and the drug serves as both a ganglionic 
depressant and stimulant; catecholamine levels in the bloodstream become 
increased, promoting the formation of chalones as the cigarette is smoked.  This 
process stimulates cardiac output and causes adrenergic vasoconstriction.  The 
chalones also inhibit epithelialisation, undermining the healing process 
(Lefkowitz, 1976; Waeber et al., 1984; Winniford et al., 1986; Cobb et al., 1994; 
Al-Hadithy et al., 2012).   
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Nicotine decreases blood flow to the extremities due to the increased peripheral 
vasoconstriction, especially relating to digital and forearm haemodynamics 
(Bornmyr and Svensson, 1991).  Indeed, smoking just 2 cigarettes was found to 
decrease blood flow to the hand by 29 % (van Adrichem et al., 1992).  Nicotine 
also influences blood coagulation by increasing platelet aggregation, causing the 
sludging of blood in the small vessels and a generalised reduction in 
microvascular perfusion (Mosely and Finseth, 1977).  Blood viscosity and 
fibrinogen levels are both raised, inducing a state of hypercoagulation, thus, 
increasing the risk of polycythaemia and microvascular clotting (Folsom, 1995; 
El-Zayadi et al., 2002; Balaji, 2008).   
 
Nicotine has a significant and wide ranging effect on plasma hormone levels; 
vasopressin, B-endorphin, adrenocorticotropic hormone (ACTH) and cortisol are 
all raised in the circulation of smokers (Seyler et al., 1984; Seyler et al., 1986).  
At the cellular level, nicotine damages osteoblasts, fibroblasts and macrophages 
(de Vernejoul et al., 1983; Nolan et al., 1985; Sherwin and Gastwirth, 1990; Fang 
et al., 1991).  There is an increased risk of atherosclerosis due to the damage 
caused to the vascular endothelium  by the toxins inhaled with smoking (Krupski, 
1991; Balaji, 2008). 
 
1.7.3 Carbon Monoxide 
Carbon monoxide has a 200-fold greater affinity for haemoglobin binding than 
oxygen, which reduces O2 tension in tissues (Jorgensen et al., 1998; Leow and 
Maibach, 1998).  The toxic gas arises as a consequence of incomplete paper and 
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tobacco combustion, forming carboxyhaemoglobin as it binds preferentially with 
the haemoglobin molecule.  Cigarette smoke is known to contain 2-6% CO and 
can convert up to 15% of haemoglobin into carboxyhaemoglobin.  The formation 
of carboxyhaemoglobin (as opposed to oxyhaemoglobin) attenuates O2 transport 
and dissociation, resulting in hypoxia (Rees et al., 1984; Nolan et al., 1985; 
Barnoya and Glantz, 2005).  Ten minutes of smoking has been shown to reduce 
tissue O2 tension in tissues for 1 hour and a regular smoker consuming 20 
cigarettes per day, therefore, is tissue-hypoxic for 20 hours each day (Sorensen et 
al., 2009). 
1.7.4 Cigarette Smoking and Cellular Damage 
Mesenschymal stem cells, fibroblasts, acute-phase proteins and growth factors are 
crucial mediators of fracture repair and become exposed to the circulating 
components that are present in the bloodstream associated with cigarette smoking 
(Czernin and Waldherr, 2003).  The adverse effects can be seen in the skin of 
chronic smokers who develop a loss of dermal elasticity, which arises because of 
abnormal fibroblast function (Frances et al., 1991).  Patients who smoke are 
advised by their surgeon not to do so perioperatively, not only to improve lung 
and cardiovascular function, but also to optimise the healing process (Akoz et al., 
2002).  The morbidity associated with tobacco smoke inhalation presents 
challenges in terms of defective healing and also over-healing, which are not 
limited to merely cosmetic problems; a systemic underlying impediment is 
believed to exist (Siana et al., 1989; Sorensen et al., 2002; Sloan et al., 2010). 
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Mesenchymal stem cells and fibroblasts are key producers of cytokines that are 
instrumental in the induction of the initial inflammatory response and have an 
important role in the formation of granulation tissue in bone healing.  
Chemokines, for example, which are vital in attracting neutrophils and other 
leukocytes to the wound area, are secreted by MSCs and fibroblasts (Wong and 
Martins-Green, 2004).   
 
Successful fracture repair is highly dependent on tightly-controlled mechanisms 
that are directly involved in the expansion of fibroblast-rich granulation tissue.  
Severe consequences can arise if this process is deregulated and an excessive 
fibrotic reaction and impaired healing can ensue.  Cigarette smoking is thought to 
influence and exacerbate these pathobiological processes (Gabbiani, 2003; Wong 
and Martins-Green, 2004; Patel et al., 2013) .   
 
Reactive oxygen species produced by smoking have an effect on mitochondrial 
morphology, but the specific mechanisms influencing this are not clear.  The best 
studied catalyst for mitochondrial fission, however, implicated the dynamin-like 
protein-1, which has been shown to cause aberrant mitochondrial morphology, or 
‘punctuated’ mitochondria, under environmental stress (Smirnova et al., 1998; 
Pitts et al., 1999; Frank et al., 2001).  
 
The precise biological effects of cigarette smoke on cells remain largely unknown 
due to a lack of scientific research in this area.  However, Wong and Martins-
Green (2004) found that non-lethal levels of mainstream whole smoke (MSW) led 
to the inhibition of fibroblast migration, which is a vital aspect of the healing 
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process.   This study concentrated on fibroblast cells explanted and cultured from 
chicken embryos and it was discovered that even moderate levels of nicotine, 
whilst not in sufficient quantities to kill cells, did have a serious effect on them.  
Indeed, modest doses of MSW can affect ATP production by primary fibroblasts, 
stimulating the production and activation of stress response proteins that are 
recognised as survival factors.  Survival factors increase cell lifespan, inhibiting 
apoptosis.  They have been shown to result in the accumulation of fibroblasts and 
consequently a build-up of connective tissue, leading to excessive and detrimental 
healing, fibrosis and scarring of tissues (Wong and Martins-Green, 2004).  
Sustained stimulation of survival factors has implications for diseases such as 
cancer and fibrosis and levels of the p53 and p21 protein become increased, 
allowing cells to repair their DNA during cell cycle arrest (Helt et al., 2001; 
Whyte et al., 2002; Patel et al., 2013).   
 
Cigarette smoke disrupts the microtubule arrangement in fibroblasts that can 
disrupt effective healing.  Microtubules are major cytoskeletal elements that are 
involved in the transportation of signalling molecules and organelles to different 
parts of the cell, enabling them to carry out their tasks effectively.  The effect of 
smoking on microtubule organisation impinges on mitochondrial function, since 
mitochondria are located along these microtubules, as opposed to being randomly 
distributed throughout the cell.  Therefore, changes in microtubule structure are 
likely to affect the distribution and morphology of these organelles.  A disordered 
microtubule function can also contribute to mitochondrial fragmentation and 
accumulation in the perinuclear region.  This can inevitably give rise to a reduced 
amount of ATP production (Hollenbeck, 1996; Rinker, 2013). 
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A principal function of fibroblasts in the healing process is migration into the 
wound area in order to secrete growth factors and cytokines and to deposit and 
remodel the ECM.  A disruption to this process will give rise to poor healing and 
can lead to chronically unhealed  wounds in the patient and is a common problem 
associated with smoking (Wong and Martins-Green, 2004).   
 
1.8 CIGARETTE SMOKING AND FRACTURE HEALING 
Over one million fractures are sustained each year in the United Kingdom (3.6 per 
100 people per year) and 5% to 10% are reported not to heal satisfactorily.  The 
prevalence of lifetime fracture is over 50% in middle-age men and 40% in women 
aged over 75.  Fracture is less common in non-white population and this is seen in 
the majority of black and minority ethnic groups, as reported in the literature 
(Donaldson et al., 2008).  It is imperative that the orthopaedic surgeon is aware of 
the likely factors that are associated with impaired healing of bone, so that they 
may be avoided whenever practicable.   There are numerous theories as to how 
smoking can impact on the fracture healing process and include a reduced blood 
supply to the injury site, high levels of reactive oxygen intermediates in the 
circulation, low levels of antioxidants and vitamins and the attenuating effect 
nicotine has on endothelial nitric oxide synthase (eNOS).  There are also findings 
that high doses of nicotine, associated with cigarette smoking, are toxic to 
proliferating osteoblasts and calcitonin (Gaston and Simpson, 2007; Lee et al., 
2013).  The role of the hormone calcitonin opposes that of PTH and is crucial in 
regulating levels of circulatory Ca
2+
 in the blood.  Smoking is said to increase 
levels of calcitonin, which in turn lowers calcium levels, making it less available 
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for bone formation in fracture healing (d'Herbomez et al., 2007).  Bone health is 
compromised by cigarette smoke and is well known to contribute to accelerated 
osteoporosis and femoral osteonecrosis in men as well as women (Wright, 2006).  
However, female smokers were found to commence menopause two years earlier 
than non-smoking women, presenting a greater risk for osteoporosis (Baron, 
1984).  Fracture rates in smokers tend to be higher due to increased skeletal 
fragility and higher rates of accidents; work-related injuries and automobile 
collisions are also more common in smokers.  The explanation as to why smokers 
are more at risk of injury is unclear, although general weakness, inferior balance 
and poorer neuromuscular function have been identified as possible reasons (Kyro 
et al., 1993; Nelson et al., 1994; Sacks and Nelson, 1994; Porter and Hanley, 
2001). 
The adverse effects of smoking on fracture healing were reported by Whitesides et 
al. (1994) in patients that underwent spinal fusion (spondylosyndesis or 
arthrodesis), with smokers generally having a higher rate of pseudoarthritis than 
the non-smoking control groups (40% vs. 8%), which was supported in another 
study that showed smokers who underwent instrumental spinal infusion suffered 
increased rates of nonunion compared to non-smokers (26.5% vs. 14.2% 
(p<0.05)) (Glassman et al., 2000).  Several clinical studies have been carried out 
on human subjects regarding fracture healing and smoking (Whitesides et al., 
1994; Silcox et al., 1995).  Carpenter et al. (1996), reported that outcomes of 
lumbar fusion operations were significantly more favourable for non-smokers 
(p<0.02).  The group also found that non-smokers were more likely to return to 
work on time than smokers following this surgical procedure (Carpenter et al., 
1996). 
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A seminal trial undertaken by Adams et al. (2001), involving 140 smoking and 
133 non-smokers, found that the mean time to union of open tibial fractures was 
32 weeks for smokers, compared with just 28 weeks for non-smokers.  The 
authors also found that, in the same groups of patients, bone grafting was 
necessary in 36 smokers, but only 24 non-smokers required the procedure in order 
to stimulate bone healing (Adams et al., 2001).   These results were statistically 
significant (p<0.05) and showed that smoking is deleterious to human fracture 
healing.  The findings were consistent with previous experimental studies, which 
also demonstrated a nicotine-impaired blood flow to the fracture site (Nolan et al., 
1985; van Adrichem et al., 1992).   
 
High doses of nicotine were reported to have a toxic effect on proliferating 
osteoblasts but, in smaller doses, it actually stimulated the growth of these cells 
(Gullihorn et al., 2005).  This paradoxical function was supported by another 
study, where it was shown that tobacco extract not containing nicotine impaired 
the mechanical strength of femoral fractures in rats, whereas nicotine alone had no 
detrimental effect on the healing of the animals.  In fact, nicotine was later found 
to actually increase the strength (perhaps due to over-healing) of repaired bones in 
a dose-dependent manner in rat femurs (Skott et al., 2006).  These results suggest 
a possible benefit of low dose nicotine replacement therapy (NRT) in smokers 
who, after sustaining a fracture, have been instructed to cease smoking in the peri- 
and postoperative recovery period.   The data suggests that it is the other 
components in the smoke that can posses osteoblast damaging properties (Gaston 
and Simpson, 2007).  However, nicotine was actually shown to inhibit repair in a 
different fracture model (Raikin et al., 1998).   
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Surgical fixation is recommended for fractures that are not able to be reduced by 
external, non-surgical methods.  This is especially true of fractures that involve 
joints, as iatrogenic mal-alignment of articular surfaces may contribute to the 
development of arthritis and nonunion.  Once the patient has been anaesthetised, 
the bone is placed in the correct position and screws, pins, or plates are attached to 
or placed in the bone either temporarily or permanently.  Alternatively, long bones 
may be fixed with nails which are normally placed in the medullary cavity to 
support immobilisation (Shapiro, 2008).   
 
The cessation of smoking, therefore, is routinely advised perioperatively, but 
temporal guidelines are vague as conclusive studies regarding this have yet to be 
undertaken.  The few published recommendations state that smoking cessation 
should commence 1-21 days preoperatively (where permissible) and 5-28 days 
postoperatively (Campanile et al., 1998; Rinker, 2013).  Twelve hours prior to 
surgery is certainly a minimum, as this is the amount of time required to clear the 
human body of CO (Sherwin and Gastwirth, 1990).  Five smoke-free days prior to 
surgery has been documented as having a favourable outcome on wound healing 
(Abidi et al., 1998), although one week was implicated by Lind et al. (1991) due 
to the pharmacokinetics of free radicals and thrombotic components (Lind et al., 
1991).   
 
However, longer periods of abstinence have been suggested than those 
recommended by Campanile et al. (1998) and Lind et al. (1991).  Whitesides et 
al. (1994) showed that non-smokers took 2 months to produce 1.0 cm of bone, 
whereas smokers took 3 months to grow the same amount of tissue.  This led to 
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the suggestion by the authors that a period of 60 smoke-free days should elapse 
before surgery can take place in elective spinal arthrodesis patients (Whitesides et 
al., 1994).  On the other hand, Porter and Hanley (2001) have argued that smoking 
causes irreversible damage to tissues and, therefore, surgical treatment should not 
be denied on the grounds of the failure to stop smoking until further research has 
been carried out in this area (Porter and Hanley, 2001). 
 
1.9 SUMMARY OF INTRODUCTION 
Fracture regeneration is a complex process involving many factors and molecules 
that are present at and recruited to, the site of injury during the inflammatory, 
proliferative and maturation phases of healing.  The effects of smoking are 
thought to be mediated via the vasoconstrictive, platelet-activating and 
aggregating properties of nicotine, the hypoxia-promoting effects of carbon 
monoxide and the inhibition of oxidative metabolism by hydrogen cyanide at the 
cellular level. 
 
The mechanisms that take place in response to the trauma are temporal in nature 
and in the majority of cases, follow a specific pathway that is tightly controlled 
and regulated by many mediators of both stimulatory and inhibitory origin.  
Tobacco smoking is known to have a deleterious effect on the dynamics of both 
wound and fracture healing and numerous studies involving animals and humans 
have been undertaken to demonstrate this.  However, very few investigations at 
the cellular and molecular level involving human fractures and smoking have been 
carried out.  Orthopaedic surgeons have recommended that there should be a 
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period of smoking cessation prior to surgery and therefore a history of cigarette 
smoking should be obtained from individuals so that the risks and complications 
may be discussed in detail.  Both surgeon and patient should be completely aware 
of the harmful effects of smoking when assessing or planning a surgical 
intervention.   These observations notwithstanding the evidence available to date, 
strongly implicate tobacco smoking in inducing delayed and nonunion of bone 
during fracture healing and ultimately suggests that smoking  should be avoided 
by patients who attend hospital with a fracture.  
 
1.10 Aims and Objectives 
There are two aims to this study.  The first aim is to isolate and culture MSCs 
from fracture haematomas collected from those eligible and consenting patients 
who have sustained a tibial fracture.  The donated tissue is to be processed within 
the first 24 hours of injury.  The extracted MSCs are then analysed using various 
methods, in order to observe the biochemical differences and to make 
comparisons between those cells from the smoking patients and those from non-
smoking patients.  The inclusion of a smoking model can also be used to assess 
some of the impacts of smoking on cells extracted from the fracture haematoma.  
The second aim is to compare the expression of acute phase proteins that are 
involved in the early healing phases of fracture repair.  In order to accomplish 
this, extra- and intracellular cytokines will be analysed in both the sera extracted 
from the fracture haematoma and cell cultures.  A variety of techniques will be 
employed to separate, determine and quantitate acute-phase proteins of interest 
and a summary outlining these methods can be found in Figure 18, overleaf. 
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Figure 18: Proposal for Outline of Study  
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2.1 METHODS I: CELLULAR ASPECTS 
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2.2 SPECIMEN PROCESSING 
2.2.1 Patient Handling 
Those patients taking anticoagulants, steroids or anti-inflammatory drugs in the 
three months prior to injury were excluded from the trial.  The study involved 
adult patients from each group, as detailed below in Table 9.  The age and sex of 
each patient, ethnic group and daily number of cigarettes smoked (where 
applicable) was noted and logged and this paperwork accompanied each sample.  
Informed written consent from all patients, as well as ethical approval from the 
NHS Research Ethics Committee (application ref: 06/Q2401/80) and the 
University of Lincoln Ethics Committee (GS4) was obtained.   
 
Table 9: Sample Information 
 
 Total 
Respondents 
(Smokers vs. 
Non-smokers) 
Smokers 
(Cells) 
Non-
Smokers 
(Cells) 
Smokers 
(Serum) 
Non-
Smokers 
(Serum) 
Male 34 (11 vs. 20) 5 8 10 15 
Female 14 (4 vs. 10) 2 3 4 10 
Total 48 (18 vs. 30) 7 11 14 25 
 
Table 9 above shows the outcome of respondents’ fracture haematomas in terms 
of tissue type.  Of the 48 fracture patients recruited into the study, 18 specimens 
produced progenitor cells (7 smokers vs. 11 non smokers).  Serum was derived 
from 39 patient samples (14 smokers vs. 25 non-smokers).  Male casualties were 
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more common than females, representing a male-to-female ratio of more than 2:1.  
Medical notes and x-ray radiographs of patients’ fractures were reviewed 
periodically to identify any clinical problems or comorbidities with regard to the 
healing process. 
 
 
Health and Safety: The Control of Substances Hazardous to Health (CoSHH) 
Regulations 2002 have been strictly adhered to and appropriate risk assessments 
were in place throughout the entirety of all of the following experiments.  
Designated laboratory coats were worn at al times, along with nitrile examination 
gloves and eye protection.  Enhanced personal protective equipment was used 
when handling liquid nitrogen (N2) due to an increased risk of freeze-burn. 
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2.2.2 Extraction and Isolation of Haematoma Cells (HCs) 
The following basic materials and consumables are required for the haematoma 
cell culturing experiments: 
 
Product     Amount Required  
 
SIGMA-ALDRICH (Gillingham) 
Phosphate Buffered Saline (PBS)     1 L 
  
 
Iscove's Modified Dulbecco’s  
Medium (IMDM) (17633)    1 L        
 
Trypsin EDTA (T3924)    500 mL  
 
Foetal Calf Serum (FCS) (N4762)    500mL  
 
Penicillin/Streptomycin (P4333)    100mL  
 
Dimethylsulfoxide (DMSO) (D2659)   x5 vials  
 
L-Glutamine (200mM)     200mL 
        
 
      (cont.) 
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Product     Amount Required 
 
SARSTEDT (Nümbrecht) 
 
25 cm2 Cell Culture Flask (coated)   500 
   
Pipetboy Tubes: 
 
25 mL      500 
 
5 mL      500 
   
Cryotube (RY960257)     500 
    
 
Blue pipette tips      
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2.2.3 Tissue Collection and Processing 
 
1. After exposure of the fracture site, the haematoma (~2.0 mL) was recovered 
manually and placed in an untreated sterile polypropylene container (Fisher, 
Loughborough) by theatre staff at Lincoln County Hospital.  Patient consent 
forms were obtained, completed and placed on file. 
 
2. The sample was immediately transported to the University of Lincoln 
Biomedical Research Laboratory, on wet ice, for processing. 
 
3. A primary culture was prepared by placing ~8 small droplets of the semi-solid 
haematoma onto the base of a 25 cm
2
 non-coated culture flask (Sarstedt, 
Nümbrecht).   
 
4. The spots of haematoma (see step 3) were allowed to clot for ~1 hour.   
 
5. 50.0 mL of Iscove’s Modified Dulbecco’s Media (IMDM) containing 10% 
Fetal Calf Serum (FCS), 100 g mL-1 Streptomycin, 100 U mL-1 Penicillin 
antibiotic, 500 L of Fungizone antifungal reagent (equivalent to 0.25 g mL-1 
amphotericin B) and 2.0 mM L-glutamine (all Sigma-Aldrich, Gillingham), was 
prepared as the stock cell-culture medium. 
 
6. Using a disposable Pasteur pipette, 5.0 mL of the stock cell culture solution 
(preheated to 37ºC) was carefully dispensed into each of the cell culture flasks 
(Sarstedt, Nümbrecht) so as not to disturb the clots of blood.  Each flask and its 
                                                                                              Materials and Methods 
94 
contents were then placed in a Galaxy R incubator (Wolf Laboratories, York), 
which was set at 37°C with humidified 5% CO2.  Ambient O2 levels 
(approximately 20-21%) are reported by the manufacturer to be standard with this 
model of incubator. 
 
7. After 7 days of incubation, 2.5 mL of the cell culture supernatant was removed 
from the flask and safely discarded into a solution of Virkon disinfectant. 
 
8. 2.5 mL of freshly-prepared culture media (as step 5) was dispensed into each 
flask, which were then returned to the incubator (as step 6).  The media was 
changed on a regular basis (every 4-5 days). 
 
9. Serum was also extracted from the remainder of the specimen for analysis; 
this was achieved via centrifugation (30 mins; 3500 rpm; 4ºC) (Beckman Coulter 
Allegra X-12R, California) in a collection tube manufactured with a gel serum 
separator (Vacuette, Kremsmünster). 
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2.2.4 Isolation of Haematoma Cells (HCs) via Subculture  
 
1. After ~21 days of primary-culture, the adherent cells were harvested from 
the primary culture flasks by passing 2.0 mL proteolytic enzyme solution of 
0.25% trypsin, containing 0.02% ethylenediaminetetra-acetic acid (EDTA) 
(Sigma-Aldrich), onto the haematoma cell (HC) surface monolayer.  The flasks 
were placed in the incubator (as previously described) for 5 minutes.   
 
2. The solution, containing, media, trypsin and cells, was withdrawn from the 
vessel and dispensed into a centrifuge tube using a serological pipette.  The flask 
was then washed out with 2.0 mL of phosphate buffered saline (PBS), which was 
also added to the same centrifuge tube. 
 
3. 2.0 mL of the complete IMDM was immediately added to the solution of 
HCs, trypsin and EDTA so that the proteolytic enzyme became neutralised.   
 
4. The solution was centrifuged at 1200 rpm, 18°C for 15 minutes (Beckman 
Coulter Allegra X-12R, California).  A cell-pellet formed at the base of the tube; 
the resulting supernatant was safely discarded by pouring swiftly into a receptacle. 
 
5. After tapping-out the pellet to disperse cells, 1.0 mL of the prepared 
complete media solution (from step 3) was added to form a suspension of HCs.  
The cell suspension was dispensed into a non-coated cell-culture flask (Sarstedt, 
Nümbrecht) that contained 5.0 mL of fresh complete media.   
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6. The flasks were labelled 1st passage and then placed in the incubator as 
previously; the media was changed every 5-7 days thereafter.  Figure 19 (overleaf) 
illustrates the processes involved in cell culture. 
 
7. A control culture was produced, employing the stated methods above, 
using a commercially available human mesenchymal stem cell line (Lonza, 
Tokyo). 
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Figure 19: Schematic Diagram of Methods Involved in Extraction and 
Isolation of Haematoma Cells (HCs) 
 
 
 
 
  
Figure 19:  The stages of processing the patient sample.  The excised haematoma tissue is placed 
into a sterile polypropylene sample tube in theatre. The clotted portion is removed and washed in 
PBS prior to explanting into tissue culture flasks in small pieces (~2.0 mm
3
).  After allowing to 
clot for approximately 1h, 5.0 mL of complete culture media is added before incubation for 
approximately 26 d. 
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Figure 20: Fracture Haematoma Processing 
 
           
 
a)    The Excised Haematoma from theatre     b) Sample Washed in PBS 
 
 
 
 
    
 
a) The Explanted Haematoma  d) Addition of Culture Media 
 
 
 
Figures 20 (a-d):  The stages of haematoma processing from a) receiving the excised sample from 
theatre before b) washing in PBS, c) explanting the specimen into tissue culture flasks and 
allowing solidification before d) finally adding complete IMDM complete culture media. 
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2.2.5 Cell Counting Using Flow Cytometry 
 
1. Flow cytometric absolute cell counting was used to generate data for the 
purpose of cell-seeding and cell-doubling analysis.  It was also used to assess 
cellular recovery in later experiments. 
 
2. The Epics XL flow cytometer (Beckman Coulter, High Wycombe) was 
switched on and the system was allowed to become pressurised (~15 minutes), 
after which a ‘flowcheck’ was carried-out (as per manufacturer’s standard 
operating procedures).  This ensured that the item of equipment was calibrated 
correctly.  (See appendices for flowcheck documentation). 
 
 
3. 100 L of the 1000 L cell suspension (following subculture protocol) 
was combined with 1000 L of Isoton 3 solution and 100 L of fluorescent flow-
count beads (Beckman Coulter, California), producing a final solution of 1200 L.   
 
4. 1200 L of the solution (see step 3) was transferred to a cytometer tube by 
means of an automatic pipette.  The tube was inserted into the stage of the flow 
cytometer. 
 
5. A suitable protocol programme, or listmode (LMD), was selected from the 
software before running the sample.  After the processing the specimen, data was 
collected and the machine was cleansed by running a standard common cleaning 
panel protocol. 
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2.3 CHARACTERISATION OF HAEMATOMA CELLS 
In addition to being counted, cells were labelled with antibodies specific to 
mesenchymal lineage and the markers CD29 (Caltag, Carlsbad, CA; 
Cat#LCD2901), CD44 (Caltag, Carlsbad, CA; Cat#MHCD4401), CD73 
(phycoerythrin conjugate (PE)) (eBioscience, San Diego; Cat# 12-0731-82 
Lot#E027728), CD105 (Immunostep, Salamanca; Cat#105F Batch# 180608/0105) 
and CD166 (Medical and Biological Laboratories Co., Naka-ku Nagoya 
Cat#K0044-4 Lot011) were used in both the immunofluoresence (not CD73 as the 
conjugate was phychoerythrin) and immunophenotyping assays.  The 
haematopoietic stem cell marker CD34 (Novocastra Laborotories Ltd, Newcastle 
upon Tyne; Cat#QBEnd/10) was used as a negative control, in addition to staining 
an un-probed sample of cells with secondary antibody only (rabbit, anti-mouse) 
(DAKO Cytomation, Ely Cat#PO260 Lot 00043039).  The protocols used for the 
assays are as follows: 
 
2.3.1 Immunofluorescence Assay 
1.  After the application of the trypsin EDTA and the re-suspension into 1.0 ml 
of complete media, the cell suspensions were placed in a cytospin (Thermo 
Shandon, Runcorn) in order that they became uniformly fixed onto a glass 
microscope slide.  200 L of the cell suspension containing approximately 5 x 104 
was pipetted into a cytofunnel chamber that was attached to a filter and clamped 
to a glass slide (Thermo Shandon, Runcorn). 
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2. The apparatus was programmed to run at 700 rpm for 5 minutes.  After 
completion of the cycle, cytofunnels were carefully removed to reveal a ‘button’ 
of cells that had formed on the glass slides.  Cells were fixed with ice-cold pure 
methanol and air-dried; slides were wrapped in aluminium foil and then placed in 
a freezer for storage (-20ºC). 
 
3. After removing from the freezer, cells were briefly thawed at room 
temperature (~1 minute).  50 L of human monoclonal primary antibody (mouse; 
anti-human, conjugated to fluorescein isothiocyanate (FITC); CD29, CD44, 
CD105, CD166 or CD34) was pipetted onto the cell button and left to incubate at 
humidified room temperature for 30 minutes.  One slide was stained with FITC 
secondary antibody only as an additional control. 
 
4. Cells were gently washed using phosphate buffered saline (PBS).  50 L 
diluted (1:30) secondary polyclonal antibody (rabbit; anti-mouse) (Sigma-Aldrich, 
Gillingham) was pipetted onto the cells, which were then incubated in the dark at 
humidified room temperature.  This was necessary to further amplify the signal 
from the already-conjugated antibody so that it could be seen under fluorescent 
microscopy. 
 
 
5. Following incubation, cells were washed once again in PBS and glass cover 
slips were applied to the slides.  Samples were analysed immediately using a 
fluorescent microscope (Nikon, Livingston), which was set to the FITC mode. 
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2.3.2 Immunophenotyping Assay 
 
1. After being subjected to trypsin/EDTA, centrifugation and re-suspension, 
harvested cells were counted using a flow cytometer and specific  amounts (5 x 
10
5
) were each diluted in 900 L of Isoton II diluent (Beckman Coulter, High 
Wycombe). 
  
2. 10 L of monoclonal primary antibody (either CD29, CD34, CD44, CD105 
or CD106), conjugated with fluorescein isothiocyanate (FITC), was also added to 
the solution and left to incubate at room temperature in the dark for 30 minutes.   
 
 
3. Samples were then processed on a flow cytometer to quantify the level of 
positive cells within the cell population for each given CD marker, shown as 
normalised percentages.   
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2.3.3 Generation of Cigarette Smoke Extract (CSE) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21:  Apparatus set-up for the generation of Cigarette Smoke Extract 
(CSE) 
 
 
The cigarette smoke extract (CSE) generation was based on a validated pump 
system as reported by Bernhard et al. (Bernhard et al., 2004).  Four cigarettes 
were smoked through 30 mL of IMDM.  Each cigarette was smoked for 10 puffs, 
each puff being 35 mL of smoke every 30 seconds, which burnt approximately 
75% of the cigarette. The volume of smoke generated was therefore 350 mL.  
Each millilitre of CSE contains 0.133 (4/30) of a cigarette’s smoke-derived 
constituents.  The resultant CSE was sterilised by filtering through a 0.2 m 
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syringe filter and the pH was adjusted to 7.4, pipetted into 1.0 mL aliquots and 
frozen at -20ºC.  The brand of cigarettes used was Marlboro Reds Class A and 
were rated as 10.0 mg tar, 0.8 mg of nicotine and 10.0 mg of carbon monoxide.   
 
Bernhard’s validated volumetric equations are based on the assumptions that a 
human generates 350 mL of smoke with each cigarette and has a blood volume of 
6L.  A person smoking 20 cigarettes per day will have the equivalent of 1 
cigarette’s toxins in each 300 mL (6000/20) of blood.  Therefore, each mL of 
blood contains 0.0033 (1/300) of 1 cigarette’s smoke-derived constituents.  By 
this calculation, CSE can be considered to contain 40 times (0.133/0.0033) the 
amount of smoke-derived constituents that would be expected to be contained in 
the blood of a smoker who smokes 20 cigarettes per day.  A 2.5% (1/40) solution 
of CSE in the IMDM would, therefore, equate to 20 cigarettes per day. 
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2.3.4 Nitric Oxide (NO) Analysis in CSE-Treated MSCs 
 
 
 
Figure 22: The Seivers 180i NOA Nitric Oxide (NO) Analyser (Analytix, 
Durham).   
 
Nitric oxide can be a biomarker of cellular damage in MSCs and NO is involved 
in fracture healing.  Corbett et al. (1999) hypothesised that NO isoforms, 
responsible for the generation of NO, are expressed during fracture healing.  They 
reported higher levels of endothelial eNOS in cortical blood cells and osteocytes 
in the early stages of normal fracture repair (Corbett et al., 1999; Corbett et al., 
1999), thus rendering the apparatus as a suitable analytical tool in this study. 
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2.3.5 Nitric Oxide (NO) Analytical Assay in CSE-Treated MSCs 
 
NB: NO reacts with volatile organic compounds in the presence of sunlight to 
form Ozone.  Ozone can cause adverse effects such as damage to lung tissue and 
reduction in lung function.  
 
1.  MSCs extracted from non-smokers were counted on a flow cytometer and 
divided into 2 numerically-equal groups (CSE treated vs. CSE untreated). The 
cells were seeded-out into new cultures; the inoculum being 10x10
5 
cells in each 
flask. 
 
2. Cigarette smoke extract (2.5% in culture media by volume; 20 
cigarettes/day) was infused into the first group; a second group contained non-
infused IMDM as a control. Both groups were incubated for 7 days in 37ºC 
humidified 5% CO2. 
 
3. After incubation, cells were exposed to trypsin and centrifuged, in their 
respective media, in 15.0 mL centrifuge tubes.  The supernatant was discarded and 
pellets were tapped-out, to disperse cells, which were then washed in 1.0 mL of 
PBS; they were again centrifuged and the resulting supernatant discarded. 
 
4. After tapping-out the cell pellet from step 3, 100 L of cell lysis buffer* 
(Bender Medsystems, Vienna) was pipetted into each of the sample tubes, which 
were then agitated on an orbital shaker set at 100 rpm for 60 minutes. 
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5. Cell suspensions were transferred to eppendorf tubes and microfuged in a 
benchtop microfuge set at 5000 rpm for 15 minutes at room temperature.  The 
supernatant was discarded, leaving a gel-like liquid behind in the tube as the 
analyte.   
 
6. The lysed cell analytes were then processed and analysed on the Seivers 
NOA 180i nitric oxide analyser. 
 
 
*For 500 mL stock solution of lysis buffer; 324 mL H2O, 10 mL 1.0 M Tris HCl, 
pH 8, 50 mL 10% Tx-100, 100 mL of 50% w/v in H2O glycerol, 2.0 mL 0.5 M 
EDTA (pH 8.0), 13.7 mL NaCl.  Store a 4ºC.  Before use, add 1% 100 mM 
phenylmethylsulfonyl fluoride (PMSF), 100 nM vanadate, 1 mg mL
-1
 leupeptin, 
0.01% 1.0 mg mL
-1
 aprotinin. 
 
2.3.6 Cell Necrosis Assay 
 
1. After trypsinisation, centrifugation and re-suspension, harvested cells were 
counted using a flow cytometer and known amounts (5 x 10
5
) were each diluted in 
900 L of Isoton II diluent (Beckman Coulter, High Wycombe). 
 
2. Since necrotic cells become unattached to the plastic substratum, it was 
important not to discard the media prior to counting.  When reseeding out into the 
next passage, the media was changed after 24 hours to ensure viable cells had 
become attached to the floor of the flask. 
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3. 10 L of propidium iodide (Sigma-Aldrich, Gillingham; Cat#P4864) was 
added to the solution and samples were immediately processed on a flow 
cytometer to quantify the level of necrotic cells within the cell population and 
were recorded as percentages.   This was conducted on cells over four passages of 
7days. 
2.3.7 MSC Recovery Assay 
 
1. Cells from ten non-smoking patients were cultured in IMDM and allowed to 
become confluent.  Three experimental groups were set up as follows: 
 
Group I (Smoking, n=10):  CSE (2.5%; 20 cigarettes/day equiv.) was 
infused into the cell culture media; this was maintained through the 
entirety of the assay.  
Group II (Recovery, n=10):  CSE was infused for 5 days only, which 
was then withdrawn in subsequent cultures prior to analysis.  Normal 
media was used for the remainder of the assay 
Group III (Non-Smoking, n=10): Untreated MSC culture media 
throughout. 
 
2. Periodic observations were made on the morphology of the cells using light 
microscopy; photographs were taken. 
 
3. Cells were incubated and counted in three consecutive passages, each of 
which was 5d, from the baseline count.  Data was normalised as percentage 
change from baseline count and values from each group were compared.  
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2.3.8 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
Assay:  In Vitro Effect of BMP-2 on Cell Viability Enhancement 
 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a yellow 
tetrazole), is reduced to purple formazan in living cells.  The solubilisation 
solution, dimethyl sulfoxide (DMSO), is added to dissolve the insoluble purple 
formazan product into a coloured solution. The absorbance of this solution can be 
quantified by measuring at a wavelength of 570 nm by a spectrophotometer.  The 
deeper the purple colour, the greater the cellular activity, proliferation and 
viability.   
This assay is often used in order to analyse the viability of cells in cultured 
populations.  It is particularly suitable where a growth factor or drug is 
incorporated into the culture media, necessitating relatively small quantities of the 
former due to costing and availability issues.  Samples are analysed in 96-well 
uncoated plates, which are read on a spectrophotometer for absorbance 
determination.  The MTT assay was used in order to determine the effects of bone 
morphogenetic protein-2 (BMP-2) on CSE-treated haematoma progenitor cells. 
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2.3.8.1 Cell Preparation – MTT Assay 
1.  Haematoma-derived progenitor cells were retrieved from the vapour phase 
of the N2 dewar.  Cells used were all extracted from non-smoking patients (n=10). 
 
2. Cells were allowed to expand in culture until flask-confluency, which 
occurred in all 10 samples after 5 days of culture. 
 
3. After the application of trypsin and re-suspending in 1.0 mL of complete 
media, cells were combined with an Isoton II solution containing a known 
quantity of Flowcount beads and counted using a flow cytometer so that 
suspension concentrations could be determined prior to plating-out in 96 well 
plates. 
 
4. Cells were plated-out in wells at an inoculum of 3.0 x 103 per well.  Three 
groups were created in duplicate; 24h, 48h and 72h of various amounts of BMP-2 
(product no. H4791, Sigma Aldrich, Gillingham) (10 ng mL
-1
, 100 ng mL
-1
 and 
500 ng mL
-1
 per well).  An additional control group that did not contain any of the 
BMP-2 growth factor was added to the plate.   
 
5. All wells (including those from the control group) were subjected to CSE 
infusions of 2.5%, representing the circulating tobacco-derived toxins comparable 
to the blood of an individual smoking 20 cigarettes per day.    
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6. Volumes in each well were normalised to 250 L; surrounding empty wells 
were filled with media only to prevent dehydration.  Plates were covered and 
incubated at 37ºC in a humidified incubator for their respective times. 
 
7. In order to run a separate control study, an additional plate was prepared that 
was composed of cells that had not been subjected to CSE.  This plate had 3 
groups of cells in duplicate, each containing differing amounts of BMP-2; 0, 10 
and 100 ng mL
-1
. 
 
MTT Preparation 
 
1. 10 mg of MTT was weighed on a balance and dissolved in 1.0 mL of dH2O. 
2. A final concentration of 1 mg mL-1 of MTT in IMDM was aliquoted. 
3. 50 L of the MTT solution was added to each well at the lapsed time as 
appropriate. 
4. The reaction was allowed to continue for 4 hours in the incubator after 
adding the MTT compound.  After 4 hours, the MTT reagent was dispensed from 
the plate.  100 L of DMSO was then added to each well in order to dissolve the 
purple formazan product within the mitochondria of the adherent haematoma 
cells. 
5. Plates were read at 570 nm using a microplate reader for each plate at 24h, 
48h and 72h intervals once the DMSO had been added. 
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2.3.9 Cryopreservation of MSCs 
 
1. After 3 passages had been subjected to sub-culture, the fracture MSCs were 
stored in the vapour phase of liquid nitrogen (N2) at -160ºC for later analyses.  
 
2. 100 L of dimethyl sulfoxide (DMSO) (Sigma-Aldrich, Gillingham), 900 l 
of Fetal Calf Serum (FCS) and 800 L of suspended HCs were aliquoted into a 
1.8 mL labelled cryogenic storage vial (Sarstedt, Nümbrecht). 
 
3. Vials containing the cells were placed into a small freezing vessel that 
contained 250 mL of isopropanol (at room temperature) and then placed in a 
freezer (-80°C) for 24 hours (where the temperature of isopropanol gradually 
reduces by 1ºC per minute), before transferring into the vapour phase of the N2 (-
160°C) reefer, for indefinite storage.  Details were logged. 
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2.4 METHODS II:  MOLECULAR ASPECTS 
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2.4.1 Serum Protein Determination Using SDS-PAGE 
 
 
Sample Preparation: 
 
 
1.  The liquid component associated with the haematoma was pipetted into a 5 
mL Z serum separator and clot activator tube (Vacuette, Kremsmünster) and 
allowed to clot for 60 minutes in a water bath at 37˚C.  The haematoma samples 
were then centrifuged at 3500 rpm for 15 minutes at room temperature; the 
resulting serum was filtered using a 0.2 m filter (Sterilin, Bargoet), pipetted into 
1.0 mL aliquots and stored at -20˚C.  
 
 
SDS-PAGE Assay: 
 
 
2. The serum that had been extracted from the haematoma (step 1) was 
retrieved from the -20°C freezer and thawed in a water bath that was set at 37°C. 
 
3. 50 L of haematoma serum was pipetted from the sample (step 2) and 
dispensed into a 15 mL centrifuge tube that contained 950 L of phosphate 
buffered saline (PBS).  This formed a dilution of 5% serum in 95% PBS. 
 
 
 
 
4. The serum/PBS solution was centrifuged at 3500 rpm for 15 minutes at 4°C 
to exclude any debris.  Control samples, using FCS and human peripheral blood 
sera, were prepared in exactly the same way as the haematoma serum sample.  A 
protein marker (SERVA, Heidelberg) was also included as a separate lysate to 
estimate the molecular weight of proteins in the gel. 
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5. 45.0 L of each centrifuged lysate (from step5) was pipetted into an 
eppendorf tube that contained 45.0 L of sample buffer (SERVA, Heidelberg) 
(Tris-HCl pH 6.8, 126mM, glycerol 20%, SDS 4%, bromophenol blue 0.02%).  
5.0 L of 2-mercaptoethanol (Sigma-Aldrich, Gillingham) was then added to each 
solution to reduce the disulphide bonds present in protein. 
 
6. Each eppendorf tube was suspended (but not fully immersed) vertically in 
boiling water for 5 minutes to denature the proteins; the tubes were then placed on 
wet ice for 10 minutes. 
 
7. The TV-50 electrophoresis cell (Scie-Plas, Cambridge) was fitted with a 10 
cm x 10 cm precast gel-cassette (Tris-Glycine Gel 16%) (SERVA, Heidelberg).  
The apparatus was then filled with 290 mL of Laemmli buffer (0.25 M Tris, 1.92 
M glycine and 1.0% SDS) (SERVA, Heidelberg). 
 
8. After removal of the comb, 5.0 L of each sample was carefully loaded into 
the wells of the stacking gel in a specified arrangement (see later) using a 10.0 L 
pipette (Gilson, Middleton).  The electrophoresis cover was placed onto the 
apparatus.  
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Electrophoresis stacking conditions: 
 
9. The electrophoresis power pack (Consort E815, Brussels) was switched on 
and stacking conditions were programmed (and then ran) as follows:  10 mA, 100 
V, 300W, 15 minutes.   
 
Electrophoresis resolving conditions: 
 
10. After the stacking cycle had finished, the electrophoresis power pack was 
reprogrammed (and ran) for resolving conditions as follows: 20 mA, 100 V, 
300W, 120 minutes. 
 
Gel Staining I:  Coomassie Blue 
 
11. A Coomassie blue stain was prepared by dissolving 1 Phast R tablet 
(Sigma-Aldrich, Gillingham) into 120 mL of dH2O and 80.0 mL methanol. 
 
12. After the gel had completely undergone electrophoresis, it was removed 
from the apparatus and the cassette housing was carefully removed with the 
supplied plastic key (SERVA, Heidelberg). 
 
13. The gel was placed into a clean plastic container and gently washed for 1 
minute in dH2O. 
 
14. 100 mL of Coomassie blue staining solution was poured into the container 
that contained the gel.  It was then covered with a lid and placed on an orbital 
shaker, which had been set at 50 rpm for 30 minutes. 
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15. After 30 minutes, the Coomassie blue stain was poured away and safely 
discarded and the gel was washed again in two changes of dH2O. 
 
Gel destaining: 
 
16. The gel was placed in 100 mL of destaining solution (60% dH2O, 30% 
methanol, 10% glacial acetic acid), covered and placed on an orbital shaker set at 
50 rpm for 60 minutes.  This step was repeated twice. 
 
17. The gel was then immersed in 250 mL dH2O and left overnight to remove 
excess stain and was later photographed. 
 
Gel Staining II:  Silver Nitrate Staining 
 
Polyacrylamide gels were also stained using the silver nitrate method to further 
improve clarity of resolution of protein bands.  This method is described as 
follows; 
 
1.  After opening and removal from the plastic housing following electrophoresis 
as previously described, the gel was placed in a fixing solution of 50% dH2O, 
40% absolute ethanol and 10% glacial acetic acid for 30 minutes. 
 
2.  The gel was then immersed for 30 minutes in a sensitizing solution of 63% 
dH2O, 30% ethanol, 6.8% anhydrous sodium acetate (FW. 82.03) and 0.2% 
sodium thiosulphate pentahydrate (FW. 248.18).  0.5 mL of 25% gluteraldehyde 
per 100 mL of this solution was added. 
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3.   The gel was washed for 30 minutes in a silver solution (Sigma-Aldrich, 
Gillingham) containing 0.25g of silver nitrate (FW. 169.87) in 100 mL of dH2O.  
40.0 L of 37% formaldehyde was added.  After 30 minutes, the gel was washed 
in dH2O for 1 minute (x2 washes). 
 
4.  A developing solution consisting of 2.5g of anhydrous sodium carbonate (FW. 
105.99) dissolved in 100 mL of dH2O was prepared with the addition of 20 L of 
37% formaldehyde.  The gel was immersed in this solution for 5 minutes. 
 
5.  A stop solution was prepared using 1.5g of Na2 EDTA 
(ethylenediaminetetraacetic acid) in 100 mL of dH2O.  The resolved gel was 
placed in the solution for 10 minutes before being washed in dH2O (3 x 5 minute 
washes). 
 
7. Preserving solution was prepared as follows; 64 mL dH2O, 30 mL absolute 
ethanol and 4.0 mL glycerol; the constituents were mixed thoroughly.  The gel 
was stored in this solution under refrigeration at 4ºC.  Gels can be stored in this 
way for up to 2 years. 
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2.4.2 SDS-PAGE Gel Production: 
 
1. On certain occasions, SDS-PAGE gels were made in the laboratory to save 
on cost and delivery times.  The gel pouring protocol is as follows: 
 
15% Running Gel 
44.4% acrylamide/1.2% bis acrylamide   (3.38 mL) 
1M Tris/HCL (pH 8.8)    (3.75 mL) 
dH2O      (2.72 mL) 
10% SDS     (100 L) 
10% ammonium persulfate   (50.0 L) 
TEMED (to be added directly prior to pouring)  (5.0 L) 
Isopropanol for sealing gel 
Polymerisation time = 30 minutes   
 
5% Stacking  Gel 
44.4% acrylamide/1.2% bis acrylamide   (500 L) 
1M Tris/HCL (pH 6.8)    (625 L) 
dH2O      (3.8 mL) 
10% SDS     (50 L) 
10% ammonium persulfate   (25 L) 
TEMED (to be added directly prior to pouring)  (5.0 L)  
Polymerisation time = 30 minutes 
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2.  The glass casting plates were filled with running gel approximately 1.0cm 
from the top, air bubbles were minimised, ensuring the surface was level.  The top 
was sealed with isopropanol and left to polymerise for 30 minutes.   
 
3. After 30 minutes, the isopropanol was discarded and the liquid stacking gel 
was pipetted onto the polymerised running gel before inserting comb.  The gel 
was ready to use 30 minutes thereafter.   
 
 
NB. Glass plates should be sealed with Blu-Tack
®
 to prevent leakage. 
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2.4.3 Analysis of SDS-PAGE GELS via Mass Spectrometry  
 
Unknown bands on SDS-PAGE gels can be excised from the acrylamide polymer, 
the gel digested to solubilise proteins, which can then be detected and given an 
identity, using mass spectrometry (MS).  The following protocol was supplied by 
the Biopolymer Synthesis and Analysis Unit (BSAU) at the University of 
Nottingham: 
  
 
1. Gel bands were manually excised and subjected to automated in-gel 
chemical modification of cysteine residues with dithiothreitol (dtt) and 
iodoacetamide followed by tryptic digestion and peptide extraction on the 
MassPrep robotic system (Waters, Milford). 
 
2. The extracted peptide mixture was run on a Waters QTOF2 hybrid 
quadruple mass spectrometer incorporating an integrated capillary lc system. A 
total of 5L of the digest was introduced via an autosampler.  
 
 
3. This was initially loaded onto a small C18 packed pre-column for desalting 
and then products of the tryptic digest were eluted onto an analytical capillary C18 
column (100mm X 0.75mm id). The lc system incorporated a flow splitting device 
to give a final flow through the column of 200 nL per minute.  
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4. A solvent gradient was run over a total of 1 hour to elute peptides from the 
column and re-equilibrate prior to loading the next sample. Where samples were 
observed to contain high levels of peptides a blank run was usually incorporated 
between sample runs to establish that there was no significant carry-over of one 
sample to the next. 
 
5. Eluted peptides from the analytical column were directly submitted into the 
mass spectrometer via a nanosprayer device attached to the outflow from the lc 
system and operating at 3kV. In addition, a reference solution containing a peptide 
of known mass was sprayed into the mass spectrometer from a separate sprayer. 
This ion source was sampled at regular intervals throughout the run to assist in 
maintaining accurate mass measurements of the ionised peptides from the analyte 
spray.  
 
6. Data-dependent switching was incorporated so that whenever a peptide with 
an associated charge of 2+ or 3+ was detected above a pre-set threshold signal, the 
mass spectrometer would automatically switch to ms-ms mode to generate 
fragmentation data from the detected peptide. The software was set up to scan 
over multiple channels in order to simultaneously fragment up to 3 co-eluting 
peptides and collect the fragmentation data from each one individually. A preset 
range of collision voltages was set up in the method in order to fragment each 
peptide as efficiently as possible. 
 
 
 
                                                                                              Materials and Methods 
123 
7. Raw data files were analysed using MassLynx 4.0 (incorporating BioLynx) 
and ProteinLynx Globalserver 2 (Waters, Milford) in order to assess the identities 
of proteins present in the digest.  The peak list files generated from PLGS2 
analysis were also used in an alternative search program accepting this format of 
data file (Matrix Science, Boston). In addition some fragmentation data was 
analysed manually and de novo sequencing carried out on selected peptides. 
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2.4.4 TGF- and IL-6; Intracellular Markers in MSCs 
Immunocytochemical analysis of cytoplasmic acute-phase proteins, using flow 
cytometry, qualitatively detects the presence of these within the haematoma cells.  
Probing permeated cells with markers specific for TGF- and IL-6 was 
undertaken.  If cultured haematoma cells are expressing these cytokines, which 
are involved in fracture healing and are known to be secreted by MSCs, then 
further analyses could be conducted to measure them quantitatively in order to 
establish differences between smokers’ and non-smokers’ cells. 
 
 
Cell Preparation 
 
 
1. Confluent MSC cultures from non-smoking patients were trypsinised, 
centrifuged and washed and re-suspended in 1.0 mL of PBS.  Cell cultures were 
each divided into two groups; cigarette smoke extract (CSE) was infused into one 
group and the other left untreated.  MSC concentrations were determined on a 
flow cytometer. 
 
2. Equal concentrations of 10 x 105 MSCs were calculated in each sample and 
pipetted into 15.0 mL centrifuge tubes.  
 
3. Suspensions were centrifuged at 1000 rpm for 10 minutes at room 
temperature; the supernatant was discarded before adding 100 L of ice-cold 
methanol (-20ºC).  Samples were incubated at -20ºC for 10 minutes. 
 
4. To permeablise cells, 100 L of PBS with 0.1% triton X-100 was added to 
each sample, which were then incubated at room temperature for 15 minutes. 
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5. A further 1.0 mL of PBS containing 0.1% triton X-100 was added to each 
sample, which were then centrifuged at 2000 rpm for 5 minutes; 4ºC.   
 
6. The supernatant was discarded and the cell pellet tapped-out in order to 
disperse the permeablised cells. 
 
Intracellular Staining (FITC) 
 
7. 5.0 L of primary monoclonal antibody conjugated to FITC (Sigma-
Aldrich, Gillingham), mouse, anti-human, specific to TGF- or IL-6 (as 
appropriate) was added, separately, to each sample and incubated for 45 minutes 
at 4ºC in a refrigerator. 
 
8. After the incubation period with the primary antibody specific to either 
TGF- or IL-6, cells were washed by centrifuging at 1200 rpm for 10 minutes in 
1.0 mL of PBS and then re-suspended in 1 mL of PBS 
 
9. 50 L of secondary polyclonal antibody (diluted 1:30 with 3% bovine serum 
albumin (BSA) and 97% PBS) was added to each sample, which were then 
incubated for 30 minutes at room temperature in a dark place. 
 
10. Cells were washed as step 8 in 1.0 mL of PBS before re-suspending in ice-
cold (~4ºC) PBS containing 3% BSA and 1% acetone. 
 
11. The protein-labelled cells were analysed using a flow cytometer; data was 
filed and stored. 
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2.4.5 VEGF and IL-6 Quantitation via ELISA in Haematoma Serum 
and Lysed Fracture MSCs:  A Preliminary Study 
  
ELISA kits used for the following assays were the VEGF-A (EK3099-A) (Arcus 
Biologicals, Modena) and IL-6 ELISA (BMS213INSTCE) (Bender Medsystems, 
Vienna). 
 
1. Cells from smokers (n=4) and non-smokers (n=5) were trypsinised and 
suspended in 1.0 mL of complete media and were diluted 1:10 with the supplied 
prepared assay buffer, which is composed of animal serum with buffer and 
preservative (20L sample:180 L buffer:). Haematoma serum was diluted 50:50 
with the prepared assay buffer.  This was the recommended dilution in the 
manufacturer’s datasheet. 
 
2.  20 L 1N HCL was added to 200 L of pre-diluted sample, which was 
mixed and incubated for 1 hour at room temperature.  This reaction was then 
neutralised by the addition of 20 L of 1 M Na OH. 
 
3. All reagents were mixed thoroughly without foaming before use. 
 
4. The number of microwell strips that were required to test the desired 
number of samples was determined, plus the appropriate number of wells required 
for running blanks and standards.  Each sample, standard, blank and optional 
control sample were all assayed in triplicate. 
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5. The required amount of microwell strips were washed 3 times with 300 mL 
of wash buffer per well; all microwell contents were aspirated between washes, 
taking care not to scratch the base of the coated microwells. 
 
6. After the final wash, the microwell strips were tapped on an absorbent 
disposable pad or paper towel to remove excess wash buffer.  The microwell 
strips were used immediately after washing, taking care not to allow the wells to 
dry. 
 
ELISA standard preparation (VEGF and IL-6)   
 
1. 100L of assay buffer, in duplicate, was added to all standard wells.  
Standard solutions were prepared by pipetting 100L of the standard, in duplicate, 
into wells A1 and A2; the contents mixed by repeated aspiration and ejection.  
100L was transferred from well A1 to well B1 and from A2 to B2, respectively.  
This process was repeated four more times, until wells G1 and G2 were filled; 100 
L was discarded from each of these wells.  The two rows of standard dilutions 
ranged from 30.0 to 0.5 ng mL
-1
. 
 
2. 100L of assay buffer, in duplicate, was added to the blank wells. 
 
3. 100 L of each pre-treated sample, in duplicate, was added to each of the 
designated wells. 
 
4. Horse radish peroxidase (HRP) conjugate was prepared as per the datasheet 
and 50L of diluted HRP conjugate was added to all wells. 
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5. The plate was covered with a cover (supplied) and incubated at room 
temperature for 4 hours on an orbital shaker set at 50 rpm. 
 
6. The plate cover was removed and the wells were emptied.  The microwell 
strips were washed 3 times.   
 
7. 100L of tetramethylbenzidine (TMB) substrate solution was pipetted into 
all wells, including the blank wells. 
 
8. The microwell strips were incubated at room temperature for 10 minutes, 
avoiding exposure to light.  The colour development was monitored; 100L of the 
stop solution was added when the highest standard developed a dark blue colour.  
The stop solution causes a change in colour from blue to yellow. 
 
9. The results were read immediately on a plate reader set at 420 nm. 
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2.4.6 Bone Alkaline Phosphatase (b-ALP) Quantitation in Fracture Serum 
 
Skeletal, or bone-specific alkaline phosphatase (b-ALP) is a tetrameric 
glycoprotein found on the surface of osteoblastic cells and is therefore involved in 
the laying-down of the bone matrix as seen in fracture repair.  Although the 
precise function of b-ALP is not fully understood, it is accepted that it is a useful 
biochemical marker of bone turnover (Frost-Pineda et al., 2010).  An assay was 
performed to measure the amounts of b-ALP present in the fracture haematoma 
serum collected from patients involved in this study and data was compared 
between smokers and non-smokers in respect of this biomarker.  The details of the 
assay (Horiba datasheet) are summarised as follows: 
 
p-Nitrophenylphosphate + H2O 
[alp]   
Phosphate + p-Nitrophenol 
 
1. Processed fracture haematoma serum samples were retrieved from the -80ºC 
freezer and divided into non-smoking (n=10) and smoking (n=10) patient groups. 
 
2. The samples were numbered accordingly (1-10 (smokers), 11-20 (non-
smokers) and allowed to thaw at room temperature prior to placing on wet ice 
ready for analysis. 
 
 
3. The biochemical analyser (Horiba ABX Pentra DF-DX 120, Tokyo), was 
prepared as per the manufacturer’s specifications. 
 
4. ALP Reagent 1 was prepared as follows: 2-amino-2-methyl-1-propanol (pH 
10.4) - 440 mMol L
-1
, magnesium sulphate - 2.0 mMol L
-1
, zinc sulphate - 1.25 
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mmol L
-1
, HEDTA (hydroxyethylethylenediaminetriacetic acid) - 2.5 mMol L
-1
, 
sodium azide - < 1g L
-1
. 
 
5. ALP Reagent 2 was prepared as follows: p-nitrophenylphosphate - 80 mMol 
L
-1
, sodium azide - < 1 g L
-1
. 
 
6. The required volume of ALP Reagent 1 was transferred into a 15 mL test 
tube. 
 
7. The required volume of ALP Reagent 2 was transferred in a 10 mL test tube. 
 
8. The reagents were placed in the rack in the refrigerated ABX Pentra 400 
reagent compartment ready for use. 
 
9. For calibration, ABX Pentra MultiCal, Ref. A11A01652 was used. 
 
10. The ABX Pentra Ref. A11A01653 was used as a control. 
 
11. Reagent 1 was placed in position 1 of one available sector of the analyser. 
 
12. Reagent 2 was placed in position 2 of same selected sector of the analyser. 
 
13. 100 L of each sample, combined with 400 L dH2O (1:4) was loaded into 
Eppendorf tubes which were then placed into the test wells ready for analysis. 
 
14. The machine generated the results and this data was recorded and analysed 
statistically using a Microsoft Excel spread sheet. Datasheets available overleaf. 
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ABX Pentra 
Form-0846 Rev. 2 
Use in reagent rack 
2007/06/08 
A93A00012N EN 
A11A01626 
26 ml 
6.5 ml 
HORIBA ABX 
BP 7290 
34184 Montpellier- cedex 4 - France 
S.A.S. au capital de 41.700.000 € - RCS Montpellier 328 031 042 - SIRET 328 031 042 000 42 - APE 332 B Latest version documents 
on www.horiba-abx.com 
ABX Pentra ALP CP (Use in reagent rack) 
Ref.: A11A01626 
Volume R1: 26 ml 
Volume R2: 6.5 ml 
Diagnostic reagent for quantitative in-vitro 
determination of Alkaline Phosphatase (ALP) 
in serum or plasma. 
Clinical Interest (1,2) 
Alkaline phosphatase (ALP), an hydrolytic enzyme acting optimally at 
alkaline pH, exists in blood in numerous distinct forms which originate 
mainly from bone and liver, but also from other tissues as kidney, 
placenta, intestine, testes, thymus, lung and tumors. Physiological 
increases are found during bone growth in childhood and in 
pregnancy, while pathological increases are largely associated with 
hepatobiliary and bone diseases. In hepatobiliary disease they 
indicate obstruction of the bile ducts as in cholestasis caused by gall 
stones, tumors or inflammation. Elevated activities are also observed 
in infectious hepatitis. In bone diseases elevated ALP activities 
originate from increased osteoblastic activity as in Paget’s disease, 
osteomalacia (rickets), bone metastases and hyperparathyroidism. 
Method 
Kinetic photometric test, according to the International Federation of 
Clinical Chemistry (IFCC). 
(ALP = Alkaline Phosphatase) 
Reagents 
ABX Pentra ALP CP is ready-to-use. 
ABX Pentra ALP CP should be used according to this reagent notice. 
HORIBA ABX cannot guarantee its performance if used otherwise. 
Handling 
Transfer the required volume of Reagent 1 in a container 15, 10 or 4 
ml. 
Transfer the required volume of Reagent 2 in a container 10 or 4 ml. 
Reagent 1 and Reagent 2 should be placed on the same reagent rack 
sector A, B or C (see diagram below, sector A is taken as an example). 
Reagent 1: 2-Amino-2-methyl-1-propanol pH 10.4 440 mmol/l 
Magnesium sulphate 2.0 mmol/l 
Zinc sulphate 1.25 mmol/l 
HEDTA 2.5 mmol/l 
Sodium azide 1 g/l 
Reagent 2: p-Nitrophenylphosphate 80 mmol/l 
Sodium azide 1 g/l 
p-Nitrophenylphosphate + H2O Phosphate + p-Nitrophenol 
ALP 
Place Reagent 1 in position 1 of one available sector using either: 
• Reagent container 15 ml 
• Reagent container 10 ml + its specific adaptor 
• Reagent container 4 ml + its specific adaptor 
Place Reagent 2 in position 2 of same selected sector using either: 
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• Reagent container 10 ml 
• Reagent container 4 ml + its specific adaptor 
Place the reagent rack in the refrigerated ABX Pentra 400 reagent 
compartment. 
Calibrator 
For calibration, use: 
ABX Pentra MultiCal, Ref. A11A01652 (not included) 
10 x 3 ml (lyophilisate) 
Control 
For internal quality control, use: 
ABX Pentra N Control, Ref. A11A01653 (not included) 
10 x 5 ml (lyophilisate) 
ABX Pentra P Control, Ref. A11A01654 (not included) 
10 x 5 ml (lyophilisate) 
Each control should be assayed daily and/or after each calibration. 
ABX Pentra ALP CP 
Reagent 2 
ABX Pentra ALP CP 
Reagent 1 
ALP CP 
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The frequency of controls and the confidence intervals should 
correspond to laboratory guidelines and country-specific directives. 
The results must be within the range of the defined confidence limits. 
Each laboratory should establish a procedure to follow if the results 
exceed these confidence limits. 
Materials required but not provided 
• Automated clinical chemistry analyser 
• Standard laboratory equipment. 
Specimen 
• Serum. 
• heparin plasma. 
Loss of activity within 2 - 3 days at 15 - 25 °C 10 %. 
Reference range (4,5) 
Adults: 
Children: 
Storage and Stability 
Reagents, in unopened cassettes, are stable up to the expiry date on 
the label if stored at 2-8 °C protected from light and contamination is 
avoided. 
Stability after opening : refer to the paragraph ’’Performance on ABX 
Pentra 400’’. 
Do not freeze the reagents. 
Assay Procedure 
Test instructions for other automated systems than ABX Pentra 400 are 
available on request. 
Waste Management 
1. Please refer to local legal requirements. 
2. This reagent contains sodium azide (0.95 g/l) as a preservative. As 
sodium azide may react with lead or copper to form explosive metal 
azides, this reagent should be disposed of by flushing with copious 
amounts of water. 
General Precautions 
1. This reagent is for professional in-vitro diagnostic use only. 
2. Do not swallow! Avoid contact with skin and mucous membranes. 
3. During reaction p-nitrophenol is produced which is poisonous 
when inhaled, swallowed or absorbed through skin. If the reaction 
mixture comes in contact with skin or mucous membranes wash 
copiously with water. 
4. Take the necessary precautions for the use of laboratory reagents. 
5. The reagent cassettes are disposable and should be disposed of in 
accordance with the local legal requirements. 
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6. Please refer to the MSDS associated with the reagent. 
Performance on ABX Pentra 400 
The performance data listed below have been obtained on the ABX 
Pentra 400 analyser. 
Number of tests: 125 tests 
Reagent Stability: 
Use fresh reagent each day. Discard the remaining reagent in container 
after use. Once open, the cassette is stable for 29 days. 
Sample volume: 4 l/test 
Detection limit: 
The detection limit is determined according to the Valtec protocol (6) 
and equals 6 U/l. 
Accuracy and Precision: 
• Repeatability (within-run precision) 
3 specimens of low, medium and high concentration and 2 controls are 
tested 20 times according to the recommendations found in the Valtec 
protocol (6). 
Stability : 7 days at 4 - 8 °C 
2 months at - 20 °C 
37 °C 
Women [U/l] 35 - 104 
Men [U/l] 40 - 129 
37 °C 
1 day [U/l] 250 
2 to 5 days [U/l] 231 
6 days to 6 months [U/l] 449 
7 months to 1 year [U/l] 462 
1 to 3 years [U/l] 281 
4 to 6 years [U/l] 269 
7 to 12 years [U/l] 300 
13 to 17 years (female) [U/l] 187 
13 to 17 years (male) [U/l] 390 
Mean value U/l CV % 
Normal control 90.79 1.27 
Pathological control 252.68 0.62 
Specimen 1 28.05 3.98 
Specimen 2 54.88 2.42 
Specimen 3 430.87 0.84 
ALP CP 
ABX Pentra 
S.A.S. au capital de 41.700.000 € - RCS Montpellier 328 031 042 - SIRET 328 031 042 000 42 - APE 332 B Latest version documents 
on www.horiba-abx.com 
• Reproducibility (run-to-run precision) 
2 specimens of medium and high levels and 2 controls are tested in 
duplicate for 20 days (2 series per day) according to the 
recommendations found in the NCCLS, EP5-A protocol (7). 
Linearity and Measuring Range: 
The reagent linearity is determined according to the recommendations 
found in the NCCLS, EP6-P protocol (8). 
Low linearity: 6 U/l 
High linearity: 1500 U/l, with automatic post-dilution: 6000 U/l. 
Correlation: 
100 patient samples are correlated with a commercial reagent taken as 
reference according to the recommendations found in the NCCLS, EP9- 
A2 protocol (9). 
The equation for the allometric line obtained is: 
Y = 0.99 x - 1.22 with a correlation coefficient r2 = 0.99. 
Interferences: 
Calibration stability: 
The calibration stability is 7 hours. 
Note: A recalibration is recommended when reagent lots change, and 
when quality control results fall outside the range established. 
Application releasea: 7.xx 
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2.4.7 Albumin Quantitation in Fracture Serum 
 
Albumin is a main constituent of plasma protein and has a vital role in the 
maintenance of osmotic pressure.  It is a key mediator for the fixation and 
transport of a plethora of circulatory products.  It is known that albumin serum 
constitutes a predictive factor in the altered levels of bilirubin, calcium and 
hormones due to an impaired hepatic function and inflammatory processes.  An 
increase in albumin is indicative of dehydration, whereas decreases may represent 
malnutrition, synthesis alteration, liver disease and the acute-phase response  
(Doumas and Peters, 1997; Nolen et al., 2013).  
 
From Horiba datasheet: Colorimetric determination is via bromoscol green 
(BCG).  At pH 4.2 the BCG selectively fixes itself to albumin, colouring it blue.  
The biochemical analyser (Horiba, Montpellier) can quantitatively determine in 
serum via colorimetry, as per the following methodology; 
 
1.  Steps 1-3 were repeated as for the b-ALP protocol, as previous. 
 
2.  The ABX Pentra Albumin ready-to-use reagent was employed.  The solution is 
comprised of the following constituents: 
 Succinate acid: 58 mMol L-1 
 Bromocresol green: 0.14 g L-1 
 Brij 35: 7 mL L-1 
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3.  The reagent was placed in the relevant compartment in the machine.  
Commercially available calibrator (ABX Pentra Multical) and control (ABX 
Pentra N and P control) were also used alongside the albumin-binding reagent. 
 
4.  Samples were processed on the analyser as previous protocol.  Datasheets 
available overleaf. 
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ABX Pentra Micro-albumin CP (Serum/Plasma) 
Ref.: A11A01623 
Volume R1: 19 ml 
Volume R2: 4.5 ml 
Diagnostic reagent for quantitative in-vitro 
determination of Albumin (ALB) in serum 
and plasma by immunoturbidimetric assay. 
Clinical Interest 
Albumin constitutes a prediction factor in the transport alteration of 
bilirubin, calcium and hormones related to hepatic dysfunction and/or 
inflammation. 
ABX Pentra Micro-albumin CP is a immunoturbidimetric assay 
developed to accurately measure ALB concentration in serum and 
plasma samples. 
Method 
When an antigen-antibody reaction occurs between ALB in a sample 
and anti-ALB antibody agglutination results. This agglutination is 
detected as an absorbance change, with the magnitude of the change 
being proportional to the quantity of ALB in the sample. The actual 
concentration is then determined by interpolation from a calibration 
curve prepared from calibrators of known concentration. 
Reagents 
ABX Pentra Micro-albumin CP is ready-to-use. 
1. After measurements are taken, reagent cassettes should remain in 
ABX Pentra 400 refrigerated tray. 
2. Care should be taken not to interchange the caps of the reagent 
cassettes. 
3. Reagents with different lot numbers should not be interchanged or mixed. 
4. ABX Pentra Micro-albumin CP should be used according to this 
reagent notice. HORIBA ABX cannot guarantee its performance if 
used otherwise. 
Handlinga 
Remove both caps of the cassette. If present, remove foam by using a 
plastic pipette. 
Position the respective protective cap, ref. GBM0969 on R1 and Ref. 
GBM0970 on R2 and place in the refrigerated ABX Pentra 400 reagent 
compartment. 
Calibrator 
For calibration, use: 
ABX Pentra Protein Cal, Ref. A11A01698 (not included) 
4 x 1 ml 
Reagent 1: Buffer solution 
Glycine buffer solution 
Reagent 2: Antiserum 
Anti-human ALB antibody (goat) 
containing 1.2-2.4 units per 1ml 
a. Modification from index H to I: new handling. 
Control 
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For internal quality control, use: 
ABX Pentra Protein Control L/H, Ref. A11A01700 (not included) 
2 x 1 ml + 2 x 1 ml (Only the low control is titrated) 
Each control should be assayed daily and/or after a calibration. 
The frequency of controls and the confidence intervals should 
correspond to laboratory guidelines and country-specific directives. 
The results must be within the range of the defined confidence limits. 
Each laboratory should establish a procedure to follow if the results 
exceed these confidence limits. 
Materials required but not provided 
• Automated clinical chemistry analyser 
• ABX Pentra Sample diluent CP, Ref. A11A01662, 99 ml 
• Standard laboratory equipment. 
Specimen 
• Serum. 
• Plasma. 
After sampling, the test should be performed without delay. If the test 
can not be done immediately, the sample should be placed in a tightly 
sealable container and stored at -20 °C. Repeated freezing and 
thawing should be avoided. 
Reference range 
35 - 52 g/l. 
Because values could vary according to the age, the diet, the gender 
and the geographic repartition, we recommend that each laboratory 
establishes its own reference range. 
Micro- albumin CP 
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Storage and Stability 
Reagents, in unopened cassettes, are stable up to the expiry date on 
the label if stored at 2-10 °C and protected from light. 
Stability after opening : refer to the paragraph ’’Performance on ABX 
Pentra 400’’. 
Assay Procedure 
Test instructions for other automated systems than ABX Pentra 400 are 
available on request. 
Waste Management 
1. Please refer to local legal requirements. 
2. This reagent contains less than 0.1 % of sodium azide as a 
preservative. As sodium azide may react with lead and copper to 
form explosive metal azides, this reagent should be disposed of by 
flushing with copious amounts of water. 
General Precautions 
1. This reagent is for professional in-vitro diagnostic use only. 
2. Diagnosis should only be made after taking clinical symptoms and 
the results of other tests into consideration. 
3. Specimens should be treated as potentially infectious (HIV, 
Hepatitis B virus, Hepatitis C virus, etc.) and handled with 
appropriate caution. 
4. The reagent cassettes are disposable and should be disposed of in 
accordance with the local legal requirements. 
5. Please refer to the MSDS associated with the reagent. 
Performance on ABX Pentra 400 
The performance data listed below have been obtained on the ABX 
Pentra 400 analyser. 
Number of tests: 150 tests 
On board Reagent Stabilitya: 
Once opened, the reagent cassette placed in the refrigerated ABX 
Pentra 400 reagent compartment is stable for 35 days. 
Sample volume: 12 l/test 
Detection limit: 
The detection limit is determined according to the Valtec protocol (2) 
                                                                                              Materials and Methods 
138 
and equals 1 g/l. 
Accuracy and Precision: 
• Repeatability (within-run precision) 
3 specimens of low, medium and high concentration and 1 control are 
tested 20 times according to the recommendations found in the Valtec 
protocol (2). 
• Reproducibility (run-to-run precision) 
2 specimens of low and high levels and 1 control are tested in 
duplicate for 20 days (2 series per day) according to the 
recommendations found in the NCCLS, EP5-A protocol (3). 
Linearity and Measuring Range: 
The reagent linearity is determined according to the recommendations 
found in the NCCLS, EP6-P protocol (4). 
Low linearity: 1 g/l 
High linearity: 67.7 g/l, with automatic post-dilution: 677 g/l. 
Correlation: 
100 patient samples are correlated with a commercial reagent taken as 
reference according to the recommendations found in the NCCLS, EP9- 
A2 protocol (5). 
The equation for the allometric line obtained is: 
Y = 1.17 x - 3.07 with a correlation coefficient r2 = 0.96. 
Interferences: 
Prozone effect: 
No excess of antigen has been detected up to a critical concentration 
of 450 g/l. 
Calibration stability: 
The reagent is calibrated on Day 0. The calibration stability is checked 
by testing 2 control specimens. 
The calibration stability is 23 days. 
Note: A recalibration is recommended when reagent lots change, and 
when quality control results fall outside the range established. 
Application releaseb: 4.xx 
a. Modification from index H to I: new on board reagent stability. 
Mean value g/l CV % 
Normal control 40.32 0.90 
Specimen 1 15.50 1.65 
Specimen 2 37.52 1.07 
Specimen 3 50.18 1.19 
Mean value g/l CV % 
Normal control 42.54 3.36 
Specimen 1 19.83 5.84 
Specimen 2 49.20 3.18 
Haemoglobin: No significant influence is observed up to 260 mol/l 
Triglycerides: No significant influence is observed up to 7 mmol/l 
Total Bilirubin: No significant influence is observed up to 530 mol/l 
Direct Bilirubin: No significant influence is observed up to 720 mol/l 
b. Modification from index H to I: suppression of minor index. 
Micro- albumin CP 
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2.4.8 Total Protein Quantitation in Fracture Serum 
 
The clinical significance of gross total protein changes suggests a presence of 
disease states.  The test is normally performed in conjunction with additional 
biochemical tests such as serum albumin, liver function and protein 
electrophoresis.  The albumin/globulin ratio can be calculated to procure more 
rigorous details regarding a patient’s condition.  Increased levels of total protein 
are associated with dehydration, lymphoma and chronic liver disease, whilst 
terminal liver disease and renal failure are synonymous of decreased amounts 
(Passing and Bablok, 1983; Nolen et al., 2013). 
 
From Horiba datasheet:  The principles of the total protein method are concerned 
with the reaction of peptide bonds of protein with copper II ions in alkaline 
solution to form a blue-violet complex; known as the biuret reaction.  The colour 
formed is proportional to the protein concentration. 
 
1. The samples were prepared as the two previous biochemical assays. 
2. The ABX Pentra total protein 100 CP ready-to-use reagent was obtained, 
which consisted of the following constituents: 
 Copper II sulphate 12 mMol L-1  
 Potassium sodium tartrate  32  mMol L-1 
 Potassium iodide  30  mMol L-1 
 Sodium hydroxide  600  mMol L-1 
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3.  The reagent was placed in the relevant compartment in the machine.  
Commercially available calibrator (ABX Pentra Multical) and control (ABX 
Pentra N and P control) were also used alongside the albumin-binding reagent.  
Samples were processed on the analyser as previous protocol.  Datasheet available 
overleaf. 
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A11A01669 
61 ml 
HORIBA ABX 
BP 7290 
34184 Montpellier - cedex 4 - France 
ABX Pentra Total Protein CP 
Ref.: A11A01669 
Volume: 61 ml 
Diagnostic Reagent for quantitative in-vitro 
determination of Total Proteins in serum by 
colorimetry. 
Clinical Interest 
Blood plasma is a concentrated solution of proteins, 60% of which is 
albumin. Considered in their entirety, plasma proteins perform very 
different tasks ranging from the maintenance of oncotic pressure to 
the transport of various molecules. They are involved in the complex 
mechanisms of blood coagulation and immunological reactions against 
antibodies. Enzymes, contained at low levels, constitute one group of 
the various proteins. An increase in their activity is a reliable indicator 
for cell injuries. 
The variations of the global level of proteins thus present a value of 
diagnostic orientation, which however should be completed with a 
more specific balance. 
Hypoproteinaemias reflect low levels of albumin linked to an abnormal 
renal protein escape, a protein synthesis defect (hepatic insufficiency) 
or a deficiency disease. 
Hyperproteinaemias are notably observed in connection with 
dehydration symptoms, but they can also result from dysglobulinaemia 
or a myeloma. 
Method 
Biuret reaction 
End-point method 
In the presence of copper salts, serum proteins form a coloured 
complex in an alkaline environment. 
Reagents 
ABX Pentra Total Protein CP is ready-to-use. 
ABX Pentra Total Protein CP should be used according to this reagent 
notice. HORIBA ABX cannot guarantee its performance if used otherwise. 
Handling 
Remove cap of the cassette. If present, remove foam by using a plastic 
pipette. Position the protective cap, ref. GBM0969 and place in the 
refrigerated ABX Pentra 400 reagent compartment. 
Calibrator 
For calibration, use: 
ABX Pentra MultiCal, Ref. A11A01652 (not included) 
10 x 3 ml (lyophilisate) 
Reagent: Potassium iodide 6 mmol/l 
Potassium sodium tartrate 21 mmol/l 
Copper sulphate 6 mmol/l 
Sodium hydroxide 58 mmol/l 
Control 
For internal quality control, use: 
ABX Pentra N Control, Ref. A11A01653 (not included) 
10 x 5 ml (lyophilisate) 
ABX Pentra P Control, Ref. A11A01654 (not included) 
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10 x 5 ml (lyophilisate) 
Each control should be assayed daily and/or after each calibration. 
The frequency of controls and the confidence intervals should 
correspond to laboratory guidelines and country-specific directives. 
The results must be within the range of the defined confidence limits. 
Each laboratory should establish a procedure to follow if the results 
exceed these confidence limits. 
Materials required but not provided 
• Automated clinical chemistry analyser 
• Standard laboratory equipment 
Specimen 
• Serum 
Reference range(8) 
We recommended that each laboratory establishes its own reference 
range. 
Ambulatory patients: 64 - 83 g/l 
6.4 - 8.3 g/dl 
Stationary patients: 60 - 78 g/l 
6.0 - 7.8 g/dl 
Total Protein CP 
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Storage and Stability 
Reagents, in unopened cassettes, are stable up to the expiry date on 
the label if stored at 2-8° C and protected from light. 
Stability after opening: refer to the paragraph "Performance on ABX 
Pentra 400". 
Assay Procedure 
Test instructions for other automated systems than ABX Pentra 400 are 
available on request. 
Waste Management 
Please refer to local legal requirements. 
General Precautions 
1. Reagent, for professional in-vitro diagnostic use only. 
2. The reagent cassettes are disposable and should be disposed of in 
accordance with the local legal requirements. 
3. Please refer to the MSDS associated with the reagent. 
Performance on ABX Pentra 400 
The performance data listed below have been obtained on the ABX 
Pentra 400 analyser. 
Number of tests: 300 tests. 
On board Reagent Stability: 
If the ABX Pentra Total Protein CP cassette is left on board the 
instrument at all times, the cassette is stable for 17 days. 
Sample volume: 2 l/test 
Detection limit: 
The detection limit is determined according to the Valtec protocol (4) 
and equals 1.56 g/l. 
Accuracy and Precision: 
• Repeatability (within-run precision) 
3 specimens of low, medium and high concentration and 2 controls are 
tested 20 times according to the recommendations found in the Valtec 
protocol (4). 
• Reproducibility (run-to-run precision) 
2 specimens of low and high levels and 2 controls are tested in 
duplicate for 20 days (2 series per day) according to the 
recommendations found in the NCCLS, EP5-A protocol (5). 
Linearity and Measuring Range: 
The reagent linearity is determined according to the recommendations 
found in the NCCLS, EP6-P protocol (6). 
Low linearity: 1.56 g/l 
High linearity: 100 g/l, with automatic post-dilution: 300 g/l. 
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Correlation: 
100 patient samples are correlated with a commercial reagent taken as 
reference according to the recommendations found in the NCCLS, EP9- 
A2 protocol (7). 
The equation for the allometric line obtained is: 
Y = 1.05 x - 2.6 with a correlation coefficient r = 0.9919. 
Interferences: 
Calibration stabilitya: 
The calibration stability is 1 day. 
Note: A recalibration is recommended when reagent lots change, and 
when quality control results fall outside the range established. 
Application release: 4.xx 
Warning 
It is the user's responsibility to verify that this document is applicable 
to the reagent used. 
Reference 
1. Bernard S. Biochimie Clinique. Edition Maloine, Paris (1982), 5, 
135. 
2. Gornall A. et al., Determination of serum proteins by means of the 
biuret reaction, J. Biol. Chem., 177, (1949), 751. 
3. Weichselbaum P.E., An accurate and rapid method for the 
determination of proteins in small amounts of blood serum and 
plasma, Am. J. Path, 16, (1946), 40. 
4. Vassault A., Grafmeyer D. Naudin C. et al., Protocole de validation 
de techniques (document B), Ann. Biol. Clin., 1986, 44, 686-745. 
5. Evaluation of Precision Performance of Clinical Chemistry Devices, 
Approved Guideline, NCCLS document EP5-A, Vol. 19, No. 2, 
february 1999. 
Mean value g/l CV % 
Normal control 51.6 1 
Pathological control 51.7 1.2 
Specimen 1 42.3 1.1 
Specimen 2 60.6 0.9 
Specimen 3 79.3 0.7 
Mean value g/l CV % 
Normal control 52.5 2.48 
Pathological control 51.8 2.35 
Specimen 1 44.9 2.79 
Specimen 2 66.69 2.17 
Haemoglobin: No significant influence is observed up to 72.5 mol/l 
Triglycerides: No significant influence is observed up to 4.79 mmol/l 
Total Bilirubin: No significant influence is observed up to 616 mol/l 
Direct Bilirubin: No significant influence is observed up to 616 mol/l 
a. Modification from index K to L: Modification of calibration stability. 
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6. Evaluation of the Linearity of Quantitative Analytical Methods, 
Proposed Guideline, NCCLS document EP6-P, Vol. 6, No. 18, 
september 1986. 
7. Method Comparison and Bias Estimation Using Patient Samples, 
Approved Guideline, 2nd ed., NCCLS document EP9-A2, Vol. 22, No. 
19, 2002. 
8. Tietz, N.W., Clinical guide to laboratory tests, 3rd Ed., (W.B. 
Saunders eds. Philadelphia USA), (1995), 518. 
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2.4.9 Statistical Data Analysis 
 
The datasets generated by the experimental procedures were subjected to 
statistical analysis to gauge the level of significance.  The statistical 
methodologies employed in this study were the Mann-Whitney U-test for non-
parametric data and the Student’s t-test and the one-way analysis of variance test 
(ANOVA) for the parametric data. 
 
2.4.9.1 The Mann-Whitney U-test 
 
This is a non-parametric test to a hypothesis about the difference in the medians of 
two populations using unpaired, independent data samples.  The U value is 
calculated and then compared to the tabulated U value obtained from a published 
table.  The null hypothesis (H0) is tested directly by assuming it is true and a 
conclusion is reached to either reject H0 or not to reject H0.  The alternative 
hypothesis is two-sided.  If the calculated U value is less or equal to (≤) the 
tabulated U value, then H0 is rejected.  If the calculated U value is more than (>) 
the tabulated U value, then H0 is not rejected.  The calculated U value in the 
Mann-Whitney U-test is calculated using the following formula: 
 
U1 = n1n2 + 0.5 n1 (n1 + 1) – R1 
 
U2 = n1n2 + 0.5 n2 (n2 + 1) – R1 
 
Whereby n1 and n2 are the sizes of the two samples; R1 and R2 are the sums of 
the ranks of observations in the first and second sample respectively.  The Mann-
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Whitney U test was used in the current study to calculate the statistical 
significance of data where differences were tested between two conditions (i.e., 
non-smokers and smokers) and using individual participants in each group.  The 
test can also be applied when n is unequal between groups and if the data is not 
normally distributed (Field, 2009).  
 
2.4.9.2 Student’s t-Test 
 
In the parametric experiments in the study where only one comparison was made 
(e.g., comparing treated cells with non-treated cells), the Student’s t-Test was 
applied.  The Student’s t-Test was introduced in 1908 by William Sealy Gosset; 
‘Student’ being a pen name.  The t-Test interrogates the statistical hypothesis 
which follows a Student's t distribution if the null hypothesis is accepted.  It can 
be used to determine if two sets of data are significantly different from each other, 
and is applied when the test statistic would follow a normal distribution.  Paired 
samples t-Tests typically consist of a group of matched pairs of units that have 
been tested twice, which are termed ‘repeated measures’.  The t-Test is employed 
where subjects are tested prior to a treatment, as in the CSE studies, when cells 
from the same patient are tested once more after the infusions of the extract.  By 
comparing the same patient's results before and after treating, each individual is 
effectively providing their own control.  In this way, the correct rejection of the 
null hypothesis can become much more likely, with statistical power increasing 
due to the elimination of the random inter-variation amongst different patients 
(Field, 2009).   
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2.4.9.3 Analysis of Variance (ANOVA) 
 
The analysis of variance method was applied to data which was normally 
distributed and was parametric; i.e., whereby an individual sample generated 
multiple datasets.  Where there was more than one comparison, as in the 
experiments involving differing BMP-2 concentrations, a one-way ANOVA was 
employed.  The ANOVA test is a collection of statistical models that are applied 
to configure differences between group means and their associated intervention(s), 
including variation within and between groups.  With the ANOVA method, the 
observed variance in a specific variable is divided into components attributable to 
diverse sources of variation.  In its simplest form, ANOVA affords a statistical 
test of whether or not the means of several groups are equal and applies a t-test to 
more than two groups.  Undertaking multiple dual-sample t-Tests in one assay 
would result in an increased chance of committing a type I error.  Type I errors 
occur when H0 is true, but is rejected, declaring something that is absent, or 
claiming a false result.  A type I error may be compared with a false positive in 
tests where a single condition is analysed.  The ANOVA test is therefore justified 
in comparing three or more means (groups or variables) for showing statistical 
significance (Field, 2009). 
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3.1 CLINICAL OBSERVATIONS 
Patient notes were obtained in order to ascertain any clinical issues that arose 
during the fracture healing process.  The following micrographs pertain to a 
number of difficulties that were uncovered at follow-up. 
3.1.1 Nonunion of fracture in a smoking patient 
 
 
 
 
 
 
 
 
 
 
 
Figure 23 (a):  2 days post presentation, plaster of Paris immobilisation in a 
smoking patient 
 
 
 
 
 
 
 
 
 
  
 
   
Figure 23 (b): 6 weeks post injury after external fixation (unilateral frame) 
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Figure 23 (c):  Nonunion of fracture, 6 months post-reduction 
 
Figure 23 (a), (b) and (c):  Radiographs taken from a smoking patient at presentation (a), 6 weeks 
post fracture (b) and at follow-up, 6 months after external fixation of the tibia and fibula.  The 
patient was a female smoker aged 43 at the time of injury, with no stated comorbidity.  Clinical 
reports state that there was no significant callus seen at 6 months, consistent with nonunion.  
Interestingly, no cells were expressed from this patient’s sample during processing in the 
laboratory. 
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3.1.2 Malunion Due to Obesity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
        
Figure 24 (a):  Obese patient 3 days post-injury, after internal fixation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24 (b):   Obese patient 6 months post surgery at follow up  
Figure 24 (a) and (b):  Radiographs taken from a non-smoking, 33 year old female obese patient 
at presentation (a) and (b), at follow-up, 6 months after internal operative fixation of the tibia and 
fibula.  The right image on radiograph (b) depicts broken screws at the distal portion of the lateral 
tibia (red circle). 
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3.1.3 Patient with Osteopenia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
                            (a)                                                               (b) 
Figures 25 (a) and (b):  Oblique x-ray images of osteopenic patient on day 1  
of presentation of fracture 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25 (a), (b) and (c):  Radiographs taken from a non-smoking, 84 year old female osteopenic 
patient at presentation (a) and (b) and at follow-up (c), 6 months after fracture of the tibia and 
fibula.   
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3.1.4 Patient with a History of Compartment Syndrome 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
                          (a)                                                             (b) 
Figures 26 (a) and (b):  Images of patient with compartment syndrome on (a) 
day 1 and (b) 6 months following fracture of tibia and fibula 
 
Figure 26 (a) and (b):  Radiographs taken from a non-smoking, 27 year old male patient, with a 
history of compartment syndrome and prolonged pain (for 6 months) at presentation (a) and (b) at 
follow-up, 6 months after internal fixation of the tibia.   
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3.1.5 Patient with Crohn’s Disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
                          (a)                                                             (b) 
Figures 27 (a) and (b):  Patient with Crohn’s Disease 
 
 
 
Figure 27 (a) and (b):  Radiographs taken from a non-smoking, 35 year old male, with a history 
of Crohn’s disease.  Radiographs show fracture at presentation (a) and (b) at follow-up, 6 months 
after internal fixation of the tibia and fibula.   
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3.2 FRACTURE HAEMATOMA CELL CULTURES 
The cellular morphology in the following micrographs (Figures 28-34), is 
indicative of a progenitor lineage and rapid division and widespread growth was 
observed in the cultures.  Cells were of a fibroblast-like, undifferentiated nature, 
spindle-shaped morphologically and were able to replicate themselves in the 
unspecialised culture media.  The cells readily became dislodged from the 
polystyrene substratum of the tissue culture flask by using a solution of trypsin 
and EDTA during the subculture, rendering them suitable for in vitro studies. 
 
Figures 28-34:  Fracture Haematoma Cells in Culture 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28:  A micrograph (x100) of fibroblast-like cells, migrating from the explanted fracture 
haematoma in vitro, after 7 days in the primary culture following collection from the patient. 
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Figure 29:  Micrograph of fibroblast-like cells (x100), isolated from the fracture haematoma, after 
72 hours in the first passage and displaying rapid growth.   
 
 
 
 
 
 
Figure 30:  Micrograph of confluent fibroblast-like cells (x100), after 7 days in the first passage.   
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Figure 31:  Micrograph of haematoma cells after 48 h in the second passage (x100).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32:  Micrograph of haematoma fibroblast-like cells (x100) after 72h in the second passage. 
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Figure 33:  Micrograph of haematoma fibroblast-like cells (x100) in the 7th day of the second 
passage.   
 
3.2.1 Mesenchymal Stem Cell Control Slide 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34:  Micrograph of MSCs cultured from control commercial cell line (Lonza, Tokyo).
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3.3 CHARACTERISATION OF HAEMATOMA CELLS USING 
QUALITATIVE IMMUNOCYTOCHEMICAL ANALYSES 
 
3.3.1 Immunofluorescence via Fluorescent Microscopy 
 
The following images were observed using a fluorescent microscope after cyto-
spinning and subsequent probing, of the extracted cells with various 
commercially-available antibodies for characterisation.  All cells were taken from 
5
th
 passages.  The antibody binds to the specific cell surface antigens and 
fluoresces due to the presence of conjugated FITC on the haematoma cells. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35: CD29.  Immunofluorescent labelling of slide-mounted cells isolated from haematoma 
cells using antibodies against CD29, a known mesenchymal stem cell surface antigen.   
 
 
____________________________________________________________Results 
159 
 
 
 
 
 
 
 
 
 
 
 
Figure 36:  CD44.  Positive immunofluorescent labelling of cells isolated from haematoma cells 
using antibodies against CD44, a mesenchymal stem cell surface antigen.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37:  CD105.  Immunofluorescent labelling of cells isolated from haematoma cells using 
antibodies against CD105 (Endoglin), a mesenchymal cell surface antigen.   
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Figure 38:  CD166.  Immunofluorescent labelling of cells isolated from haematoma cells using 
antibodies against CD166, a mesenchymal stem cell surface antigen.   
 
 
 
 
 
 
Figure 39:  CD34.  The haematopoietic stem cell marker, CD34 was used as a negative control on 
the mesenchymal cells and there was little evidence of uptake of this antibody. 
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Figure 40: Control Slide.  Non-probed MSCs stained with FITC under normal light microscopy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41: Control Slide.  Non-probed MSCs stained with FITC polyclonal antibody under 
fluorescent microscopy. 
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3.4 CELL ANALYSES USING FLOW CYTOMETRY 
 
Flow cytometry is a useful tool capable of performing a variety of assays on cell 
populations.  The instrument used in this study (Epics XL; Beckman Coulter, 
High Wycombe) confirmed the characterisation of the cells extracted from the 
fracture haematomas, which was done so alongside the immunofluorescence that 
had previously been performed.  Immunophenotyping is a quantitative technique 
that affords ‘triangulation’ within the study following observation of the typical 
morphological and physical properties, as well as a series of other 
immunocytochemical methods and therefore offers improved robustness of the 
notion that the cells of interest are indeed of a mesenchymal origin. The same CD 
markers used for the previous fluorescent microscopy assays were used for 
immunophenotyping; suspended cells were labelled with commercially available 
antibodies (CD markers), conjugated with either FITC or PE (phycoerythin) as 
applicable. 
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3.4.1 Cellular Immunophenotyping via Flow Cytometry
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 42:  Immunophenotyping CD29. Positive expression of CD29 MSC marker using flow 
cytometry immunophenotyping. 
 
 
 
 
 
 
 
Figure43:  Immunophenotyping CD44.  Highly-positive expression of CD44 MSC marker via 
immunophenotyping on flow cytometry. 
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Figure 44:  Immunophenotyping CD73.  Positive expression of CD73 (PE) MSC marker. 
 
 
 
 
 
 
 
 
Figure 45:  Immunophenotyping CD105.  Positive expression of CD105 MSC marker using 
flow cytometry (FITC). 
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Figure 46:  Immunophenotyping CD166.  Positive expression of CD166 MSC marker by flow 
cytometry. 
 
 
 
 
 
 
 
Figure 47:  Immunophenotyping CD34.  Negative expression of CD34 MSC marker via flow 
cytometry immunophenotyping, which was used as a negative control. 
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Figure 48:  Immunophenotyping Control.  Negative control via flow cytometry 
immunophenotyping, using non-probed, FITC-stained MSCs.  The histogram on the right shows a 
negligible amount of autofluorescence taking place in cell suspensions. 
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Table 10:  Summary of Mesenchymal Stem Cell Markers Over 10 Passages 
 
 
Marker 
 
 
1
st
 
Passage 
 
 
2
nd
 
Passage 
 
3
rd
 
Passage 
 
4
th
 
Passage 
 
5
th
 
Passage 
 
6
th
 
Passage 
 
7
th
 
Passage 
 
8
th
 
Passage 
 
9
th
 
Passage 
 
10
th
 
Passage 
 
CD29 
 
 
99.95% 
 
100% 
 
93.18% 
 
88.13% 
 
98.22% 
 
99.78% 
 
99.80% 
 
 
99.85% 
 
99.63% 
 
100% 
 
CD44 
 
 
100% 
 
100% 
 
98.27% 
 
97.29% 
 
99.49% 
 
99.79% 
 
99.83% 
 
 
100% 
 
99.65% 
 
98.87% 
 
CD73(PE) 
 
 
100% 
 
100% 
 
97.38% 
 
100% 
 
99.82% 
 
100% 
 
100% 
 
100% 
 
 
100% 
 
100% 
 
CD105 
 
 
35.72% 
 
47.58 
 
71.96% 
 
83.21% 
 
90.91% 
 
94.44% 
 
91.75% 
 
92.48% 
 
81.40% 
 
69.43% 
 
CD166 
 
 
99.36% 
 
97.33% 
 
100% 
 
98.86% 
 
98.33% 
 
100% 
 
 
99.82% 
 
99.65% 
 
 
99.49% 
 
100% 
 
CD34 
 
 
69.39% 
 
34.42% 
 
25.35% 
 
19.29% 
 
5.98% 
 
6.85% 
 
6.45% 
 
5.85% 
 
7.68% 
 
6.62% 
 
Table 10:  Expression of various cell surface antigens that are known to be expressed by mesenchymal stem cells.  The data is representative of cells extracted from one 
patient’s fracture haematoma.  Each passage number (1-10) denotes a 5-day culture. 
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3.5 Cell Population Counting Using Flow Cytometry (FACS) 
Having established the identity of the cells of interest isolated from human 
fracture haematomas, it was possible to conduct analyses that may find 
differences in cells between smoking and non-smoking groups.  Indeed, flow-
cytometric counting can determine culture proliferation rates of the cells of 
interest isolated from the fracture haematoma and would perhaps give an 
indication of healing performances between patient groups.  Qualitative 
comparisons can be made between smokers and non-smokers, the hypothesis 
being that cells extracted from smokers are of inferior quality and are 
disadvantaged in terms of proliferation, growth and development.  Quantitative 
data obtained from flow cytometry can provide information regarding the 
quantity, volume and granulation of cells processed on a flow cytometer and this 
preliminary data is shown later. 
 
 
 
 
 
 
 
  
 
 
Figure 49:  Example of data acquisition from flow cytometer counting using fluorospheres as the 
calibration medium.  The count for this particular sample was 1192 cells per l. 
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3.5.1 Flow Cytometry Cell Gating 
 
 
 
 
Figure 50:  Flow Cytometry Gating 
Example of a flow-cytometric plot of fibroblast-like cells taken from a population of cells that had 
been cultured to a level of confluence in vitro.  The flow-cytometer is capable of quantitating cells 
in a given sample (data shown later) and is able to determine this number via the addition of an 
equal quantity of flow-count Fluorosphere Beads (Beckman-Coulter, High Wycombe).  The region 
of fibroblast-like cells (blue dots) is strategically ‘gated’, such that particulate debris and obvious 
doublets (shown as red dots) are precluded from the count for each sample.  Actual plots can be 
found in the appendices. 
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Data not significant (p>0.05; Mann-Whitney U test) 
 
 
Figure 51:  Cell Proliferation   
Graph showing cell proliferation differences in fracture patients who were smokers (n=7) 
compared to those who confirmed a non-smoking status (n=11).  Values are means with standard 
error bars (±SEM) and represent 5 days of in vitro expansion after baseline counts using flow 
cytometry (%D) (actual p=0.17).  All cells were taken from 5th passage. 
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3.6.2 Mesenchymal Stem Cell Proliferation (CSE-Treated vs. Untreated) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(*p<0.05; Student’s t-test) 
 
 
Figure 52: Effect of CSE on Proliferation  
Cells extracted from only non-smoking patients (n=10) were divided into two groups; one group 
was treated with CSE and the other left untreated.  It can be seen that in vitro proliferation rates in 
those cells infused with CSE were significantly reduced when quantitated after five days (d5) 
when compared to the untreated group using ANOVA.  Values are mean counts, normalised into 
% change (% D) from baseline after 5d; standard error bars (±SEM) are also shown. All cells were 
taken from 5
th
 passage. 
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3.6.3 Cell Necrosis Comparison (CSE-Treated vs. Untreated) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(*p<0.05; Student’s t-test) 
 
Figure 53: Effect of CSE on Necrosis  
 
Graph showing necrosis in cell cultures (CSE-treated vs. untreated) as detected via propidium 
iodide flow cytometry; values are mean with standard error bars (±SEM).  After culturing through 
4 passages, non-smoker cells treated with CSE (n=10) had a higher proportion of necrotic cells 
than the untreated group.  There was a further increase of necrosis in the subsequent passage in 
CSE cultures. 
 
 
        * 
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3.6.4 Nitric Oxide Levels in Lysed Cells (CSE Treated vs. Untreated) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(*p=0.05; Student’s t-test) 
 
Figure 54:  Effect of CSE on Nitric Oxide   
Graph to show cytoplasmic nitric oxide levels in CSE-treated vs. untreated lysed cell cultures; 
values are means with standard error bars (±SEM).  The CSE-treated group (n=10) showed 
reduced levels (p=0.05) of nitric oxide within the cytoplasm of the haematoma-derived 
mesenchymal stem cells when compared to the untreated group (n=10).  All cells extracted for the 
assay were extracted from non-smoking patients. 
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3.6.5 Recovery of MSCs Subjected to CSE Infusion 
 
 
 
 
 
 
 
 
 
 
 
Figure 55 a) Cells before CSE Infusion (d7 of culture) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 55 b) Cells after CSE Infusion (2.5%) (d21) 
 
 
 
 
 
 
 
 
 
 
 
 
              Figure 55 c) Cell recovery after withdrawal of CSE (d35) 
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Figures 55 a) – c) (Previous Page):  a) Cells were cultured in IMDM and allowed to become 
confluent.  After 7 days, CSE (2.5%; 20 cigarettes/day equiv.) was infused into the cell culture 
media.  b) After 14 days of CSE infusion (d21), cell cultures became less concentrated and 
lamellipodia structures in cells became thinned and fragmented.  c)  Cultures were then allowed to 
recover following infusions in untreated IMDM for 14 days.  Cells were observed, using light 
microscopy, to be recovering in the absence of CSE; populations increased and regained a notable 
state of confluence.   
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3.6.6 MSC Cell Recovery Assay 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data not significant (p>0.05; ANOVA) 
 
 
 
Figure 56:  MSC Recovery Assay   
Graph showing haematoma cell recovery following withdrawal of a 5-day infusion of CSE from 
cell cultures after 7, 14 and 21 days (n=10), against untreated (n=10) and continuous (n=10) CSE 
infusion.  All values are normalised from the mean proliferation data in the respective groups.  
Error bars not shown due to high levels of variance within analyses. 
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(***P <0.0001; ANOVA) 
 
Figure 57:  BMP-2 Infusion in MSCS in Normal Environment.   
In vitro effects on MSC development after 72h of various amounts (10 and 100 ng mL
-1
) of 
infused exogenous bone morphogenetic factor-2 (BMP-2) on MSCs (n=10), vs. the control group 
(BMP-2=0 ng mL
-1
) (n=10), via the MTT assay.  Graph shows a concentration of 100 ng mL
-1
 to 
be highly significant with regard to enhancing cell viability in a normal environment. Values are 
means with standard error bars (±SEM). 
  
 
   *** 
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(*p>0.05, data not significant; ANOVA) 
 
 
Figure 58.  BMP-2 Infusion in CSE Environment.    
In vitro effects on MSC development after 72h of various amounts (10, 100 and 500 ng mL
-1
 of 
infused exogenous bone morphogenetic factor-2 (BMP-2), vs. control group (BMP-2=0 ng mL
-1
), 
via the MTT assay.  All values are mean with standard error bars (±SEM).  All cell groups (each 
n=10) were first treated with CSE (2.5%) for 5d prior to BMP-2 infusions. 
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3.7 MOLECULAR STUDIES 
 
3.7.1 SDS-PAGE – Fracture Haematoma Serum 
 
Following the electrophoresis of haematoma serum, polyacrylamide gels were 
digitally photographed for documentation purposes and are shown here.  In order 
to ascertain the optimal resolution of protein on the gels, two different amounts of 
lysates were used; Figure 59 shows an image of a gel where 10L of loaded 
sample was applied to each lane.  The purposely-overloaded silver nitrate stained 
gel (see Figure 60) showed no additional bands than those gels stained using the 
Coomassie blue technique. 
 
The aims of the electrophoresis were to attempt the resolution of acute phase 
proteins that are known to be present in the haematoma serum.  The patient 
samples were resolved alongside the controls foetal calf serum and human sera 
derived from peripheral blood and a protein marker (SERVA, Heidelberg) was 
included to estimate molecular weights of resolved bands.  The visible proteins 
seen only in the haematoma lanes that were resolved at 21kDa and 14 kDa were 
haptoglobin and haemoglobin chains respectively and this was confirmed using 
mass spectrometry.  
 
 
 
 
 
 
____________________________________________________________Results 
180 
3.7.2 SDS-PAGE of Fracture Haematoma Serum: Coomassie Blue Stain 
 
 
 
 
 
 
Figure 59:  Electrophoresis of Haematoma Serum Proteins (Coomassie Blue).   
 
SDS-PAGE gel (16% polyacrylamide) showing resolved haematoma serum proteins (lanes are 
haematoma serum; protein marker; foetal calf serum; human peripheral blood serum); lysates were 
loaded at a rate of 5 L per well to optimise resolution of bands.  This amount equated to 
approximately 0.01 mg of serum protein in each well, as per published data (Betgovargez et al., 
2005).  The bands that were resolved at ~67 kDa are serum albumin; the two bands visible at ~14 
kDa are haemoglobin  (lower) and haemoglobin  (upper) as identified using mass spectrometry 
(see later) and represent one patient sample. 
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3.7.3 SDS-PAGE of Fracture Haematoma: Silver Nitrate Stain  
 
 
 
SDS-PAGE 
 
  
 
 
            Ser.          Pm       H                  H                    H                 Pm          FCS 
 
 
 
 
 
Figure 60.  Electrophoresis of Haematoma Serum Proteins (Silver Nitrate).   
Photograph of SDS-PAGE (16% polyacrylamide) gel (SERVA, Heidelberg) of fracture 
haematoma serum proteins (Lanes: Ser.=human serum; Pm = Protein marker; H=Haematoma; 
FCS=Foetal Calf Serum).  The lysates were purposely overloaded at a quantity of 10 L per well, 
equating to ~0.02 g of serum protein in each lane, as again described by Betgovargez et al. 
(2005).  A silver nitrate stain was used in an attempt to further improve resolution of the proteins 
so that relevant acute phase proteins may be isolated from haematoma samples. 
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3.7.4 Peptide Mass Fingerprint (PMF) for Haemoglobin Alpha (Hb   
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Figure 61:  Mass Spectrometry (Hb ).   
Peptide Mass Fingerprint (PMF) via mass spectrometry determining the presence of Hb  on the 
SDS-PAGE gel of the bands seen at the 12kDa level, as derived from serum obtained from the 
fracture haematoma (courtesy of Kevin Bailey, University of Nottingham). 
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3.7.5 Peptide Mass Fingerprint (PMF) for Haemoglobin Beta (Hb  
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Figure 62:  Mass Spectrometry (Hb ).   
 
Peptide Mass Fingerprint (PMF), via mass spectrometry, determining the presence of Hb  on the 
SDS-PAGE gels, at the 12kDa level, as derived from the serum obtained from fracture 
haematomas (courtesy of Kevin Bailey, University of Nottingham). 
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3.7.6 Peptide Mass Fingerprint (PMF) for Haptoglobin (Hp) 
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Figure 63:  Mass Spectrometry (Hp).   
 
Peptide Mass Fingerprint (PMF), via mass spectrometry, determining the presence of haptoglobin 
(Hp) on the SDS-PAGE gels (12kDa level) in the serum of fracture haematoma (courtesy of Kevin 
Bailey, University of Nottingham). 
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3.7.7 Intracellular Labelling of MSCs Using IL-6 and TGF-A 
Preliminary Study  
The following flow cytometry histograms show cytoplasmic expression of the 
acute-phase proteins IL-6 and TGF- in MSCs extracted from smoking and non-
smoking patients. 
 
 
 
 
 
 
 
Figure 64.  Flow cytometry histogram showing intracellular expression of IL-6 in MSCs extracted 
from a smoking patient. 
 
 
 
 
 
 
 
Figure 65.  Flow cytometry histogram showing intracellular expression of IL-6 in MSCs extracted 
from a non-smoking patient. 
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Figure 66.  Flow cytometry histogram showing intracellular expression of TGF- in MSCs 
extracted from a smoking patient. 
 
 
 
 
 
 
Figure 67.  Flow cytometry histogram showing intracellular expression of TGF- in MSCs 
extracted from a non-smoking patient. 
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Sample No.→ 
 
Protein of 
Interest 
↓ 
 
 
1 
 
 
2 
 
3 
 
4 
 
Mean 
_ 
() 
 
 
IL-6 
(Smokers) 
 
 
98.69% 
 
99.05% 
 
99.20% 
 
98.55% 
 
98.87% 
 
IL-6  
(Non-Smokers) 
 
 
98.26% 
 
97.78% 
 
98.52% 
 
99.55% 
 
98.53% 
 
TGF-
(Smokers) 
 
 
99.23% 
 
97.42% 
 
98.45% 
 
98.82% 
 
98.48% 
 
TGF-
(Non-Smokers) 
 
 
97.97% 
 
98.90% 
 
98.81% 
 
94.23% 
 
97.48% 
 
 
 
Table 11:  Intracellular IL-6 and TGF- 
 
Tabulated summary of preliminary intracellular protein labelling of IL-6 and TGF- via flow 
cytometry, preliminary data: MSCs were extracted from non-smokers (n=4) and smokers (n=4).  
MSC membranes were permeablised prior to probing with IL-6 and TGB- (separately) and then 
analysed on a flow cytometer.  Values shown are amount of cells positive for each intracellular 
marker, with the respective mean value in the final column. 
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3.7.8 Quantitation of VEGF-A via ELISA in Fracture Haematoma Serum 
(Smokers vs. Non-Smokers): A Preliminary Study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data not significant (p>0.05; Mann-Whitney U test) 
 
 
Figure 68: ELISA (VEGF-A)   
Graph showing levels of VEGF-A in serum extracted from haematoma fractures using ELISA, 
which were compared between smokers (n=4) and non-smokers (n=5).  Values are means with 
standard error bars (±SEM).  This is representative of preliminary data in the study. 
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Data not significant (p>0.05; Mann-Whitney U test) 
 
 
Figure 69: ELISA (IL-6)   
Graph derived from ELISA for preliminary interleukin-6 (IL-6) quantitation, showing amounts of 
this cytokine in lysed fracture MSCs, comparing levels between non-smokers (n=5) and smokers 
(n=5).  Values are means with standard error bars (±SEM). 
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3.8 BIOCHEMICAL STUDIES 
3.8.1 Comparison of bone-Alkaline Phosphatase (b-ALP) in Fracture 
Haematoma Serum in Smokers vs. Non-Smokers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data not significant (p>0.05; Mann-Whitney U test) 
 
 
Figure 70: b-ALP Levels in Serum  
 
Comparison of bone alkaline phosphatase (b-ALP) levels between smokers (n=10) and non-
smokers (n=10) in fracture serum.  Normal reference range in peripheral blood: women, 35-104 
IU; men, 40-129 IU.  Smokers’ serum showed higher levels of b-ALP, but a wide variation in data 
rendered the result not significant.  Values are means with standard error bars (±SEM). 
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3.8.2 Serum Albumin Biochemical Quantitation in Fracture Haematoma 
Serum (Smokers vs. Non-Smokers) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(*p<0.05, Mann-Whitney U test) 
 
 
 
Figure 71:  Serum Albumin Levels 
 
 
Comparison of serum albumin levels; smokers vs. non-smokers (smokers (n=10) and non-smokers 
(n=10)).  Graph shows albumin levels in smokers’ fracture haematoma serum is significantly 
reduced (p=0.016) when compared to non-smokers’ levels. Values are means with standard error 
bars (±SEM). 
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3.8.3 Comparison of Total Protein in Fracture Haematoma Serum 
(Smokers vs. Non-Smokers) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(**p<0.01; Mann-Whitney U test) 
 
 
 
Figure 72: Total Protein Levels  
 
 
Comparison of serum total protein (albumin + globulin) between smokers (n=10) and non-smokers 
(n=10).  Graph shows levels of total protein in smokers’ fracture haematoma serum is significantly 
reduced (actual p=0.007) compared to amounts in non-smokers’ serum.  Values are means with 
standard error bars (±SEM). 
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4 DISCUSSION 
 
 
This study focuses on the clinically-recognised problem of delayed fracture 
healing in people who smoke tobacco.  The convincing findings of orthopaedic 
investigative groups, such as Adams et al. (2001), have demonstrated a 
significantly-delayed union time in the healing of tibial fractures in human 
patients who smoke.  The literature concerning the clinical issues of smoking and 
fracture healing is relatively more common than the biochemical aspects on 
human, which are poorly documented.  Indeed,  inserting ‘effects of smoking on 
fracture healing’ into the Pubmed online search engine returns just 68 
publications, of which less than 30 are more recent than 5 years old.  Those that 
are available are mainly in the form of reviews, focus upon studies undertaken on 
animals or are written about the generalised problems associated with fracture 
healing.  The aims of this study were therefore two-fold and were focused on the 
i) cellular and ii) molecular mechanisms that are relevant in human fracture repair 
and how smoking can impact on certain biochemical processes.  The primary aim 
was to isolate and study cells, from the fracture microenvironment, particularly 
those that are directly involved in bone regeneration; the second was to identify 
and analyse the acute-phase proteins in both haematoma serum and fracture cells 
that had been extracted from patient samples, with specific regard to making 
comparisons between smokers and non-smokers. The hypothesis is that cells and 
acute-phase proteins, the latter produced by the cells and those present in the 
ECM, extracted and isolated from those patients who were smokers, are inferior in 
terms of both quality and quantity than those isolated from non-smoking patients.   
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4.1.1 Clinical Findings from Patient Histories 
 
The patient records were obtained from the hospital registry so as to identify any 
anomalies that were apparent during the fracture healing process.  Of the 48 
patients recruited into this study, the majority of fractures healed satisfactorily 
without any problems.  However, there were five patients whose injuries were 
hampered by certain medical conditions.  These idiosyncrasies included nonunion 
of fracture, obesity, osteopenia, compartment syndrome and Crohn’s disease and 
are discussed here. 
 
4.1.1.1 Smoking-Related Nonunion of Fracture 
 
The radiographs shown in Figures 23 (a), (b) and (c) were acquired from a 
smoking patient at presentation (a), 6 weeks post fracture (b) and at follow-up, 6 
months after external fixation of the tibia and fibula.  The patient was a female 
smoker aged 43 at the time of injury, with no stated underlying comorbidity.  
Clinical reports state that there was no significant callus seen at 6 months, which 
is consistent with nonunion. The individual required external fixation using a 
unilateral frame, which was surgically introduced after it became evident that the 
fracture was not healing in a satisfactory manner.  Interestingly, no cells were 
expressed from this patient’s sample during processing in the laboratory.  Indeed, 
the volume of sample was insufficient for any in vitro analysis of any description.  
The miniscule nature of the haematoma sample likely suggests that there was a 
general lack of it at the fracture site, which has resulted in nonunion.  As it is the 
callus that is derived from the ECM within the haematoma, then this would 
correlate with the comment in the patient notes that there was no callus seen even 
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after 26 weeks post-injury.  It would appear therefore that smoking has caused a 
diminished fracture haematoma in this particular patient.  There were no previous 
comorbidities stated in the medical notes and the individual was otherwise 
healthy.  It is probable that cigarette smoking has been contributory to reduced 
extravasation at the point of injury due to vasoconstriction, hypoxia and toxicity to 
the mediators that are involved in haematoma synthesis in early fracture repair.  
This patient would possibly have benefited from receiving clinical intervention(s), 
such as BMP-2, to accelerate the rate of healing and stimulation of callus 
synthesis within the fracture site. 
 
Yu et al. (2010) showed that exogenous BMP-2 has the potential to be effective in 
patients that require clinical intervention to assist in bone regeneration.  The group 
defined the role of BMP-2 during the early stages of fracture repair and how the 
growth factor can regulate the fate of skeletal progenitor cells in live rats.  
Fractures were produced in the anaesthetised animals and rhBMP-2 was then 
injected directly into the fracture site.  It was reported that the BMP-2 increased 
deposition and resorption of cartilage and bone in non-stabilised fractures via 
endochondral ossification in the rats and also induced cartilage formation in 
stabilised fractures via intramembranous ossification.  It was also shown via 
immunohistochemical techniques that BMP-2 directed cell differentiation towards 
chondrogenic lineage in the periosteum and recruited MSCs from the endosteum 
and periosteum (Yu et al., 2010).  The effects of BMP-2 on cultured MSCs was 
undertaken in this study and the results are discussed later. 
 
                                                                                                                  Discussion 
197 
4.1.1.2 Obesity 
 
Radiographs shown in Figure 24 (a) and (b) were acquired from a non-smoking, 
33 year old female obese patient at presentation (a) and (b) and at follow-up, 6 
months after internal operative fixation of the tibia and fibula.  The x-ray image 
(b) depicts a broken screw at the distal portion of the lateral tibia (red circle), 
around the lateral malleolus anatomically.  The medical notes stated that the 
patient’s BMI arose to over 35 in the 6 months following internal fixation, which 
is classified as Grade II obesity under the Edmonton obesity staging system 
(Padwal et al., 2011).  The internal fixators used in surgical reduction and fixation 
are composed of either titanium (Yang et al., 2013) or stainless steel (Greene et 
al., 2008) which has been sheared in this case due to the mechanical stresses that 
have been placed upon it by the weight of the patient.  This patient required 
revision surgery to reinstate the integrity of the fracture.  Ideally, weight-bearing 
should be undertaken gradually and under rehabilitative physiotherapeutic 
management, ensuring that the strength of the newly formed bone is sufficient to 
support the weight of the patient.  Obesity can become especially problematic in 
fracture due to weight gain synonymous with inactivity as a consequence of 
immobility following leg fracture, a condition that has resulted in healing 
complications for this individual.  
 
Obesity in fracture has actually been deemed to be beneficial due to the positive 
effect of mechanical loading afforded by body weight on bone development. This 
is a controversial research area and many studies support the view that fat 
accumulation has an injurious impact on bone mass.  The likelihood is that obesity 
affects bone metabolism through a number of mechanisms.  Due to the fact that 
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adipocytes and osteoblasts are both derived from multipotent mesenchymal cells, 
obesity may increase adipocyte differentiation and fat accumulation whilst 
decreasing osteoblast differentiation and bone formation.  Obesity is also 
commensurate with chronic inflammation and there is an up-regulation of 
circulatory and tissue proinflammatory cytokines, giving rise to increased 
osteoclastic activity and bone resorption via the modification of the receptor 
activator of NF- (RANK)/RANK ligand/osteoprotegerin biochemical pathway.  
The increase in proinflammatory cytokine production seen in obesity is caused by 
excessive secretion of leptin and decreased production of adiponectin, interfering 
with the mechanisms involved in normal bone formation and resorption.  High fat 
intake also impedes intestinal calcium absorption, thereby decreasing the 
availability of Ca
2+
 for bone formation (d'Herbomez et al., 2007). 
 
4.1.1.3 Osteopenia and Fracture 
 
The x-ray images seen in Figures 25 (a), (b) and (c) show a fracture from a non-
smoking, 84 year old female osteopenic patient at presentation (a) and (b) and at 
follow-up (c), 6 months after fracture of the tibia and fibula.  Whilst there were no 
complications during the repair process, this condition does pose a high risk factor 
for fractures, particularly when combined with old age where an increased 
likelihood of osteoporosis exists, especially in females who are postmenopausal.  
 
Osteopenia is characterised by low bone mineral density (BMD), where the BMD 
T score is 1-2.5 standard deviations (SDs) below the young adult mean (but is not 
sufficiently low enough to be classified as osteoporosis, which is 2.5 SDs or more 
below), as defined by The World Health Organisation (WHO) (Kanis et al., 
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2008).  There is a micro-architectural deterioration of bone tissue, rendering the 
bone increasingly fragile and at high risk of fracture.  Osteoporotic fracture is a 
major cause of morbidity and mortality and was responsible for 300,000 fractures 
in the United Kingdom in 2010 costing the National Health Service over 2 billion 
pounds.  The disease is often secondary to underlying factors such as 
hypogonadism, hyperthyroidism, skeletal metastases, multiple myeloma, old age, 
alcoholism and cigarette smoking  (Tuck and Francis, 2002).  There are several 
biological bone turnover markers that can be used to pathologically diagnose 
osteoporosis, including bone alkaline phosphatase (b-Alp), osteocalcin (OC), 
procollagen type I carboxy-terminal propeptide (P1CP) for bone formation and 
tartrate-resistant acid phosphatase-5b (TRAP-5b) and cathepsin k that measure 
osteoclastic enzyme activity in bone resorption (Seibel, 2006; Wheater et al., 
2013). 
 
4.1.1.4 Compartment Syndrome in Fracture Healing 
 
Figures 26 (a) and (b) are radiographs taken from a non-smoking, 27 year old 
male patient, with a history of compartment syndrome and prolonged pain (for 6 
months) at presentation (a) and (b) at follow-up, 6 months after internal fixation of 
the tibia.  There were no reported complications in terms of fracture healing 
during the recovery period of the injury.  Compartment syndrome is a severely 
debilitating, limb- and life-threatening musculoskeletal condition for fracture 
patients that arises due to an insufficient blood supply to muscle and nervous 
tissue in ‘compartments’ such as the arm and leg, leading to increased internal 
pressure.  Extended sessions of surgery (>6h) present a high risk of this sequelae 
being realised and one which is recognised by theatre staff.  Left untreated, 
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compartment syndrome can lead to severe complications such as rhabdomyolysis 
(rapid breakdown of muscle tissue) and renal failure (Crawford and Comstock, 
2010). 
 
Compartment syndrome can arise in any part of the body where there is little or no 
room for expansion of muscles; presentations can be acute, sub-acute and chronic.  
The compartments within limbs contain muscles, arteries, nerves and lymphatic 
vessels that are tightly packed together and enclosed by an inelastic connective 
tissue sheath, which limits the volumetric increase of its contents.  
Intracompartmental pressure (ICP) becomes increased in conditions where there is 
expansion in the volume of the enclosed tissues, as with fracture or soft tissue 
damage, or a decrease in the capacity of the compartment itself via, for example, 
external compression due to plaster of Paris casts and burns (Mabvuure et al., 
2012).  The most common cause of acute compartment syndrome (ACS) is 
fracture, accounting for 69% of cases in one particular study (Erdos et al., 2011).  
Tissue swelling and haematoma formation are known mechanisms responsible for 
elevating ICP, resulting in ACS (Percival et al., 2011).  Any type of fracture can 
be affected by the syndrome and even open fractures do not relieve sufficient 
pressure from the skin tear to be discounted from ACS (Elliott and Johnstone, 
2003). 
 
There is no formal indication for the management of patients with raised ICP in 
the United Kingdom, but general practice involves the removal of any dressings 
overlying the affected compartment, splitting plaster casts but leaving padding 
intact and elevating the limb to no higher than heart level in order to perfuse the 
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compartment (Kostler et al., 2004).  If clinical approaches fail to relieve 
symptoms, fasciotomy may be indicated as an emergency procedure but based 
upon a comprehensive clinical assessment.  This is where an incision is made into 
the ‘fascia’, or connective tissue separating the muscles from the internal organs, 
in order to relieve tension and/or pressure (Mabvuure et al., 2012). 
 
 
4.1.1.5 Crohn’s Disease 
 
The x-ray images in Figures 27 (a) and (b) were obtained from a non-smoking, 35 
year old male, with a history of Crohn’s disease (as seen in the medical notes).  
Radiographs show fracture at presentation (a) and at follow-up (b), 6 months after 
internal fixation of the tibia and fibula.  The fracture healed satisfactorily, without 
any difficulties being reported in the medical notes.  It is notable that the MSCs 
derived from the donated sample proliferated rapidly in comparison to cells 
acquired from other patient specimens.  Even though cell doubling time was 
reduced and 5 day passages typically saw increases in excess of 260% (average 
118%), the sample was not the most proliferative, the highest being 380% in non-
smokers’ cells.  However, the yields from cultures were by far the greatest with 
harvesting after the first passage being over 15,000 cells per L of sample on the 
flow cytometer.  This compares with an average yield of approximately 360 cells 
per L in the non-smoking group.  The sample was not therefore considered to be 
a ‘spike’ in the normalised data. 
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Crohn’s is a type of inflammatory bowel disease (IBD), resulting in swelling and 
dysfunction of the intestinal tract.  There have been several studies that have 
reported correlations between Crohn’s disease and bone metabolism disorders 
including osteoporosis and dietary calcium absorption (Zuk et al., 2001; Kumari 
et al., 2010; Klaus et al., 2011).   
 
One particular study by Vázquez et al. (2012) showed that Crohn’s disease was a 
potential risk factor for increased prevalence of vertebral fractures when 
compared with healthy subjects.  The group investigated 107 patients with IBD 
(Crohn’s n=53; ulcerative colitis n=54) and 51 healthy subjects for morphometric 
vertebral crush fractures using thoracic and lumbar x-rays of the T4-L4 region.  
The height of individual vertebrae (from T4-L4) was measured, semi-
quantitatively, in each participant and a decrease of more than 20% in the height 
of any of the bones (>4mm equiv.) when compared to the others was considered 
to be a morphometric vertebral crush.  It was found that there was a higher 
incidence of morphometric vertebral crush fractures in patients with IBD (44.5%, 
representing a total of 72 fractures) when compared to the control group (13.7%, 
representing 10 fractures) (p<0.0001) (Vazquez et al., 2012). 
 
4.1.2 Sample Collection for In Vitro Studies 
The sample collection incorporated the clinical aspiration of a small amount of the 
fracture haematoma (typically 2.0-4.0 mL) from tibial fractures of anaesthetised 
patients during the surgical fixation of the damaged bone; tissue which is said to 
be normally washed away by the surgeon during the reduction and nailing 
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procedure.  The tissue was processed for analysis in the laboratory and the two 
basic intentions were to extract mesenchymal stem cells and to acquire serum 
from the haematoma; the interstitial fluid that surrounds these cells at the fracture 
site that forms much of the extra cellular matrix.  The methodology regarding 
stem cell analyses from fracture haematomas was first published by Oe et al. 
(2007), who were successful in characterising what were referred to as progenitor 
cells from human fracture haematomas.  Their work was pioneering and there are 
very few comparable publications currently available that emulate their work in 
the field.  However, the presence of non-haematopoietic cells in bone marrow is 
not a new concept, as it was first reported by the German physicist Conheim, over 
130 years ago, that bone marrow is a rich source of fibroblasts that deposit 
collagen fibres during normal wound repair (Prockop, 1997).  Therefore, for the 
cellular aspects, the objective was to obtain cells from the donated tissue that are 
relevant in bone repair; mesenchymal stem cells, so-called due to their ability to 
differentiate into mesenchymal-type cells (Chamberlain et al., 2007).   
 
4.2 Cellular Analysis of Fracture Healing      
Cell culture is necessary in order to isolate cells of interest that have properties 
which allow them to be readily studied in vitro; their ability to divide rapidly 
ensures a constant availability in the liquid nitrogen.  As previously stated, Oe et 
al. (2007) successfully isolated mesenchymal stem cells from human fracture 
haematomas and demonstrated their renewable capabilities in vitro.  The identity 
of these cells was confirmed by undertaking immunocytochemical assays that 
involved the binding of specific antibodies to MSC surface antigens and the 
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techniques that were used by Oe and co-workers formed the basis of the 
characterisation work in this current study.  After extraction and population 
doubling, the group were able to differentiate haematoma cells into adipose, 
muscular, bone and cartilage tissue in vitro by using specialised differentiating 
media.  The cells were reported to have a good viability for subculture, in vitro 
analysis and differentiation.  Indeed, Oe and colleagues stated that cells of this 
nature could be cultured through at least 10 passages with minimal decline in 
proliferative capacity or volume.  It was therefore deemed in this study that 
comparable cells extracted from donated human fracture haematomas were suited 
to laboratory-based investigation.  
 
4.2.1 Cell Explantation 
In the primary cultures, excised portions of the fracture haematoma were 
explanted and incubated and left undisturbed, for 7 days, a process based on 
methods described by Niikura (2005) (Niikura et al., 2005). Ordinary light 
microscopy was used to study the unstained primary cultures, which were 
observed as mixed populations of cells and other material within the tissue culture 
flasks. Not all samples, however, bestowed the desired cell type and, 
unfortunately, unsuccessful attempts outnumbered successful extractions over the 
course of the study (see Table 9, Ch. 2).  Methodologies involving the direct 
explantation and Ficoll Paque centrifugation proved to be the most effective in 
extracting progenitor cells and as such were both adopted as the standard 
procedures in which cells were procured from donated tissue.  Sample quality 
often differed across specimens, rendering the consistency to be unpredictable.  
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Smokers’ cells were particularly difficult to extract in the laboratory, mainly due 
to both the low frequency of donations and, ironically, their lack of quantity and 
quality when compared to the non-smokers’ specimens, perhaps a valid 
observation in itself.  This is reflected by the low sample sizes in some of the 
cellular experiments, which did eventually extend to n=7 for smokers and n=11 
for non-smokers. When samples did express cells, confluent, localised pockets of 
adherent, fibroblast-like structures were observed, which appeared to be migrating 
from some of the explanted haematoma tissue in the culture flasks and which were 
adherent to the base of the polystyrene tissue culture flasks (see Figures 28-34).  
The commercial mesenchymal stem cell line was also cultured in the same way as 
the cells derived from the fracture haematoma and displayed a very similar 
morphology under light microscopy (Figure 34). 
 
4.2.2 Adherent Properties of Fracture Cells in Culture 
 
Cell adherence is bridged by amphoteric proteins and the prerequisite for the 
attachment onto an in vitro substratum is due to the adsorption of proteins and 
other factors to the culture surface.  The substratum on which cells grow (for 
example, polypropylene plastic, polystyrene or collagen) possesses either a net 
negative or positive charge.  The charge density on these surfaces is responsible 
for attachment and spreading of cells rather than their polarity.  It is also known 
that cell adhesion is regulated by specific cell surface receptors.  The cells become 
attached to the substratum before producing their own glycoproteins and matrix 
proteins prior to spreading-out.  It is this matrix that adheres to the charged 
surface and the cells then become bound to the matrix via specific receptors.  
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Surfaces, or substrata, that have been conditioned by previous cell growth are 
often said to provide a better surface for attachment, but this was not adopted in 
this study (Mukhopadhyay et al., 1993). 
 
Cell adhesion also depends on a functional contractile system, involving multiple 
contacts with the surface.  Lamellipodia structures, which are filled with bundled 
actin filaments, fit into a lattice structure formed by the glycoproteins on the 
substratum.  This is followed by cytoplasmic webbing and flattening of the cell 
mass (Hirtenstein et al., 1980).  Once the cells became anchored to the 
substratum, they grew and consumed the nutrients that were available to them in 
their culture medium, including the infused CSE toxins, applicable to a number of 
experiments in this study.  The liquid culture media (IMDM) has an ambient pH 
of 7.4, contains carbon and nitrogen, an energy source (L-glutamine), growth 
factors within foetal calf serum (FCS) and dissolved oxygen and other gases, all 
of which are essential for cell sustainability and development.  An anti-fungal 
agent and antibiotic were also present to maintain the health of cells, although 
overuse was avoided since continuous application of certain antimyotics could 
have a detrimental impact due to toxicity.  The lifespan of cultures can be 
compromised by media degradation, nutrient limitation, the accumulation of toxic 
metabolites and also infection, which can be fungal, bacterial and/or viral.  Other 
important considerations are environmental factors such as humidity, CO2 levels 
and correct temperature (Schmid et al., 1992).   After successful cellular 
proliferation had been achieved, it was necessary to harvest and give a formal and 
scientific identity to the cells. 
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4.2.3 Characterisation of the Haematoma Cells 
 
After a period of approximately 26 days from initial plating, the adherent cells 
were dislodged from the substratum using 0.25% trypsin containing 0.02% EDTA 
(Sigma-Aldrich, Gillingham).  The adherent, fibroblast-like cells that were 
isolated from fracture haematomas in vitro were characterised, mainly as MSCs, 
via immunofluorescence and immunophenotyping (see Figures 35-48).  The cells 
expressed antigens specific to CD29, CD44, CD105 and CD166 in the 
immunocytochemical assays, which formed both qualitative and quantitative 
analyses.  The haematopoietic stem cell marker, CD34, used as a negative control, 
was also detectable in varying degrees throughout passages and, as with the 
immunofluorescence assays, un-probed cells showed minimal autofluorescent 
characteristics.  The type of cell that is associated with the CD34 cell surface 
antigen was not of interest because it does not have a major role in the early 
stages of fracture healing (although it is said to be involved in bone osteoclastic 
remodelling in the latter stages of fracture repair (Pagliarulo et al., 2008)) and was 
therefore considered to be an undesirable contaminant in the MSC cultures.  After 
four passages, the presence of the haematopoietic surface antigen marker, CD34, 
was reduced from 69.39% in the first passage to 5.98% in the fifth, suggesting that 
the non-adherent, haematopoietic, CD34+ cells were voided during routine 
changes of media during in vitro development.  Additional immunocytochemical 
control studies were performed on cyto-spun cells (where no antibodies were used 
as probes) to demonstrate that cells were not merely auto-fluorescing in the 
original assays that did include the MSC biological markers (see Figures 40, 41 
and 48). 
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Human MSCs, sometimes referred to as marrow stromal cells, are capable of 
becoming differentiated into osteoblasts, chondrocytes, adipocytes, myoblasts and 
possibly neuronal-like cells and are therefore essential in fracture healing.  During 
in vitro culture, the haematoma cells self-renewed and divided quickly, having an 
estimated population doubling time (PDT) of around five days for non-smoking 
(or non-CSE treated) cells.  This PDT correlates with data reported by Azouna et 
al. (2012), who also reported in vitro bone marrow-derived MSC mean doubling 
times of five days (Azouna et al., 2012).  The smokers’ (and CSE treated) cells 
proliferated more slowly (discussed later).  The rate of proliferation depends on 
donor, initial plating density (inoculum) and numerous environmental factors.  
Cell yield can also be lowered via cryogenic storage conditions and mechanical 
stresses being placed upon them such as centrifuging.  Chemically-toxic reagents 
used in experiments, e.g. trypsin and EDTA, can also have a negative impact on 
cell number, so there may be some discrepancies with MSC doubling times 
reported in the literature.  More frequent counting, taken place daily, could give a 
more accurate indication of cell PDTs.  The FITC- and PE-conjugated antibody 
markers described here are not truly specific to MSCs, although it is agreed in the 
literature that these cells types do not express the antigens specific to the 
haematopoietic CD markers CD11, CD14, CD34 or CD45.  They do, however, 
express CD29, CD44, CD71, CD73, CD90, CD105, CD166, Stro-1 and 
intracellular adhesion molecule-1 (ICAM-1) (for general summary, see Table 4, 
Ch.1) (Chamberlain et al., 2007). 
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It has also been proposed by the Mesenchymal and Tissue Stem Cell Committee, 
a subdivision of the International Society for Cellular Therapy (ISCT), that MSCs 
used for laboratory-based scientific investigation should possess the following 
three criteria: 
 Adherence to plastic 
 Specific surface antigen (Ag) expression 
 Multipotent differentiation 
 
The criteria for adherence to plastic must be seen in standard culture conditions 
using tissue culture flasks.  Regarding surface antigen expression, ≥95% of the 
MSC population must express the aforementioned CD surface antigens and be 
≤2% positive for a number of haematopoietic CD markers, including CD34.  The 
final stipulation is that the MSCs must be able to differentiate to osteoblasts, 
adipocytes and chondroblasts (Dominici et al., 2006).  In the current study, cell 
adherence was well established, so has met the first criteria as listed above.  The 
cells expressed well over 95% of the cell surface antigens named, with the 
exception of CD105 (94.44%), but the lowest recorded CD34 expression was 
5.98% (see Table 10 for details). The CD105 antigen seemed to be the most 
problematic surface antigen to achieve purity, but was nevertheless very close to 
the 95% minimum threshold as stipulated by the ISCT, in spite of the fact that a 
‘cell sorter’ had not been available at any time in this study.  The CD34 
expression appeared to compliment the CD105 antigen and it can be noted from 
Table 10 that early passages showed low levels of CD105 and high levels of 
CD34, totalling approximately 100% when added together.  In later passages, 
there was a reversal of this phenomenon as non adherent cells were washed out of 
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tissue culture flasks and the adherent cells proliferated, which forms an interesting 
observation regarding the cross section of cell populations; simply put that 
adherent cells are proliferating, whilst non-adherent cells are being expelled from 
flasks during media changes.  A lingering ‘background’ CD34 expression in later 
cultures was observed and was likely due to a small proportion of haematopoietic 
cells having adherent properties, as noted in the literature (Pagliarulo et al., 2008).  
A diminishing CD105 expression in the later passages was also noted in Table 10 
and could be owed to either a temporal-induced reduction in the expression of this 
particular antigen in subsequent cultures, or just simply that the quality of the 
FITC antibody reagent was deteriorating over time and therefore more difficult to 
detect by the flow cytometer.  The third ISCT stipulation (multipotent 
differentiation potential) was not performed as part of this study, mainly due to 
costs, but also because it has been reported in the literature and would be an 
experiment to be undertaken in future studies.  Oe et al. (2007) showed that cells 
extracted from fracture haematomas were capable of in vitro differentiation into 
osteoblasts, adipocytes and chondrocytes, thus meeting a capacity for tri-lineage 
mesenchymal differentiation.  It is therefore feasible that the cells isolated from 
patient fracture haematomas in the current study are indeed, beyond reasonable 
doubt, stem cells of a mesenchymal lineage that are involved in the early stages of 
fracture healing. 
 
4.2.4 Cell Counting 
The cells were cultured through several passages and counts were performed at 
the end of each, usually as confluent colonies.  In vitro proliferation rates were 
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compared between smokers and non-smokers after five days (non-parametric 
significance testing using the Mann-Whitney U Test), to assess differences that 
may reflect the cellular damage caused by smoking.  It was found that the cells 
extracted from smokers, as well as those treated with cigarette smoke extract 
(CSE), proliferated more slowly than the non-smoker and non-treated cells.  
However, unlike the direct smokers vs. non-smokers comparisons using 
independent samples, the CSE assays (parametric significance testing via 
ANOVA) showed a significant difference (p<0.05), which was likely due to 
reduced variance in the results and possibly equal group sizes resulting in normal-
distribution of data.  However, if the patient comparisons had been reported as 
n=7 for both groups, then a significant difference would have been achieved 
(p<0.05, compared to the reported p=0.17), as the variance was improved. 
 
A similar study by Wong and Martins-Green (2004) focused on how infused 
cigarette smoke affected the survival and migration of chicken embryo fibroblast 
cells (CEFs) in vitro.  These galline cells were exposed to measured doses of 
cigarette smoke components that were comparable to the levels of circulatory 
serum nicotine found in regular smokers (0.04 mg mL
-1
-0.07 mg mL
-1
) (Russell et 
al., 1980).  It was found that the smoke, whilst not killing cells, did inflict a 
detrimental effect on health by stimulating the production and activation of 
intracellular stress-response proteins.  When allowed to recover, the treated cells 
divided significantly slower (p<0.05) than those fibroblasts not previously 
exposed to cigarette smoke, which was also shown in our study on the human 
MSCs that were infused with CSE (see Figure 56).  Wong and Martins-Green 
(2004) also reported damaging alterations in the cytoskeleton and cell adhesion 
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molecules, giving rise to abnormal inhibition of cell migration, which is essential 
for proper wound healing and closure (Wong and Martins-Green, 2004).  This was 
perhaps replicated on the fracture MSCs, as the decline in proliferation rates were 
much lower in smokers’ cells compared to non-smokers’ cells after 3 passages, 
thus demonstrating the serious cell damage that is caused by tobacco smoking. 
 
4.2.5 The Infusion of Cigarette Smoke Extract (CSE) into MSC Cultures 
The cigarette smoke extract (CSE) was introduced into the study as a means to 
incorporate a synthetic model of cigarette smoking that was similar to the one 
used by Wong and Martins-Green (2004) and was itself based on a protocol 
published by Bernard et al. (2004).  A lack of available haematoma samples, in 
addition to sporadic frequency and patient anamnesis, may also have necessitated 
the introduction of this model in order to project the possible effects of smoking 
ahead of collecting the required amount of samples needed to produce robust 
conclusions.  It was also important to incorporate the model to isolate smoking as 
a singular cause of cellular damage, since it is known that other factors can 
contribute to fracture malunion, including obesity, malnutrition, iatrogenic 
pathologies and old age (Massari et al., 2013).  Proliferation rates showed that the 
CSE was having a significant toxic effect by slowing down growth and 
development, or even perhaps causing the death of cells in culture, when smoke 
toxin levels were equivalent to a person smoking 20 cigarettes per day (equivalent 
2.5% CSE in the culture media).  In addition to proliferation rates, nitric oxide 
levels were found to be lower in the treated cells and necrosis was higher with 
CSE infusion.  The damaging impact of the CSE was significant in all the assays 
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where it was included and showed that so called ‘average’ levels, equating to a 
person smoking twenty cigarettes per day, were enough to harm cells in a way that 
would definitely compromise the development of cells that are involved in the 
fracture healing process.   
 
4.2.6 Cellular Nitric Oxide (NO) Quantitation 
Nitric oxide is a free radical gas which is known to be a secondary messenger 
metabolite in various biochemical pathways and has been implicated in a number 
of orthopaedic pathologies, including inflammation, osteoporosis, arthritis and 
aseptic loosening  (Kaur and Halliwell, 1994; Stefanovic-Racic et al., 1994; 
Sakurai et al., 1995; Wimalawansa et al., 1996; Hukkanen et al., 1997).   NO is 
synthesised by the conversion of the amino acids L-arginine to L-citrulline; 
catalysation is achieved via a group of isoenzymes consisting of endothelial nitric 
oxide synthase (eNOS type III), neuronal NOS (nNOS type I) and inducible NOS 
(iNOS type II).  The former two are thought to occur naturally; they are calcium-
dependent and are essential in generating basal levels of NO in homeostasis.  
Synthesis of the latter is accomplished by proinflammatory cytokines and is 
reported to be calcium-independent; indeed iNOS is frequently present in 
pathologies when induction results in the production of large amounts of NO.  The 
widely-held view advocates that NO production by endothelial cells is affected by 
cigarette smoking, which is believed to interfere with endothelium-dependent 
vasodilatation in a range of vessels (Barua et al., 2001). 
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Notwithstanding this, nitric oxide has a major role in fracture healing and is 
widely reported to have a major effect on osteoblasts, osteoclasts and osteocytes, 
with eNOS and iNOS having significant cell signalling roles in osteoblastic 
proliferation and function (Ralston et al., 1994; Hukkanen et al., 1995; Riancho et 
al., 1995).  Conversely, iNOS has been shown to have an inhibitory effect on 
osteoblastic cultures and studies have shown that cytokine-induced iNOS activity, 
associated with high NO production, causes a reduction in osteoblastic 
proliferation and differentiation, in addition to triggering apoptotic activity and is 
relevant in late fracture healing (Hukkanen et al., 1995; Corbett et al., 1999).  
Osteoclastic activity is also known to be suppressed by iNOS (Brandi et al., 
1995).  These characteristics give further weighting to NO’s regulatory role in 
fracture healing in both the early and late stages of fracture repair (Paskalev and 
Goranov, 2012). 
 
Nitric oxide is, therefore, a mediator of osteocyte function and epiphyseal bone 
remodelling. NOS inhibitors, such as N
G
-nitro-L-arginine methyl ester (L-
NAME), are known to reduce bone turnover and repress mechanically-induced 
bone formation, implicating NO as an early mediator of increased bone formation.  
Higher levels of the metabolite present in osteoblasts would suggest more 
effective bone repair (Fox et al., 1996).   
 
A vascular response is required in bone repair and there is a significant increase in 
blood flow at the site of injury following fracture, combined with hyperactive 
vascular formation prior to the development of the fracture callus.   Nitric oxide 
has been described as an endothelial-derived relaxing factor (EDRF) and is a 
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mediator of endothelial-dependent vasodilatation.  It has also been stated that 
surrounding bone, smooth muscle, vascular endothelial cells, chondrocytes and 
certain leukocytes are all sources of NO (Corbett et al., 1999).   
 
Corbett et al. (1996) investigated whether NOS isoforms were expressed during 
the healing of fractures.  Unilateral tibial fractures were made in male Wistar rats 
(n=100) and comparisons were made between fracture and normal bone.  
Immunohistochemistry showed an increased expression of eNOS, which was 
strongest in the cortical blood vessels and osteocytes in the early phase of fracture 
repair.  Western blot and image analysis confirmed the increase.  They observed 
significantly-raised calcium-dependent NOS activity 1 day after fracture (p<0.05).  
Inducible NOS was localised in osteoblasts and chondroblasts in the second week 
of fracture healing.  Western blotting showed a significant, 3.64-fold reduction in 
iNOS during the early phase of healing compared to normal bone.  The group also 
showed a significantly-reduced calcium-independent NOS activity, but neuronal 
NOS was not detected.  It was stated that increased eNOS in bone blood vessels is 
likely to mediate the increased blood flow that is associated with fracture repair.  
Their results showed that eNOS was increased and iNOS reduced in early healing 
of fractures and it was concluded that this is an important factor in successful 
fracture repair. 
 
Nitric oxide was shown to be significantly reduced in the cells of CSE-treated 
cultures in the current study (p<0.05).  It is not known which of the NOS isoforms 
this represents; this would need to be determined using specific ELISA 
quantitation, but nevertheless shows that smokers are likely to have lower 
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amounts of nitric oxide at the fracture site compared to non-smokers.  It is 
therefore apparent that non-smokers would benefit from higher levels of eNOS 
than smokers, because of increased vasodilatation and calcium availability, in 
addition to increased osteoblastic and decreased osteoclastic activity, as suggested 
by Corbett et al. (1999).  It is also indicative of a reduced level of iNOS in 
smokers, demonstrating retarded cytokine mobilisation, coupled with abnormal 
osteoblastic/endothelial hyperactivity, strengthening Wong and Martins-Green’s 
(2004) theory of tobacco-induced, abnormal over-healing and fibrosis in fracture 
repair, likely due to reduced apoptosis of mature bone cells, giving rise to chronic 
cellular aging.  Indeed, such a lack of eNOS intervention could result in hindered 
apoptosis and increased osteoclastic activity with reduced angiogenesis, therefore 
having a detrimental impact on the bone repair process due to a deficiency of NO-
led mediation in smokers.   
 
Nitric oxide is indeed integral in fracture repair, as it impinges on the metabolism 
of osteoblasts, osteocytes and osteoclasts, which is vital for the successful 
derivation of the fracture callus seen in bone repair.  Lower levels of NO observed 
in CSE-treated cells suggest that smokers are therefore deprived of proper 
vascularisation and vasodilatation, have decreased cytokine and calcium 
involvement, a limited capacity for adequate cellular organisation in early fracture 
healing, as well as impaired bone remodelling in the longer term. 
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4.2.7 Cellular Necrosis in MSC Cultures 
Apoptosis is a process that is comprised of a scheduled and actively-coordinated 
series of metabolic events within cells.  Necrosis, on the other hand, is a passive 
response to a cytotoxic or injurious milieu that leads to uncontrolled cell death.  In 
apoptotic circumstances, the cell membrane remains intact until late into the 
process, which is unlike necrosis, when permabilisation of the phospholipid 
bilayer occurs in the very early stages.   Propidium iodide is a chemical probe that 
was used during flow cytometry to quantitatively measure the amount of double-
stranded nucleic acid present within a cell.  Since it cannot pass through an intact 
cell membrane, which acts as a barrier, propidium iodide can be used to test the 
viability of cells, i.e., it does not fluoresce if added to a suspension of intact cells.  
It is, for these reasons, able to cross the cell membrane of necrotic cells due to 
membrane ‘flipping’, interact with double-stranded DNA, whereby red 
fluorescence is detected by the flow cytometer.  Propidium iodide is a stain that 
was used to mark necrotic cells in this study (see Figure 58), as cells with large 
enough holes in their membranes to allow the penetration of propidium iodide are 
dead and cell viability can be measured in the presence of various toxic conditions 
(Givan, 2004), as was the case when infusing MSC cultures with  CSE. 
 
In the cell necrosis assays using propidium iodide, cell death caused by smoking 
was analysed in CSE-treated cells, with untreated cultures being used as a control.  
It was found that, after 4 passages, the cigarette smoke caused significantly more 
necrotic cell death than was occurring in the untreated cultures (p<0.05).  This 
showed that the CSE was having an injurious effect on cellular viability and was 
probably responsible, in part, for causing a reduction in cellular proliferation as 
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seen earlier-on in this study.  However, what was notable regarding the results 
was that there appeared to be an initial increase in necrotic activity in both groups, 
between the first and second passage.  This early increase can be seen as a ‘carbon 
copy’ in the graph, before a divergence into the third passage, showing a mutual 
decline in the amount of necrosis taking place before rising again with a greater 
degree of separation into the fourth passage.  The initial increase is likely due to 
there being some residual dead cells from the freeze/thaw process after samples 
were taken out of the liquid nitrogen for analysis.  It is also likely that dead cells, 
which lose their adherence properties, were being discarded during routine media 
changes and that cell proliferation resumed thereafter due to there being a healthy 
and well-established population of cells which expanded throughout later 
passages.  As cells increase in number and size, they take up more surface area in 
the flasks, become older and are perhaps more prone to mechanical stresses in 
vitro, all of which would contribute to higher levels of necrosis generally.  There 
could also be some late-stage apoptotic activity.  That accepted, the CSE simply 
served to further aggravate and amplify the necrotic processes seen in the CSE-
treated cultures.  The toxic attributes of cigarette smoke in vivo, therefore, may 
influence premature cell death in patients who are smokers.  This leads on from 
the previous discussion concerning nitric oxide, where it was stated that smoke 
placed inhibitory forces on apoptosis.  It has now been shown that necrosis is 
more prevalent and plausibly impinges on the synthesis and development of 
premature osteoblasts in early fracture repair, whilst natural and programmed cell 
death is reduced in more matured bone cells.  This thereby affords fortification to 
the argument that smoking unbalances the natural turnover of cells that are 
involved in remodelling by causing increased necrosis and reduced apoptosis in 
                                                                                                                  Discussion 
219 
fracture healing in smokers.   To complement this experiment, future work may 
investigate the effect of smoking on apoptotic activity. 
 
4.2.8 Cell Recovery Assay 
The cellular assays have thus far focused upon how cigarette smoking can impact 
upon cellular development.  These findings therefore raises the question; does the 
cessation of tobacco smoking improve cellular function and proliferation in 
fracture healing?  The cellular recovery assays does suggest this to be the case, as 
cells in vitro were shown to recover after CSE withdrawal from cultures.  
Morphological studies were undertaken initially when using the smoke extract and 
cells were observed to be fragmenting after its infusion.  When the CSE was 
omitted from culture media, cells resumed the classic fibroblast-like, spindle-
shaped structure.  This suggests that once CSE is withdrawn, it is likely that cells 
repair themselves in the media and recommence proliferation with reduced 
cellular death in populations.  These observations led to a more formal assay that 
was designed to quantitate proliferation studies, which was conducted over three 
weeks.  It was then clear that the withdrawal of CSE after a five-day infusion 
again improved cellular development and proliferation levels were markedly 
enhanced after 21 days of CSE omission in the culture media.  This data, however, 
was not significant due to considerably-overlapping standard error bars on the 
graph, relating to a substantial level of variance across small groups, which 
impacted on the SEM within the data.  The simple fact that cells are derived from 
individual patients and not from a commercially-available cell line, is probably 
due to the occurrence of this phenomenon regarding the wide variation.  In order 
                                                                                                                  Discussion 
220 
to minimise the variance and hence gain a greater degree of significance, more 
samples would need to be incorporated into the study.  In similar work published 
in the literature, scientists have used much larger sample sizes to reduce variance 
and achieve a more robust level of significance in studies, e.g. Corbett et al. 
(1999) conducted research using 100 rat specimens, Adams et al. (2001) with a 
cohort of 277 human subjects, whilst Frost-Peneda et al. (2010) performed 
research on 3,585 adult smokers and 1,077 non-smokers (Corbett et al., 1999; 
Adams et al., 2001; Frost-Pineda et al., 2010).  As quoted by Cumming et al. 
(2007) in The Journal of Cell Biology, ‘It is highly desirable to use a larger n, so 
as to achieve narrower inferential error bars and more precise estimates of true 
population values’ (Cumming et al., 2007, pg. 7).  It would therefore be 
imperative to recruit more patients if future studies are to be considered and 
ideally, from additional clinical sources to increase donor frequency.  
 
4.2.9 In Vitro Effect of Bone Morphogenetic Protein-2 (BMP-2) on Cell 
Viability via the MTT Assay 
The application of soluble growth factors, such as BMP-2, has been the subject of 
debate largely due to its suitability in the field of bone tissue engineering 
(Wozney, 2002; Turhani et al., 2007).  As members of the TGF- superfamily, 
BMPs are principally differentiation factors and regulators of the bone induction 
cascade in skeletal tissue regeneration (Wikesjo et al., 2004).  The growth factor 
BMP-2, which is up-regulated in the early stages of fracture healing (see Table 6), 
can be administered exogenously (as recombinant BMP-2 (rhBMP-2)), via a 
delivery vehicle, to various sites in order to accelerate bone regeneration.  It was 
                                                                                                                  Discussion 
221 
shown in one in vivo study to enhance bone formation in bone gap healing (Yudell 
and Block, 2000) and in another to improve osseointegration of implants when 
covalently bound to biomaterial surfaces (Schmitt et al., 1999). 
 
Turhani et al. (2007) investigated the supplementation effect of increasing 
concentrations of rhBMP-2 in vitro on the osteosarcoma cell line with a proven 
SaoS-2, which were derived from osteogenic sarcoma and have osteoblastic 
phenotype characteristics.  In the 2007 study by Turhani et al, cell cultures were 
subjected to various dose concentrations of exogenous rhBMP-2 (10 ng mL
-1
, 100 
ng mL
-1
 and 500 ng mL
-1
) and analysed after 24h, 48h and 72h for viability via 
conversion of the tetrazolium salt, XTT.  As only viable cells convert XTT to the 
coloured product and conversion is directly proportional to the number of viable 
cells, absorbance from the converted XTT solution was read on a plate reader at 
450 nm.  The group found that there was a dose-dependent increase of cellular 
viability from infusions of rhBMP-2 that was increasing in significance over time, 
so that after 72h, 10 ng mL
-1
; p<0.05, 100 ng mL
-1
; p<0.01 and 500 ng mL
-1
; 
p<0.001.  However it was concluded that ‘further investigations were needed to 
elucidate the intricate regulatory mechanisms influencing cell responses to 
exogenous growth factors’ (Turhani et al., 2007, pg.492).   
 
The MTT cell viability assay that was undertaken in our study was aimed at 
replicating the work of Turhani et al. (2007), but with the addition of CSE to 
cultures so as to synthesise an in vitro smoking environment.  The work carried 
out on the SaOS-2 was emulated in the current study as it was the most closely-
related cellular work available in the literature.  The proposal was that exogenous 
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infusions of BMP-2 could ameliorate fracture repair in smokers by accelerating 
the growth and proliferation of osteoblasts and be therefore deemed as a possible 
osteoinductive therapy to smokers who are displaying symptoms of malunion.  
The same dose concentrations used by Turhani and co-workers were replicated 
and cell viability was analysed at the same time intervals.  However, 
enhancements of BMP-2 cell viability showed no notable response until the 72h 
point.  This suggests that a cigarette smoke-induced toxic environment was likely 
to have impeded the early activity of the growth factor, implying that it perhaps 
has a limited effect on smokers’ cellular development in the preliminary stages.  
Despite this, all concentrations at the 72h point did appear to have a beneficial 
effect when compared to the control group (that did not receive any BMP-2, but 
was infused with CSE).  Regardless of the apparent improvements attributable to 
BMP-2, the smallest dose of 10 ng mL
-1
 was the only dose concentration that 
appeared to have a statistically-significant effect (p<0.05) on improving cell 
viability when significance testing was performed using the Student’s t-Test.  This 
was, however, not mirrored by the control study, where the impact of exogenous 
BMP-2 had a much more significant response in the higher dose group of 100 ng 
mL
-1
 (p<0.00001) on untreated MSCs, with the lowest dose of 10 ng mL
-1
 being 
insignificant.   
 
However, it was later found that using the Student’s t-Test in the 72 hour CSE 
MTT study returned a type I error for this data.  When using ANOVA statistical 
testing it was found to be not significant (p>0.05).  Committing a type I error has 
therefore produced a false positive in the data, and is probably due to a small 
sample size, resulting in low power of the test.  A prospective power analysis 
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would be useful in determining the optimal sample size required in the assay to 
boosting the level of statistical power in the test.  The following equation can be 
applied: 
 
Necessary Sample Size = (Z-score)² – SD x (1-SD) / (margin of error)² 
 
(Smith, 2013) 
 
Tabulated Z score for 95% confidence interval = 1.96 
Margin of error (confidence interval) = +/- 5% (0.05) 
Where SD is the standard deviation.  For the 72 hour CSE MTT  pilot study (SD = 
0.188 for 10 ng mL
-1
), this is as follows: 
 
((1.96)² x 0.188(0.188)) / (0.05)² 
 
(3.8416 x .0353) / 0.0025 
 
0.136 /0 .0025 
 
54.4 = 55 respondents are needed 
 
 
The equation has shown that 55 respondents would need to be recruited into the 
study to optimise the statistical power of this particular assay for 10 ng mL
-1
 
BMP-2 treated cells, assuming a confidence interval of +/- 5%.  This is equal to 
an additional 45 non-smoking patients’ samples, assuming that there would be a 
100% success rate in the isolation of cells from the fracture haematoma.  
However, it would be advisable to repeat the pilot study to ensure reproducibility 
prior to a larger scale study. 
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The original work by Turhani et al. (2007) suggested that the higher the dose 
concentration, the greater the benefit to cell viability, but this was not the case in 
our particular assay where CSE was infused as an intervention.  The reason for 
this is unclear, but it may be that a dose concentration of 10 ng mL
-1
 was 
sufficient to saturate the cell inoculum of 3.0 x 10
3 
per well and that using 
increased amounts led to an antagonistic, rather than the intended agonistic effect 
and actually administering too much BMP-2 could have a cytotoxic effect in vitro.  
It would be therefore beneficial to repeat this assay using a larger sample size, 
likely narrowing variance and increasing the robustness of data.  In addition, time 
increments could be extended to allow the growth factor to reach its optimal 
effect; using a larger inoculum should also be considered.  Other relevant 
exogenous growth factors may perhaps be incorporated into the study (as listed in 
Table 7, Ch. 1), in order to determine the efficacy of those which have the greatest 
potential in addressing fracture malunion in patients. 
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4.3 THE MOLECULAR ASPECTS OF FRACTURE HEALING 
The haematoma is known to contain and array of acute-phase proteins and MSCs 
which are the molecular mediators of the inflammatory response and subsequent 
healing process (Oe et al., 2007).  In order to study the interstitial growth factors 
and cytokines known to be present at the fracture site (i.e., the molecular aspects), 
the haematoma serum was extracted from the donated tissue for analysis, thus 
representing the extracellular matrix (ECM) within the fracture milieu.  The ECM 
has an intimate involvement with all aspects of bone remodelling, especially 
fibrosis and post-inflammatory regeneration, as reviewed previously.  In 
reiteration, the dynamically-modulated key stages involved in wound healing are 
accomplished through a unique capability of the ECM to generate vast arrays of 
structures at the site of injury.  The matrix therefore has a major influence on 
cellular processes, binds specific growth factors and cytokines and exquisitely 
organises the geometric framework, or scaffold, that can assist cell migration as 
well as numerous cell-to-cell interactions (Raghow, 1994; Hidalgo-Bastida and 
Cartmell, 2010). 
 
4.3.1 SDS-PAGE Assay for Protein Separation 
In addition to the studies that are focused on the cell development and 
proliferation in cultures, it was important to also consider the cytokines and 
growth factors that are involved in the healing process.  The supposition is that 
there exists a status of dysregulation of acute-phase proteins within those people 
who smoke, contributing to the clinical problems of non- and delayed-union of 
healing bones.  If the cytokines can be firstly identified in the fracture 
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haematomas, the quantitative and qualitative differences may reveal which 
mediators of healing are indeed affected by tobacco smoking.  This will serve to 
provide a proteomic feature to the project, which is intended to fortify the cellular 
work that has been undertaken. 
 
Glycine-SDS-PAGE (sodium dodecyl sulphate-polyacryamide gel 
electrophoresis), otherwise know as Laemmli SDS-PAGE, is often used to 
separate-out proteins of a molecular weight of up to 100 kiloDaltons (kDa), but is 
especially specific for the resolution of proteins smaller than 30 kDa.  The 
electrophoretic system utilised in the resolution of proteins does so via the 
migration of the lysates through a polyacrylamide gel (16% acrylamide gels were 
used) under an electrical current (10-20mA), that was immersed in a tris/glycine, 
or Leammli, buffer.  The captured proteins are then stained by using, for example, 
Coomassie blue or silver nitrate so that the resolved bands become clearly visible; 
they can then be photographed using a specialised gel imaging system (or digital 
camera) or stored (at 4˚C) for posterity in a solution of glycerol and distilled water 
for up to a couple of years (Laemmli, 1970; Schagger, 2006). 
 
The determination of proteins from complex mixtures via electrophoresis is often 
undertaken as a preliminary action for proteomic analyses and the method 
represents an essential facet of modern research in many areas.  Ideally, the 
technique employed would fractionate and isolate individual proteins on a more 
advanced, sensitive system known as 2D SDS-PAGE.  The first dimension of the 
2D system separates peptides via isoelectric focusing, whereby proteins migrate 
through a pH gradient.  The second separation dimension is then applied using a 
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standard 1D process that resolves the proteins according to their molecular weight 
(Betgovargez et al., 2005; Chuthapisith et al., 2007). 
 
In this investigation, a less complex version of the technique, 1D electrophoresis, 
was used to separate the haematoma serum, which is reported to contain around 
600 extracellular proteins (Marshall et al., 2004).  This method was used because 
of its relative availability and reproducibility and proteins were, in the main, 
resolved successfully from the patient samples.  After staining with either 
Coomassie blue or silver stain, several unknown bands appeared on the gels from 
the haematomas.  Further investigations using mass spectrometry (QTOF, lcms) 
revealed that these were haemoglobin alpha and beta chains (Hb  and Hb ) (~14 
kDa) and haptoglobin (~20 kDa).  These proteins were present in substantial 
amounts, most likely due to intravascular or extravascular haemolysis that was 
taking place within the fracture haematoma environment.  Whilst the haemoglobin 
chains are probably of no real significance in this study, other than an interesting 
observational characterisation of the microenvironment, haptoglobin is known to 
up-regulated by the liver in states of acute inflammation and trauma and is, 
therefore, classified as an acute-phase protein within its own right (O'Connell et 
al., 2005).  However, haptoglobin does have a major role in the formation and 
breakdown of red blood cells and is a natural component part of this connective 
tissue.  This widespread haemolysis of the haematoma, as seen in all collected 
samples, is likely to be the reason why fracture haematomas are present at the 
fracture site for a few days only.  The fracture haematoma is present at the milieu 
of repaired fractures for 3-5 days only; it is quickly broken down by enzymes at 
the site of injury which in turn causes this localised haemolysis (Quaye, 2008).   
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The tactic of purposely overloading the gels was undertaken, as it was thought 
that resolving more serum and therefore more acute-phase proteins, would result 
in an increased amount of the cytokines of interest apparent within the gel, but this 
did not appear to be the case.  Western blotting was performed to probe individual 
analytes for TGF- and IL-6 on SDS-PAGE gels, but both assays failed to transfer 
these proteins to a detectable level, despite a number of attempts (details not 
reported) and remained illusive on the nitrocellulose acetate membrane.  Further 
studies that would identify the acute phase proteins expressed in trauma would be 
therefore advantageous.  More specific techniques, for example 2D gel 
electrophoresis or liquid chromatography, would be required to gain a heightened 
level of resolution that is perhaps lacking in the 1D system for this particular 
study. 
 
4.3.2 Intracellular Growth Factors 
Growth factors are vital for regulating a variety of cellular processes and act as 
cell signalling molecules (see Introduction).  For the circulatory system and bone 
marrow, in which cells are free and unbound, it is preferable for them to 
communicate by soluble, circulating protein molecules (Cross and Mustoe, 2003).  
In this study, intracellular TGF- and IL-6 were detected in the cytoplasm of 
MSCs using flow cytometry.  The protocol was semi-quantitative, so could not 
offer any definitive numerical differential conclusion as to the amounts of these 
proteins that could be compared between smokers and non-smokers. Only those 
cells positive for the expression of the proteins could be determined; i.e. if there 
was any amount of these proteins present in the cells, which was almost all of the 
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cells in all samples.  A flow cytometer is capable of intracellular protein 
quantitation, but requires a dedicated protocol, a specialised commercially-
available kit and greater expertise.  The ELISA technique was instead selected to 
quantify specific proteins of interest due to its simplicity, affordability and 
widespread availability. 
 
4.3.3 ELISA: VEGF and IL-6 
Vascular endothelial growth factor gives rise to angiogenesis, contributing to a 
crucial occurrence in fracture repair, albeit that the mitogenic action of VEGF is 
largely restricted to vascular endothelial cells.  It also increases endothelial cell 
permeability, leading to (neo)extravasation of fibrinogen and subsequent 
formation of a fibrin matrix, inducing MSC migration.  This, coupled with 
endothelial cell proliferation, constitutes a potent angiogenic response that is seen 
in fracture repair.  The chemotactic function of interleukin-6 on inflammatory 
mediators, in addition to its influence on the recruitment of MSCs in the early 
phase of trauma, is crucial for the initiation of the acute-phase response.  
Importantly, IL-6 peaks at 24 hours post-fracture, but is barely detectable after 
three days, which was a major factor in collecting the samples from the trauma 
patients within 24 hours of injury in the current study.   
 
The preliminary data obtained from the ELISAs showed a 10% reduction in the 
amount of VEGF-A in smokers’ serum, which was compounded with a lowered 
expression in the quantity of cytoplasmic IL-6, by approximately 15%.  If patients 
are deficient of these growth factors, as was found by using ELISA, then this 
                                                                                                                  Discussion 
230 
could contribute to the delayed union that is synonymous with tobacco smoking 
and the healing of bones.  The concept that the ECM of smokers’ fracture sites is 
deficient of VEGF and is of inferior quality and consequently less able to deliver 
adequate angiogenesis for tissue repair, is feasible in light of these results where 
serum was involved.  Given that a main source of VEGF is derived from residual 
bone marrow MSCs (Kagiwada et al., 2008), which were found to proliferate at a 
slower rate in smokers’ cells, it may be assumed that certain growth factors are 
not actually expressed as abundantly by MSCs and are impeded due to the 
compounded, tobacco-induced, toxic processes impacting upon them.  In addition, 
cytoplasmic IL-6 down-regulation in the smoke-affected MSCs likely prevents 
chemotactic recruitment of further MSCs and mediators to the microenvironment, 
relaying an additional insult to the reparatory systems that are in situ, since IL-6 is 
known to initiate the healing process.  The preliminary findings that the cells and 
molecules observed in this study are inferior in terms of quantity and quality from 
smokers suggests that other mediators may also be altered in a detrimental way.  
Further investigations are now justified to comprehensively study those additional 
factors that are affected by tobacco smoking and the fracture healing process.  The 
ELISA data is considered preliminary due to a low sample size, so should be 
repeated using more samples.  
 
4.1 Biochemical Analysis of the Fracture Haematoma Serum 
The biochemical assays that were carried out in this study have concentrated on 
measuring the levels of b-ALP, albumin and total protein in serum that was 
derived from the fracture haematoma of smoking (n=10) and non-smoking (n=10) 
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patients.  The assays were therefore designed to make direct comparisons between 
smokers and non-smokers.  The results of the assays showed that b-ALP was 20% 
higher in smokers’ fracture serum, although this was not statistically significant, 
probably because of high levels of variance within the groups.  There were, 
however, significantly reduced levels of albumin (p<0.05) and highly significant 
lower amounts of total protein (albumin + globulin) (p<0.01) in smokers’ serum 
in comparison to non-smokers’. 
 
4.1.1 Bone-Specific Alkaline Phosphatase (b-ALP) 
Bone-specific alkaline phosphatase is synthesized by osteoblasts and levels in 
serum can be raised in certain bone disease states. This is largely due to increased 
osteoblastic activity and is for this reason seen in bone metastases and 
hyperparathyroidism.  Raised b-ALP levels were found in smokers’ fracture 
serum, which perhaps alludes to increased osteoblastic activity in patients who 
smoke.  This demonstrates an up-regulation of bone remodelling, which is likely 
due to compensatory mechanisms taking place because of cell destruction, as was 
shown to be the case in CSE-treated MSC cultures in the necrosis study (Figure 
55 (a-c), Ch.3).   It could also account for the NO imbalances that were found, 
which provides the basis for abnormal bone remodelling. 
 
The 20% increase in serum levels of b-ALP in smokers are in line with the results 
found by Frost-Peneda et al. (2010), who showed elevated levels of alkaline 
phosphatase in serum derived from the peripheral blood of smokers compared to 
non-smokers.  Their study was conducted using a large sample size (smokers 
                                                                                                                  Discussion 
232 
(n=3685) vs. non-smokers (n=1081)) and was an important investigation into the 
biomarkers of potential harm (BOPH) among adult smokers and non-smokers.  
The actual circulatory ALP levels were found to be 10.8% higher than non-
smokers and this was highly statistically significant (p<0.0001).  However, it was 
stated that age, race, gender, body mass index (BMI) and number of cigarettes 
smoked per day all had an effect on ALP (Frost-Pineda et al., 2010). 
 
The work by Frost-Pineda et al. (2010) was concentrated on circulatory ALP, 
which is mainly synthesised by the liver in the human subjects.  Our study 
quantitated levels from actual fracture sites, thus would mainly have consisted of 
localised b-ALP and therefore negligible levels of circulatory ALP, perhaps 
rendering this study more orthopaedically-relevant.  The level of raised b-ALP 
was higher than that found by Frost-Pineda and co-workers (b-ALP 20.0% in the 
current study compared with ALP 10.8% shown by Frost-Pineda et al. (2010)), 
suggesting that the problem is more pronounced at the fracture site than it is at the 
peripheral level.  Irrespective of this, it shows that patients who smoke have an 
abnormal level of bone remodelling when compared to non-smokers, reflective of 
compensatory mechanisms taking place because of damage at the cellular level.   
 
4.1.2 Albumin and Total Protein 
Albumin and total protein, the latter being the amount of albumin and globulin 
combined in serum, were the subject of quantitative assays on the serum extracted 
from the haematoma samples.  Albumin is the main component of plasma proteins 
and has an essential role in the maintenance of osmotic pressure.  Importantly, it is 
                                                                                                                  Discussion 
233 
a major transporter of a large number of products, including calcium, bilirubin and 
hormones.  It is used as a prognostic indicator of the transported products in terms 
of deteriorating function and inflammation.  Decreases in albumin levels are 
attributable to malnutrition and hepatic synthesis alteration.  Serious losses can be 
caused by trauma, kidney disease and cancer.  Total protein is useful for 
monitoring gross changes in protein levels caused by a range of disease states, 
with decreased levels indicative of terminal liver failure (Doumas and Peters, 
1997). 
 
In the current study, there were statistically-significant reduced levels of both 
serum albumin (p<0.05) and total protein (p<0.01) in the fracture serum of 
smokers compared with the non-smoking patient group.  In contrast, mean 
albumin levels in the smokers in the study by Frost-Pineda et al. (2010) remained 
unchanged when compared to non-smoker levels.  This is probably due to their 
study not being concerned with trauma patients who are in the acute phase, as is 
the case with our data.  Albumin is negatively expressed in trauma and this was 
found to be exaggerated in smokers serum, giving less scope for the transportation 
of calcium and other essential materials, such as acute phase proteins, to the 
fracture site.  This is likely to contribute further to delayed healing that is seen so 
often in those patients who have sustained a fracture that smoke. 
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4.2 Conclusions   
Fracture repair is a complex process involving many factors and molecules that 
are present in situ and recruited to the site of injury during the inflammatory, 
proliferative and maturation phases of healing. The effects of smoking are thought 
to be mediated via the vasoconstrictive and platelet-activating and aggregating 
properties of nicotine, the hypoxia-promoting effects of CO and the inhibition of 
oxidative metabolism by HCN at the cellular level. 
 
There is no doubt that serious complications exist in fracture healing due to 
smoking and cessation of the habit perioperatively can improve the prognosis for 
smokers.  Whilst clinical studies have addressed this problem very well, little 
work on the biochemical aspects has been conducted.  The cellular and molecular 
processes involved in fracture healing are thus undoubtedly compromised and this 
problem has been the focus of this report.   
 
Though much of the work undertaken was similar to that of a pilot study, it was 
found that smokers, whether via the smoking model or by direct comparison, were 
found to be disadvantaged due to detrimental changes in cellular morphology in 
terms of fragmentation and thinning, in addition to reduced proliferation and 
increased necrosis.  Cells subject to the in vitro smoking environment were shown 
to possess lower levels of nitric oxide; such deficiencies are known to contribute 
to abnormal bone remodelling and poor vascularisation and vasodilatation. 
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Cessation of smoking is known to have a beneficial influence in fractures and this 
was apparent in the cellular recovery assays.  The infusion of exogenous growth 
factor, BMP-2, offered a level of improvement to cellular viability in a smoking 
environment, offering hope to patients who are otherwise blighted with fracture 
pathologies, such malunion, nonunion and delayed union.   
Proteomic studies showed that the serum possessed numerous acute-phase 
proteins, but the study would benefit from 2D electrophoresis in order to further 
isolate proteins of interest; the quantitation of intracellular proteins in MSCs 
would also be an advantage in future studies. 
 
In biochemical analysis, b-ALP was found to be higher in smokers, confirming an 
abnormally-raised rate of bone remodelling in those patients.  Serum albumin was 
significantly lowered in the same patients, signifying a reduced capacity for 
calcium transport. 
 
In summary, tobacco smoking is known to have a deleterious effect on the 
dynamics of both wound and fracture healing and numerous studies involving 
animals and humans have been undertaken to demonstrate this.  Orthopaedic 
surgeons have recommended that there should be a period of smoking cessation 
prior to surgery and, therefore, a history of cigarette smoking should be obtained 
from individuals so that the risks and complications may be discussed in detail.  
Both the orthopaedic surgeon and patient should, therefore, be completely aware 
of the harmful effects of smoking when assessing or planning a surgical 
intervention.
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5.1 Future Studies 
Future cellular analyses would concentrate on the proteins that are synthesised by 
them as cell messengers in the fracture milieu.  The protein profile in the 
haematoma is due to two mechanisms, those produced by the liver and mobilised 
to the fracture site and those produced by cells and platelets at the site of injury.  
Since the haemolysis of the haematoma may prevent accurate study of proteins 
within it, cultured cells offer a viable alternative.  The effects of smoking can be 
synthesised using CSE in order to introduce a causative factor in cell damage and 
cell proteins may be observed following exposure to the toxic reagent using a 
variety of techniques.  To improve statistical significance, all assays in this 
research should be repeated using more fracture haematoma specimens so as to 
increase the sample size, so that each assay has a sample size of sufficient 
statistical power and also to minimise variance.  Additional sites within the 
hospital trust should be approached to widen the donor pool.  Ethical approval has 
been granted from the Local Research Ethics Committee (LREC) to do this (see 
Appendices) and additional chief investigators at these sites have agreed to 
participate.  However, using commercially-available osteoblastic cell lines may 
offer a degree of flexibility. 
 
In order that the acute-phase proteins may be studied in more detail, they may be 
analysed in the fracture haematoma serum using a 2D electrophoresing system for 
an enhanced resolution.  Due to haemolysis in samples, peripheral blood could be 
procured from participants to see if there are any differences in the quantity of 
circulating acute-phase proteins in the trauma phase.  Western blotting can isolate 
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specific proteins of interest in both the haematoma serum and cell-culture 
supernatant prior to analysis using other techniques such as MALDI-TOF and 
ELISA, which are very useful methods in the quantitation of cytokines that are 
involved in fracture repair.  MALDI-TOF can quantitate up to 5000 proteins per 
assay, making it the gold standard for protein analysis. However, flow cytometric 
probing and analysis of intracellular proteins could also measure membrane and 
intracellar proteins, DNA and RNA.   
 
Cotinine is an alkaloid found in tobacco and is also a metabolite of nicotine.  
 
It is 
used as a biomarker for exposure to tobacco.  When conducting studies comparing 
smokers with non-smokers, cotinine testing can be undertaken in the urine of 
consenting patients to quantitate nicotine levels.  This would negate the 
requirement of relying on patients’ honesty regarding number of cigarettes 
smoked per day.  This could give an insight into the differences in fracture repair 
that may exist between a heavy or light smoking habit.  However, the drawback of 
this is that patients using nicotine replacement therapy could produce a false 
positive. 
 
This said, revision and refinement of the existing protocols in the study should be 
considered employing more rigorous scientific methods.  Undertaking the 
following laboratory procedures is suggested overleaf. 
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Using Coverslips in Immunohistochemical Assays 
Culturing cells on glass coverslips within flasks instead of using a cyto-spin 
instrument enables greater detail to be studied.  Cells can then be fluorescently 
stained to identify various organelles, for example: 
 
 Lysosomes 
 Plasma membrane 
 Golgi apparatus 
 Nucleus, especially DNA.  
 
 Smooth Endoplastic Reticulum 
 Rough Endoplastic Reticulum 
 Mitochondria 
  
Various commercial biochemical stains are available in order that organelles may 
be observed under fluorescent microscopy, for example Using 4',6-diamidino-2-
phenylindole (DAPI), a fluorescent stain that binds strongly to A-T rich regions 
in DNA.   
 
Non-Expressing Cell Line 
The acquisition of a non-expressing cell line, such as the CD34+ haematopoietic 
stem cell, could also be included in control studies to show that the MSC cell 
surface antigen markers use in this study (CD29, CD44, CD73, CD105 and 
CD166) bind exclusively to membrane antigens expressed only by cells extracted 
and cultured from the fracture haematomas.  This would give further credibility 
that cells are of an osteoblastic nature. 
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Cell Cycle Analysis/Population Doubling Time 
Analysis of a large variety of cells in culture populations has revealed 
considerable variability in the lengths of their cell cycles.  It would therefore be 
advantageous to be able to study the cell cycle and the phase distribution (G1, S, 
G2, M) to see if there are any differences between smokers (or CSE treated) and 
non smokers (or non-treated) in terms of cycle length or if more cells were in the 
dormant phase (G0) in cultures.  Cell cycle analysis can be achieved via flow 
cytometry, which provides a rapid and non-radioactive method for looking at cell 
proliferation.  Maximum passage potential could also be investigated by 
continuously subculturing cells until senescence/quiescence is observed. 
 
 
Differentiation Potential 
In order to satisfy the criteria set out by the ISCT, isolated and cultured MSCs 
should be differentiated into osteocytes (osteogenic induction), chondrocytes 
(chondrogenic induction) and adipocyte (adipogenic induction). Traditional In 
vitro culturing techniques outlined as follows: 
 
 Osteogenic Induction:  Media containing dexamethasone, 
glycerphosphate, ascorbic acid.  Stain with alizarin red. 
 Chondrogenic Induction:  Chondrogenic medium (high glucose DMEM) 
with dexamethasone, ascorbic acid-2-phosphate, praline, recombinant 
TGF- and BMP-6.  Stain with toluidine blue. 
 Adipogenic Induction:  Adipogenic medium containing 3-isobutyl-1 
methylxanthene, insulin and indometacin.  Stain with oil red. 
(Oe et al., 2007) 
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Validation of CSE Production 
Additional studies could involve further validation of the CSE via mass-
spectrometry to obtain an elementary profile of the toxins within the solution; this 
would enable a degree of quality assurance for reproducibility.  The use of an 
electric pump system is likely to improve on the accuracy provided by the syringe 
method employed in this study.   Increasing the CSE exposure time to cells may 
give an insight to the chronic effects of smoking on MSCs. 
 242 
 
 
 
CHAPTER 6 
 
 REFERENCES 
________________________________________________________References 
243 
6 REFERENCES 
 
 
Abidi, N. A., Dhawan, S., Gruen, G. S., Vogt, M. T. and Conti, S. F. (1998) 
Wound-healing risk factors after open reduction and internal fixation of calcaneal 
fractures. Foot Ankle Int, 19, 856-61. 
 
Abraham, D. J., Shiwen, X., Black, C. M., Sa, S., Xu, Y. and Leask, A. (2000) 
Tumor necrosis factor alpha suppresses the induction of connective tissue growth 
factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J 
Biol Chem, 275, 15220-5. 
 
Adams, C. I., Keating, J. F. and Court-Brown, C. M. (2001) Cigarette smoking 
and open tibial fractures. Injury, 32, 61-5. 
 
Akoz, T., Akan, M. and Yildirim, S. (2002) If you continue to smoke, we may 
have a problem: smoking's effects on plastic surgery. Aesthetic Plast Surg, 26, 
477-82. 
 
Al-Hadithy, N., Sewell, M. D., Bhavikatti, M. and Gikas, P. D. (2012) The effect 
of smoking on fracture healing and on various orthopaedic procedures. Acta 
Orthop Belg, 78, 285-90. 
 
Andrew, J. G., Hoyland, J., Andrew, S. M., Freemont, A. J. and Marsh, D. (1993) 
Demonstration of TGF-beta 1 mRNA by in situ hybridization in normal human 
fracture healing. Calcif Tissue Int, 52, 74-8. 
________________________________________________________References 
244 
Arron, J. R. and Choi, Y. (2000) Bone versus immune system. Nature, 408, 535-6. 
 
Aspenberg, P. (2013) Annotation: parathyroid hormone and fracture healing. Acta 
Orthop, 84, 4-6. 
 
Azouna, B.N., Jenhani, F., Regaya, Z., Berraeis, L., Ben Othman, T., Ducrocq, E. 
and Domenech, J. (2012) Phenotypical and functional characteristics of 
mesenchymal stem cells from bone marrow: comparison of culture using different 
media supplemented with human platelet lysate or fetal bovine serum. Stem Cell 
Res Ther, 3, 6. 
 
Bainbridge, P. (2013) Wound healing and the role of fibroblasts. J Wound Care, 
22, 407-8, 410-12. 
 
Balaji, S. M. (2008) Tobacco smoking and surgical healing of oral tissues: a 
review. Indian J Dent Res, 19, 344-8. 
 
Balemans, W. and Van Hul, W. (2002) Extracellular regulation of BMP signaling 
in vertebrates: a cocktail of modulators. Dev Biol, 250, 231-50. 
 
Balemans, W. and Van Hul, W. (2004) Identification of the disease-causing gene 
in sclerosteosis--discovery of a novel bone anabolic target? J Musculoskelet 
Neuronal Interact, 4, 139-42. 
 
________________________________________________________References 
245 
Barbash, I. M., Chouraqui, P., Baron, J., Feinberg, M. S., Etzion, S., Tessone, A., 
Miller, L., Guetta, E., Zipori, D., Kedes, L. H., Kloner, R. A. and Leor, J. (2003) 
Systemic delivery of bone marrow-derived mesenchymal stem cells to the 
infarcted myocardium: feasibility, cell migration, and body distribution. 
Circulation, 108, 863-8. 
 
Barnoya, J. and Glantz, S. A. (2005) Cardiovascular effects of secondhand smoke: 
nearly as large as smoking. Circulation, 111, 2684-98. 
 
Baron, J. A. (1984) Smoking and estrogen-related disease. Am J Epidemiol, 119, 
9-22. 
 
Bartecchi, C. E., Mackenzie, T. D. and Schrier, R. W. (1994) The human costs of 
tobacco use (1). N Engl J Med, 330, 907-12. 
 
Barua, R. S., Ambrose, J. A., Eales-Reynolds, L. J., Devoe, M. C., Zervas, J. G. 
and Saha, D. C. (2001) Dysfunctional endothelial nitric oxide biosynthesis in 
healthy smokers with impaired endothelium-dependent vasodilatation. 
Circulation, 104, 1905-10. 
 
Beer, H. D., Gassmann, M. G., Munz, B., Steiling, H., Engelhardt, F., Bleuel, K. 
and Werner, S. (2000) Expression and function of keratinocyte growth factor and 
activin in skin morphogenesis and cutaneous wound repair. J Investig Dermatol 
Symp Proc, 5, 34-9. 
 
________________________________________________________References 
246 
Bennett, N. T. and Schultz, G. S. (1993) Growth factors and wound healing: 
biochemical properties of growth factors and their receptors. Am J Surg, 165, 728-
37. 
 
Bernhard, D., Huck, C. W., Jakschitz, T., Pfister, G., Henderson, B., Bonn, G. K. 
and Wick, G. (2004) Development and evaluation of an in vitro model for the 
analysis of cigarette smoke effects on cultured cells and tissues. J Pharmacol 
Toxicol Methods, 50, 45-51. 
 
Betgovargez, E., Knudson, V. and Simonian, M. H. (2005) Characterization of 
proteins in the human serum proteome. J Biomol Tech, 16, 306-10. 
 
Bevilacqua, M. P., Pober, J. S., Wheeler, M. E., Cotran, R. S. and Gimbrone, M. 
A., Jr. (1985) Interleukin 1 acts on cultured human vascular endothelium to 
increase the adhesion of polymorphonuclear leukocytes, monocytes, and related 
leukocyte cell lines. J Clin Invest, 76, 2003-11. 
 
Bond, J. S. and Beynon, R. J. (1995) The astacin family of metalloendopeptidases. 
Protein Sci, 4, 1247-61. 
 
Borisov, N., Aksamitiene, E., Kiyatkin, A., Legewie, S., Berkhout, J., Maiwald, 
T., Kaimachnikov, N. P., Timmer, J., Hoek, J. B. and Kholodenko, B. N. (2009) 
Systems-level interactions between insulin-EGF networks amplify mitogenic 
signaling. Mol Syst Biol, 5, 256. 
 
________________________________________________________References 
247 
Bornmyr, S. and Svensson, H. (1991) Thermography and laser-Doppler flowmetry 
for monitoring changes in finger skin blood flow upon cigarette smoking. Clin 
Physiol, 11, 135-41. 
 
Bostrom, M. P. (1998) Expression of bone morphogenetic proteins in fracture 
healing. Clin Orthop Relat Res, S116-23. 
 
Boyer, C. S., Bannenberg, G. L., Neve, E. P., Ryrfeldt, A. and Moldeus, P. (1995) 
Evidence for the activation of the signal-responsive phospholipase A2 by 
exogenous hydrogen peroxide. Biochem Pharmacol, 50, 753-61. 
 
Brandi, M. L., Hukkanen, M., Umeda, T., Moradi-Bidhendi, N., Bianchi, S., 
Gross, S. S., Polak, J. M. and Macintyre, I. (1995) Bidirectional regulation of 
osteoclast function by nitric oxide synthase isoforms. Proc Natl Acad Sci U S A, 
92, 2954-8. 
 
Broughton, G., 2nd, Janis, J. E. and Attinger, C. E. (2006) The basic science of 
wound healing. Plast Reconstr Surg, 117, 12S-34S. 
 
Broughton, G., 2nd, Janis, J. E. and Attinger, C. E. (2006) Wound healing: an 
overview. Plast Reconstr Surg, 117, 1e-S-32e-S. 
 
Brunet, L. J., Mcmahon, J. A., Mcmahon, A. P. and Harland, R. M. (1998) 
Noggin, cartilage morphogenesis, and joint formation in the mammalian skeleton. 
Science, 280, 1455-7. 
________________________________________________________References 
248 
Callum, C., Boyle, S. and Sandford, A. (2010) Estimating the cost of smoking to 
the NHS in England and the impact of declining prevalence. Health Econ Policy 
Law, 6, 489-508. 
 
Campanile, G., Hautmann, G. and Lotti, T. (1998) Cigarette smoking, wound 
healing, and face-lift. Clin Dermatol, 16, 575-8. 
 
Capewell, S., Hayes, D. K., Ford, E. S., Critchley, J. A., Croft, J. B., Greenlund, 
K. J. and Labarthe, D. R. (2009) Life-Years Gained Among US Adults From 
Modern Treatments and Changes in the Prevalence of 6 Coronary Heart Disease 
Risk Factors Between 1980 and 2000. Am J Epidemiol. 
 
Carpenter, C. T., Dietz, J. W., Leung, K. Y., Hanscom, D. A. and Wagner, T. A. 
(1996) Repair of a pseudarthrosis of the lumbar spine. A functional outcome 
study. J Bone Joint Surg Am, 78, 712-20. 
 
Cartmell, S. H., Rathbone, S., Jones, G. and Hidalgo-Bastida, L. A. (2011) 3D 
sample preparation for orthopaedic tissue engineering bioreactors. Methods Mol 
Biol, 695, 61-76. 
 
Chamberlain, G., Fox, J., Ashton, B. and Middleton, J. (2007) Concise review: 
mesenchymal stem cells: their phenotype, differentiation capacity, immunological 
features, and potential for homing. Stem Cells, 25, 2739-49. 
 
________________________________________________________References 
249 
Chinthamani, S., Odusanwo, O., Mondal, N., Nelson, J., Neelamegham, S. and 
Baker, O. J. (2012) Lipoxin A4 inhibits immune cell binding to salivary 
epithelium and vascular endothelium. Am J Physiol Cell Physiol, 302, C968-78. 
 
Cho, T. J., Gerstenfeld, L. C. and Einhorn, T. A. (2002) Differential temporal 
expression of members of the transforming growth factor beta superfamily during 
murine fracture healing. J Bone Miner Res, 17, 513-20. 
 
Chuthapisith, S., Layfield, R., Kerr, I. D. and Eremin, O. (2007) Principles of 
proteomics and its applications in cancer. Surgeon, 5, 14-22. 
 
Claffey, K. P., Abrams, K., Shih, S. C., Brown, L. F., Mullen, A. and Keough, M. 
(2001) Fibroblast growth factor 2 activation of stromal cell vascular endothelial 
growth factor expression and angiogenesis. Lab Invest, 81, 61-75. 
 
Clarke, B. (2008) Normal bone anatomy and physiology. Clin J Am Soc Nephrol, 
3 Suppl 3, S131-9. 
 
Cobb, T. K., Gabrielsen, T. A., Campbell, D. C., 2nd, Wallrichs, S. L. and Ilstrup, 
D. M. (1994) Cigarette smoking and nonunion after ankle arthrodesis. Foot Ankle 
Int, 15, 64-7. 
 
Comhair, S. A. and Erzurum, S. C. (2002) Antioxidant responses to oxidant-
mediated lung diseases. Am J Physiol Lung Cell Mol Physiol, 283, L246-55. 
 
________________________________________________________References 
250 
Conget, P. A. and Minguell, J. J. (1999) Phenotypical and functional properties of 
human bone marrow mesenchymal progenitor cells. J Cell Physiol, 181, 67-73. 
 
Connor, J. M. and Evans, D. A. (1982) Fibrodysplasia ossificans progressiva. The 
clinical features and natural history of 34 patients. J Bone Joint Surg Br, 64, 76-
83. 
 
Corbett, S. A., Hukkanen, M., Batten, J., Mccarthy, I. D., Polak, J. M. and 
Hughes, S. P. (1999) Nitric oxide in fracture repair. Differential localisation, 
expression and activity of nitric oxide synthases. J Bone Joint Surg Br, 81, 531-7. 
 
Corbett, S. A., Mccarthy, I. D., Batten, J., Hukkanen, M., Polak, J. M. and 
Hughes, S. P. (1999) Nitric oxide mediated vasoreactivity during fracture repair. 
Clin Orthop Relat Res, 247-53. 
 
Crawford, B. and Comstock, S. (2010) Acute compartment syndrome of the dorsal 
forearm following noncontact injury. Cjem, 12, 453-6. 
 
Cross, K. J. and Mustoe, T. A. (2003) Growth factors in wound healing. Surg Clin 
North Am, 83, 531-45, vi. 
 
Cumming, G., Fidler, F. and Vaux, D. L. (2007) Error bars in experimental 
biology. J Cell Biol, 177, 7-11. 
 
________________________________________________________References 
251 
Czernin, J. and Waldherr, C. (2003) Cigarette smoking and coronary blood flow. 
Prog Cardiovasc Dis, 45, 395-404. 
 
D'amelio, P., Grimaldi, A., Di Bella, S., Brianza, S. Z., Cristofaro, M. A., 
Tamone, C., Giribaldi, G., Ulliers, D., Pescarmona, G. P. and Isaia, G. (2008) 
Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a 
key mechanism in osteoporosis. Bone, 43, 92-100. 
 
D'herbomez, M., Caron, P., Bauters, C., Do Cao, C., Schlienger, J. L., Sapin, R., 
Baldet, L., Carnaille, B. and Wemeau, J. L. (2007) Reference range of serum 
calcitonin levels in humans: influence of calcitonin assays, sex, age, and cigarette 
smoking. Eur J Endocrinol, 157, 749-55. 
 
Daluiski, A., Engstrand, T., Bahamonde, M. E., Gamer, L. W., Agius, E., 
Stevenson, S. L., Cox, K., Rosen, V. and Lyons, K. M. (2001) Bone 
morphogenetic protein-3 is a negative regulator of bone density. Nat Genet, 27, 
84-8. 
 
De Vernejoul, M. C., Bielakoff, J., Herve, M., Gueris, J., Hott, M., Modrowski, 
D., Kuntz, D., Miravet, L. and Ryckewaert, A. (1983) Evidence for defective 
osteoblastic function. A role for alcohol and tobacco consumption in osteoporosis 
in middle-aged men. Clin Orthop Relat Res, 107-15. 
 
 
________________________________________________________References 
252 
Deckers, M. M., Van Bezooijen, R. L., Van Der Horst, G., Hoogendam, J., Van 
Der Bent, C., Papapoulos, S. E. and Lowik, C. W. (2002) Bone morphogenetic 
proteins stimulate angiogenesis through osteoblast-derived vascular endothelial 
growth factor A. Endocrinology, 143, 1545-53. 
 
Devlin, R. D., Du, Z., Pereira, R. C., Kimble, R. B., Economides, A. N., Jorgetti, 
V. and Canalis, E. (2003) Skeletal Overexpression of Noggin Results in 
Osteopenia and Reduced Bone Formation. Endocrinology, 144, 1972-1978. 
 
Devlin, R. D., Du, Z., Pereira, R. C., Kimble, R. B., Economides, A. N., Jorgetti, 
V. and Canalis, E. (2003) Skeletal overexpression of noggin results in osteopenia 
and reduced bone formation. Endocrinology, 144, 1972-8. 
 
Dewhirst, F. E., Stashenko, P. P., Mole, J. E. and Tsurumachi, T. (1985) 
Purification and partial sequence of human osteoclast-activating factor: identity 
with interleukin 1 beta. J Immunol, 135, 2562-8. 
 
Dimitriou, R. and Giannoudis, P. V. (2013) The genetic profile of bone repair. 
Clin Cases Miner Bone Metab, 10, 19-21. 
 
Dimitriou, R., Jones, E., Mcgonagle, D. and Giannoudis, P. V. (2011) Bone 
regeneration: current concepts and future directions. BMC Med, 9, 66. 
 
Dimitriou, R., Tsiridis, E. and Giannoudis, P. V. (2005) Current concepts of 
molecular aspects of bone healing. Injury, 36, 1392-404. 
________________________________________________________References 
253 
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, 
D., Deans, R., Keating, A., Prockop, Dj and Horwitz, E. (2006) Minimal criteria 
for defining multipotent mesenchymal stromal cells. The International Society for 
Cellular Therapy position statement. Cytotherapy, 8, 315-7. 
 
Donaldson, L. J., Reckless, I. P., Scholes, S., Mindell, J. S. and Shelton, N. J. 
(2008) The epidemiology of fractures in England. J Epidemiol Community Health, 
62, 174-80. 
 
Dong, Y. and Canalis, E. (1995) Insulin-like growth factor (IGF) I and retinoic 
acid induce the synthesis of IGF-binding protein 5 in rat osteoblastic cells. 
Endocrinology, 136, 2000-6. 
 
Doumas, B. T. and Peters, T., Jr. (1997) Serum and urine albumin: a progress 
report on their measurement and clinical significance. Clin Chim Acta, 258, 3-20. 
 
Dray, A. (1995) Inflammatory mediators of pain. Br J Anaesth, 75, 125-31. 
 
El-Zayadi, A. R., Selim, O., Hamdy, H., El-Tawil, A. and Moustafa, H. (2002) 
Heavy cigarette smoking induces hypoxic polycythemia (erythrocytosis) and 
hyperuricemia in chronic hepatitis C patients with reversal of clinical symptoms 
and laboratory parameters with therapeutic phlebotomy. Am J Gastroenterol, 97, 
1264-5. 
 
________________________________________________________References 
254 
Elliott, K. G. and Johnstone, A. J. (2003) Diagnosing acute compartment 
syndrome. J Bone Joint Surg Br, 85, 625-32. 
 
Erdos, J., Dlaska, C., Szatmary, P., Humenberger, M., Vecsei, V. and Hajdu, S. 
(2011) Acute compartment syndrome in children: a case series in 24 patients and 
review of the literature. Int Orthop, 35, 569-75. 
 
Ettinger, L. and Doljanski, F. (1992) On the generation of form by the continuous 
interactions between cells and their extracellular matrix. Biol Rev Camb Philos 
Soc, 67, 459-89. 
 
Faienza, M. F., Ventura, A., Marzano, F. and Cavallo, L. (2013) Postmenopausal 
osteoporosis: the role of immune system cells. Clin Dev Immunol, 2013, 575936. 
 
Fainsod, A., Deissler, K., Yelin, R., Marom, K., Epstein, M., Pillemer, G., 
Steinbeisser, H. and Blum, M. (1997) The dorsalizing and neural inducing gene 
follistatin is an antagonist of BMP-4. Mech Dev, 63, 39-50. 
 
Fang, M. A., Frost, P. J., Iida-Klein, A. and Hahn, T. J. (1991) Effects of nicotine 
on cellular function in UMR 106-01 osteoblast-like cells. Bone, 12, 283-6. 
 
Farrar, M. A. and Schreiber, R. D. (1993) The molecular cell biology of 
interferon-gamma and its receptor. Annu Rev Immunol, 11, 571-611. 
 
________________________________________________________References 
255 
Fayaz, H. C., Giannoudis, P. V., Vrahas, M. S., Smith, R. M., Moran, C., Pape, H. 
C., Krettek, C. and Jupiter, J. B. (2011) The role of stem cells in fracture healing 
and nonunion. Int Orthop, 35, 1587-97. 
 
Ferrara, N. and Davis-Smyth, T. (1997) The biology of vascular endothelial 
growth factor. Endocr Rev, 18, 4-25. 
 
Field, A. (2009) Discovering Statistics Using SPSS.  Third Edition., Sage 
Publications, Ltd., London. 
 
Fitzpatrick, F. A. and Soberman, R. (2001) Regulated formation of eicosanoids. J 
Clin Invest, 107, 1347-51. 
 
Fleet, J. C. and Schoch, R. D. (2010) Molecular mechanisms for regulation of 
intestinal calcium absorption by vitamin D and other factors. Crit Rev Clin Lab 
Sci, 47, 181-95. 
 
Folsom, A. R. (1995) Epidemiology of fibrinogen. Eur Heart J, 16 Suppl A, 21-
3; discussion 23-4. 
 
Fontaine, K., Semonin, O., Legarde, J. P., Lenoir, G. and Lucotte, G. (2005) A 
new mutation of the noggin gene in a French Fibrodysplasia ossificans 
progressiva (FOP) family. Genet Couns, 16, 149-54. 
 
________________________________________________________References 
256 
Ford, J. L., Robinson, D. E. and Scammell, B. E. (2004) Endochondral 
ossification in fracture callus during long bone repair: the localisation of 'cavity-
lining cells' within the cartilage. J Orthop Res, 22, 368-75. 
 
Fox, S. W., Chambers, T. J. and Chow, J. W. (1996) Nitric oxide is an early 
mediator of the increase in bone formation by mechanical stimulation. Am J 
Physiol, 270, E955-60. 
 
Frances, C., Boisnic, S., Hartmann, D. J., Dautzenberg, B., Branchet, M. C., 
Charpentier, Y. L. and Robert, L. (1991) Changes in the elastic tissue of the non-
sun-exposed skin of cigarette smokers. Br J Dermatol, 125, 43-7. 
 
Franceschetti, M., Pievani, A., Borleri, G., Vago, L., Fleischhauer, K., Golay, J. 
and Introna, M. (2009) Cytokine-induced killer cells are terminally differentiated 
activated CD8 cytotoxic T-EMRA lymphocytes. Exp Hematol, 37, 616-628 e2. 
 
Frangogiannis, N. G. (2008) The immune system and cardiac repair. Pharmacol 
Res, 58, 88-111. 
 
Frank, S., Gaume, B., Bergmann-Leitner, E. S., Leitner, W. W., Robert, E. G., 
Catez, F., Smith, C. L. and Youle, R. J. (2001) The role of dynamin-related 
protein 1, a mediator of mitochondrial fission, in apoptosis. Dev Cell, 1, 515-25. 
 
Friedlaender, G. E., Perry, C. R., Cole, J. D., Cook, S. D., Cierny, G., Muschler, 
G. F., Zych, G. A., Calhoun, J. H., Laforte, A. J. and Yin, S. (2001) Osteogenic 
________________________________________________________References 
257 
protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J 
Bone Joint Surg Am, 83-A Suppl 1, S151-8. 
 
Frost-Pineda, K., Liang, Q., Liu, J., Rimmer, L., Jin, Y., Feng, S., Kapur, S., 
Mendes, P., Roethig, H. and Sarkar, M. (2010) Biomarkers of potential harm 
among adult smokers and nonsmokers in the total exposure study. Nicotine Tob 
Res, 13, 182-93. 
 
Gabbiani, G. (2003) The myofibroblast in wound healing and fibrocontractive 
diseases. J Pathol, 200, 500-3. 
 
Galmiche, M. C., Koteliansky, V. E., Briere, J., Herve, P. and Charbord, P. (1993) 
Stromal cells from human long-term marrow cultures are mesenchymal cells that 
differentiate following a vascular smooth muscle differentiation pathway. Blood, 
82, 66-76. 
 
Gaston, M. S. and Simpson, A. H. (2007) Inhibition of fracture healing. J Bone 
Joint Surg Br, 89, 1553-60. 
 
Gazzerro, E., Pereira, R. C., Jorgetti, V., Olson, S., Economides, A. N. and 
Canalis, E. (2005) Skeletal overexpression of gremlin impairs bone formation and 
causes osteopenia. Endocrinology, 146, 655-65. 
 
________________________________________________________References 
258 
Gazzerro, Elisabetta, Gangji, Valerie and Canalis, Ernesto (1998) Bone 
Morphogenetic Proteins Induce the Expression of Noggin, Which Limits Their 
Activity in Cultured Rat Osteoblasts. J. Clin. Invest., 102, 2106-2114. 
 
Geesink, R. G., Hoefnagels, N. H. and Bulstra, S. K. (1999) Osteogenic activity of 
OP-1 bone morphogenetic protein (BMP-7) in a human fibular defect. J Bone 
Joint Surg Br, 81, 710-8. 
 
Gerstenfeld, L. C., Alkhiary, Y. M., Krall, E. A., Nicholls, F. H., Stapleton, S. N., 
Fitch, J. L., Bauer, M., Kayal, R., Graves, D. T., Jepsen, K. J. and Einhorn, T. A. 
(2006) Three-dimensional reconstruction of fracture callus morphogenesis. J 
Histochem Cytochem, 54, 1215-28. 
 
Gerstenfeld, L. C., Cullinane, D. M., Barnes, G. L., Graves, D. T. and Einhorn, T. 
A. (2003) Fracture healing as a post-natal developmental process: molecular, 
spatial, and temporal aspects of its regulation. J Cell Biochem, 88, 873-84. 
 
Givan, A. L. (2004) Flow cytometry: an introduction. Methods Mol Biol, 263, 1-
32. 
 
Glassman, S. D., Anagnost, S. C., Parker, A., Burke, D., Johnson, J. R. and 
Dimar, J. R. (2000) The effect of cigarette smoking and smoking cessation on 
spinal fusion. Spine (Phila Pa 1976), 25, 2608-15. 
 
________________________________________________________References 
259 
Glowacki, J. (1998) Angiogenesis in fracture repair. Clin Orthop Relat Res, S82-
9. 
 
Goldman, R. (2004) Growth factors and chronic wound healing: past, present, and 
future. Adv Skin Wound Care, 17, 24-35. 
 
Govender, S., Csimma, C., Genant, H. K., Valentin-Opran, A., Amit, Y., Arbel, 
R., Aro, H., Atar, D., Bishay, M., Borner, M. G., Chiron, P., Choong, P., Cinats, 
J., Courtenay, B., Feibel, R., Geulette, B., Gravel, C., Haas, N., Raschke, M., 
Hammacher, E., Van Der Velde, D., Hardy, P., Holt, M., Josten, C., Ketterl, R. L., 
Lindeque, B., Lob, G., Mathevon, H., Mccoy, G., Marsh, D., Miller, R., Munting, 
E., Oevre, S., Nordsletten, L., Patel, A., Pohl, A., Rennie, W., Reynders, P., 
Rommens, P. M., Rondia, J., Rossouw, W. C., Daneel, P. J., Ruff, S., Ruter, A., 
Santavirta, S., Schildhauer, T. A., Gekle, C., Schnettler, R., Segal, D., Seiler, H., 
Snowdowne, R. B., Stapert, J., Taglang, G., Verdonk, R., Vogels, L., Weckbach, 
A., Wentzensen, A. and Wisniewski, T. (2002) Recombinant human bone 
morphogenetic protein-2 for treatment of open tibial fractures: a prospective, 
controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg 
Am, 84-A, 2123-34. 
 
Greene, A. H., Bumgardner, J. D., Yang, Y., Moseley, J. and Haggard, W. O. 
(2008) Chitosan-coated stainless steel screws for fixation in contaminated 
fractures. Clin Orthop Relat Res, 466, 1699-704. 
 
________________________________________________________References 
260 
Grotendorst, G. R., Soma, Y., Takehara, K. and Charette, M. (1989) EGF and 
TGF-alpha are potent chemoattractants for endothelial cells and EGF-like peptides 
are present at sites of tissue regeneration. J Cell Physiol, 139, 617-23. 
 
Gruer, L., Hart, C. L., Gordon, D. S. and Watt, G. C. (2009) Effect of tobacco 
smoking on survival of men and women by social position: a 28 year cohort study. 
Bmj, 338, b480. 
 
Gullihorn, L., Karpman, R. and Lippiello, L. (2005) Differential effects of 
nicotine and smoke condensate on bone cell metabolic activity. J Orthop Trauma, 
19, 17-22. 
 
Hartigan, N., Garrigue-Antar, L. and Kadler, K. E. (2003) Bone morphogenetic 
protein-1 (BMP-1). Identification of the minimal domain structure for procollagen 
C-proteinase activity. J Biol Chem, 278, 18045-9. 
 
Hata, A., Lagna, G., Massague, J. and Hemmati-Brivanlou, A. (1998) Smad6 
inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor 
suppressor. Genes Dev, 12, 186-97. 
 
Haynesworth, S. E., Baber, M. A. and Caplan, A. I. (1992) Cell surface antigens 
on human marrow-derived mesenchymal cells are detected by monoclonal 
antibodies. Bone, 13, 69-80. 
 
________________________________________________________References 
261 
Helt, C. E., Rancourt, R. C., Staversky, R. J. and O'reilly, M. A. (2001) p53-
dependent induction of p21(Cip1/WAF1/Sdi1) protects against oxygen-induced 
toxicity. Toxicol Sci, 63, 214-22. 
 
Heo, S. C., Jeon, E. S., Lee, I. H., Kim, H. S., Kim, M. B. and Kim, J. H. (2011) 
Tumor necrosis factor-alpha-activated human adipose tissue-derived 
mesenchymal stem cells accelerate cutaneous wound healing through paracrine 
mechanisms. J Invest Dermatol, 131, 1559-67. 
 
Hidalgo-Bastida, L. A. and Cartmell, S. H. (2010) Mesenchymal stem cells, 
osteoblasts and extracellular matrix proteins: enhancing cell adhesion and 
differentiation for bone tissue engineering. Tissue Eng Part B Rev, 16, 405-12. 
 
Hirtenstein, M., Clark, J., Lindgren, G. and Vretblad, P. (1980) Microcarriers for 
animal cell culture: a brief review of theory and practice. Dev Biol Stand, 46, 109-
16. 
 
Hoffmann, D. and Hoffmann, I. (1997) The changing cigarette, 1950-1995. J 
Toxicol Environ Health, 50, 307-64. 
 
Holick, M. F. (2011) Vitamin D: evolutionary, physiological and health 
perspectives. Curr Drug Targets, 12, 4-18. 
 
Hollenbeck, P. J. (1996) The pattern and mechanism of mitochondrial transport in 
axons. Front Biosci, 1, d91-102. 
________________________________________________________References 
262 
Horowitz, M., Vignery, A., Gershon, R. K. and Baron, R. (1984) Thymus-derived 
lymphocytes and their interactions with macrophages are required for the 
production of osteoclast-activating factor in the mouse. Proc Natl Acad Sci U S A, 
81, 2181-5. 
 
Horton, J. E., Raisz, L. G., Simmons, H. A., Oppenheim, J. J. and Mergenhagen, 
S. E. (1972) Bone resorbing activity in supernatant fluid from cultured human 
peripheral blood leukocytes. Science, 177, 793-5. 
 
Howell, J. M. (1992) Current and future trends in wound healing. Emerg Med Clin 
North Am, 10, 655-63. 
 
Huang, X., Sakamoto, H. and Ogawa, M. (2009) Thrombopoietin controls 
proliferation of embryonic multipotent hematopoietic progenitors. Genes Cells. 
 
Hukkanen, J., Jacob, P., 3rd and Benowitz, N. L. (2005) Metabolism and 
disposition kinetics of nicotine. Pharmacol Rev, 57, 79-115. 
 
Hukkanen, M., Corbett, S. A., Batten, J., Konttinen, Y. T., Mccarthy, I. D., 
Maclouf, J., Santavirta, S., Hughes, S. P. and Polak, J. M. (1997) Aseptic 
loosening of total hip replacement. Macrophage expression of inducible nitric 
oxide synthase and cyclo-oxygenase-2, together with peroxynitrite formation, as a 
possible mechanism for early prosthesis failure. J Bone Joint Surg Br, 79, 467-74. 
 
________________________________________________________References 
263 
Hukkanen, M., Hughes, F. J., Buttery, L. D., Gross, S. S., Evans, T. J., Seddon, S., 
Riveros-Moreno, V., Macintyre, I. and Polak, J. M. (1995) Cytokine-stimulated 
expression of inducible nitric oxide synthase by mouse, rat, and human osteoblast-
like cells and its functional role in osteoblast metabolic activity. Endocrinology, 
136, 5445-53. 
 
Hynes, R. O. (1986) Fibronectins. Sci Am, 254, 42-51. 
 
Itoh, F., Asao, H., Sugamura, K., Heldin, C. H., Ten Dijke, P. and Itoh, S. (2001) 
Promoting bone morphogenetic protein signaling through negative regulation of 
inhibitory Smads. Embo J, 20, 4132-42. 
 
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T. and Thun, M. J. 
(2008) Cancer statistics, 2008. CA Cancer J Clin, 58, 71-96. 
 
Jilka, R. L. (2007) Molecular and cellular mechanisms of the anabolic effect of 
intermittent PTH. Bone, 40, 1434-46. 
 
Jimenez, P. A. and Rampy, M. A. (1999) Keratinocyte growth factor-2 accelerates 
wound healing in incisional wounds. J Surg Res, 81, 238-42. 
 
Jones, A. (2013) Salisbury's Graduate Histology. [Online]  Available from 
http://graduatehistology.blogspot.co.uk/.  Accessed 04.10.13 
 
________________________________________________________References 
264 
Jorgensen, L. N., Kallehave, F., Christensen, E., Siana, J. E. and Gottrup, F. 
(1998) Less collagen production in smokers. Surgery, 123, 450-5. 
 
Kagiwada, H., Yashiki, T., Ohshima, A., Tadokoro, M., Nagaya, N. and Ohgushi, 
H. (2008) Human mesenchymal stem cells as a stable source of VEGF-producing 
cells. J Tissue Eng Regen Med, 2, 184-9. 
 
Kalish, B. T., Kieran, M. W., Puder, M. and Panigrahy, D. (2013) The growing 
role of eicosanoids in tissue regeneration, repair, and wound healing. 
Prostaglandins Other Lipid Mediat, 104-105, 130-8. 
 
Kanczler, J. M. and Oreffo, R. O. (2008) Osteogenesis and angiogenesis: the 
potential for engineering bone. Eur Cell Mater, 15, 100-14. 
 
Kanis, J. A., Mccloskey, E. V., Johansson, H., Oden, A., Melton, L. J., 3rd and 
Khaltaev, N. (2008) A reference standard for the description of osteoporosis. 
Bone, 42, 467-75. 
 
Kaur, H. and Halliwell, B. (1994) Evidence for nitric oxide-mediated oxidative 
damage in chronic inflammation. Nitrotyrosine in serum and synovial fluid from 
rheumatoid patients. FEBS Lett, 350, 9-12. 
 
Kellum, E., Starr, H., Arounleut, P., Immel, D., Fulzele, S., Wenger, K. and 
Hamrick, M. W. (2009) Myostatin (GDF-8) deficiency increases fracture callus 
size, Sox-5 expression, and callus bone volume. Bone, 44, 17-23. 
________________________________________________________References 
265 
Keramaris, N. C., Calori, G. M., Nikolaou, V. S., Schemitsch, E. H. and 
Giannoudis, P. V. (2008) Fracture vascularity and bone healing: a systematic 
review of the role of VEGF. Injury, 39 Suppl 2, S45-57. 
 
Kilfeather, S. (2002) 5-lipoxygenase inhibitors for the treatment of COPD. Chest, 
121, 197S-200S. 
 
Kingsley, D. M. (1994) The TGF-beta superfamily: new members, new receptors, 
and new genetic tests of function in different organisms. Genes Dev, 8, 133-46. 
 
Kitaori, T., Ito, H., Schwarz, E. M., Tsutsumi, R., Yoshitomi, H., Oishi, S., 
Nakano, M., Fujii, N., Nagasawa, T. and Nakamura, T. (2009) Stromal cell-
derived factor 1/CXCR4 signaling is critical for the recruitment of mesenchymal 
stem cells to the fracture site during skeletal repair in a mouse model. Arthritis 
Rheum, 60, 813-23. 
 
Klaus, J., Reinshagen, M., Herdt, K., Adler, G., Von Boyen, G. B. and Von 
Tirpitz, C. (2011) Intravenous ibandronate or sodium-fluoride--a 3.5 years study 
on bone density and fractures in Crohn's disease patients with osteoporosis. J 
Gastrointestin Liver Dis, 20, 141-8. 
 
Kleiner, G., Marcuzzi, A., Zanin, V., Monasta, L. and Zauli, G. (2013) Cytokine 
levels in the serum of healthy subjects. Mediators Inflamm, 2013, 434010. 
 
________________________________________________________References 
266 
Kobayashi, S., Takahashi, H. E., Ito, A., Saito, N., Nawata, M., Horiuchi, H., 
Ohta, H., Ito, A., Iorio, R., Yamamoto, N. and Takaoka, K. (2003) Trabecular 
minimodeling in human iliac bone. Bone, 32, 163-9. 
 
Kostler, W., Strohm, P. C. and Sudkamp, N. P. (2004) Acute compartment 
syndrome of the limb. Injury, 35, 1221-7. 
 
Kroll, S. S. (1994) Necrosis of abdominoplasty and other secondary flaps after 
TRAM flap breast reconstruction. Plast Reconstr Surg, 94, 637-43. 
 
Krupski, W. C. (1991) The peripheral vascular consequences of smoking. Ann 
Vasc Surg, 5, 291-304. 
 
Kumari, M., Khazai, N. B., Ziegler, T. R., Nanes, M. S., Abrams, S. A. and 
Tangpricha, V. (2010) Vitamin D-mediated calcium absorption in patients with 
clinically stable Crohn's disease: a pilot study. Mol Nutr Food Res, 54, 1085-91. 
 
Kurkinen, M., Vaheri, A., Roberts, P. J. and Stenman, S. (1980) Sequential 
appearance of fibronectin and collagen in experimental granulation tissue. Lab 
Invest, 43, 47-51. 
 
Kusu, N., Laurikkala, J., Imanishi, M., Usui, H., Konishi, M., Miyake, A., 
Thesleff, I. and Itoh, N. (2003) Sclerostin is a novel secreted osteoclast-derived 
bone morphogenetic protein antagonist with unique ligand specificity. J Biol 
Chem, 278, 24113-7. 
________________________________________________________References 
267 
Kwan Tat, S., Padrines, M., Theoleyre, S., Heymann, D. and Fortun, Y. (2004) 
IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption 
pathophysiology. Cytokine Growth Factor Rev, 15, 49-60. 
 
Kyro, A., Usenius, J. P., Aarnio, M., Kunnamo, I. and Avikainen, V. (1993) Are 
smokers a risk group for delayed healing of tibial shaft fractures? Ann Chir 
Gynaecol, 82, 254-62. 
 
Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the 
head of bacteriophage T4. Nature, 227, 680-5. 
 
Le Blanc, K., Tammik, C., Rosendahl, K., Zetterberg, E. and Ringden, O. (2003) 
HLA expression and immunologic properties of differentiated and 
undifferentiated mesenchymal stem cells. Exp Hematol, 31, 890-6. 
 
Le Bras, G. F., Taubenslag, K. J. and Andl, C. D. (2012) The regulation of cell-
cell adhesion during epithelial-mesenchymal transition, motility and tumor 
progression. Cell Adh Migr, 6, 365-73. 
 
Lee, J. J., Patel, R., Biermann, J. S. and Dougherty, P. J. (2013) The 
musculoskeletal effects of cigarette smoking. J Bone Joint Surg Am, 95, 850-9. 
 
 
 
________________________________________________________References 
268 
Lee, J. Y., Choo, J. E., Choi, Y. S., Shim, I. K., Lee, S. J., Seol, Y. J., Chung, C. 
P. and Park, Y. J. (2009) Effect of immobilized cell-binding peptides on chitosan 
membranes for osteoblastic differentiation of mesenchymal stem cells. Biotechnol 
Appl Biochem, 52, 69-77. 
 
Lee, M. W., Choi, J., Yang, M. S., Moon, Y. J., Park, J. S., Kim, H. C. and Kim, 
Y. J. (2004) Mesenchymal stem cells from cryopreserved human umbilical cord 
blood. Biochem Biophys Res Commun, 320, 273-8. 
 
Lefkowitz, R. J. (1976) Editorial: Smoking, catecholamines, and the heart. N Engl 
J Med, 295, 615-6. 
 
Leker, R. R., Toth, Z. E., Shahar, T., Cassiani-Ingoni, R., Szalayova, I., Key, S., 
Bratincsak, A. and Mezey, E. (2009) Transforming growth factor alpha induces 
angiogenesis and neurogenesis following stroke. Neuroscience. 
 
Leow, Y. H. and Maibach, H. I. (1998) Cigarette smoking, cutaneous vasculature, 
and tissue oxygen. Clin Dermatol, 16, 579-84. 
 
Lieberman, J. R., Daluiski, A. and Einhorn, T. A. (2002) The role of growth 
factors in the repair of bone. Biology and clinical applications. J Bone Joint Surg 
Am, 84-A, 1032-44. 
 
________________________________________________________References 
269 
Lin, C. M., Chiu, J. H., Wu, I. H., Wang, B. W., Pan, C. M. and Chen, Y. H. 
(2009) Ferulic acid augments angiogenesis via VEGF, PDGF and HIF-1alpha. J 
Nutr Biochem. 
 
Lind, J., Kramhoft, M. and Bodtker, S. (1991) The influence of smoking on 
complications after primary amputations of the lower extremity. Clin Orthop 
Relat Res, 211-7. 
 
Liu, Y., Dulchavsky, D. S., Gao, X., Kwon, D., Chopp, M., Dulchavsky, S. and 
Gautam, S. C. (2006) Wound repair by bone marrow stromal cells through growth 
factor production. J Surg Res, 136, 336-41. 
 
Luster, A. D. (1998) Chemokines--chemotactic cytokines that mediate 
inflammation. N Engl J Med, 338, 436-45. 
 
Mabvuure, N. T., Malahias, M., Hindocha, S., Khan, W. and Juma, A. (2012) 
Acute compartment syndrome of the limbs: current concepts and management. 
Open Orthop J, 6, 535-43. 
 
Maddox, J. F., Colgan, S. P., Clish, C. B., Petasis, N. A., Fokin, V. V. and Serhan, 
C. N. (1998) Lipoxin B4 regulates human monocyte/neutrophil adherence and 
motility: design of stable lipoxin B4 analogs with increased biologic activity. 
Faseb J, 12, 487-94. 
 
________________________________________________________References 
270 
Madduri, S., Papaloizos, M. and Gander, B. (2009) Synergistic effect of GDNF 
and NGF on axonal branching and elongation in vitro. Neurosci Res. 
 
Marcacci, M., Kon, E., Moukhachev, V., Lavroukov, A., Kutepov, S., Quarto, R., 
Mastrogiacomo, M. and Cancedda, R. (2007) Stem cells associated with 
macroporous bioceramics for long bone repair: 6- to 7-year outcome of a pilot 
clinical study. Tissue Eng, 13, 947-55. 
 
Marsell, R. and Einhorn, T. A. (2011) The biology of fracture healing. Injury, 42, 
551-5. 
 
Marshall, J., Jankowski, A., Furesz, S., Kireeva, I., Barker, L., Dombrovsky, M., 
Zhu, W., Jacks, K., Ingratta, L., Bruin, J., Kristensen, E., Zhang, R., Stanton, E., 
Takahashi, M. and Jackowski, G. (2004) Human serum proteins preseparated by 
electrophoresis or chromatography followed by tandem mass spectrometry. J 
Proteome Res, 3, 364-82. 
 
Martin, T. J. and Sims, N. A. (2005) Osteoclast-derived activity in the coupling of 
bone formation to resorption. Trends Mol Med, 11, 76-81. 
 
Massari, L., Falez, F., Lorusso, V., Zanon, G., Ciolli, L., La Cava, F., Cadossi, 
M., Chiarello, E., De Terlizzi, F., Setti, S. and Benazzo, F. M. (2013) Can a 
combination of different risk factors be correlated with leg fracture healing time? 
J Orthop Traumatol, 14, 51-7. 
 
________________________________________________________References 
271 
Matzuk, M. M., Lu, N., Vogel, H., Sellheyer, K., Roop, D. R. and Bradley, A. 
(1995) Multiple defects and perinatal death in mice deficient in follistatin. Nature, 
374, 360-3. 
 
Mayer, A. M., Hall, M. L., Lynch, S. M., Gunasekera, S. P., Sennett, S. H. and 
Pomponi, S. A. (2005) Differential modulation of microglia superoxide anion and 
thromboxane B2 generation by the marine manzamines. BMC Pharmacol, 5, 6. 
 
Mcgowan, S. E. (1992) Extracellular matrix and the regulation of lung 
development and repair. Faseb J, 6, 2895-904. 
 
Mckibbin, B. (1978) The biology of fracture healing in long bones. J Bone Joint 
Surg Br, 60-B, 150-62. 
 
Mcnamara, L. M. (2010) Perspective on post-menopausal osteoporosis: 
establishing an interdisciplinary understanding of the sequence of events from the 
molecular level to whole bone fractures. J R Soc Interface, 7, 353-72. 
 
Mcrobert, J. (2013) Smoking and its effects on the healing process of chronic 
wounds. Br J Community Nurs, Suppl, S18, S20-3. 
 
Mlodzikowska-Albrecht, J., Steinborn, B. and Zarowski, M. (2007) Cytokines, 
epilepsy and epileptic drugs - is there a mutual influence? Pharmacol Rep, 59, 
129-38. 
 
________________________________________________________References 
272 
Mosely, L. H. and Finseth, F. (1977) Cigarette smoking: impairment of digital 
blood flow and wound healing in the hand. Hand, 9, 97-101. 
 
Mukhopadhyay, A., Mukhopadhyay, S. N. and Talwar, G. P. (1993) Influence of 
serum proteins on the kinetics of attachment of Vero cells to cytodex 
microcarriers. J Chem Technol Biotechnol, 56, 369-74. 
 
Mundy, G. R., Raisz, L. G., Cooper, R. A., Schechter, G. P. and Salmon, S. E. 
(1974) Evidence for the secretion of an osteoclast stimulating factor in myeloma. 
N Engl J Med, 291, 1041-6. 
 
Murakami, G., Watabe, T., Takaoka, K., Miyazono, K. and Imamura, T. (2003) 
Cooperative inhibition of bone morphogenetic protein signaling by Smurf1 and 
inhibitory Smads. Mol Biol Cell, 14, 2809-17. 
 
Nash, T. J., Howlett, C. R., Martin, C., Steele, J., Johnson, K. A. and Hicklin, D. 
J. (1994) Effect of platelet-derived growth factor on tibial osteotomies in rabbits. 
Bone, 15, 203-8. 
 
Nathan, C. (2002) Points of control in inflammation. Nature, 420, 846-52. 
 
Nelson, A. M., Loy, D. E., Lawson, J. A., Katseff, A. S., Fitzgerald, G. A. and 
Garza, L. A. (2013) Prostaglandin D2 inhibits wound-induced hair follicle 
neogenesis through the receptor, Gpr44. J Invest Dermatol, 133, 881-9. 
 
________________________________________________________References 
273 
Nelson, H. D., Nevitt, M. C., Scott, J. C., Stone, K. L. and Cummings, S. R. 
(1994) Smoking, alcohol, and neuromuscular and physical function of older 
women. Study of Osteoporotic Fractures Research Group. Jama, 272, 1825-31. 
 
Netscher, D. T. and Clamon, J. (1994) Smoking: adverse effects on outcomes for 
plastic surgical patients. Plast Surg Nurs, 14, 205-10. 
 
Niikura, T., Miwa, M., Sakai, Y., Lee, S. Y., Kuroda, R., Fujishiro, T., Kubo, S., 
Doita, M. and Kurosaka, M. (2005) Human hemarthrosis-derived progenitor cells 
can differentiate into osteoblast-like cells in vitro. Biochem Biophys Res Commun, 
336, 1234-40. 
 
Nolan, J., Jenkins, R. A., Kurihara, K. and Schultz, R. C. (1985) The acute effects 
of cigarette smoke exposure on experimental skin flaps. Plast Reconstr Surg, 75, 
544-51. 
 
Nolen, B. M., Orlichenko, L. S., Marrangoni, A., Velikokhatnaya, L., Prosser, D., 
Grizzle, W. E., Ho, K., Jenkins, F. J., Bovbjerg, D. H. and Lokshin, A. E. (2013) 
An extensive targeted proteomic analysis of disease-related protein biomarkers in 
urine from healthy donors. PLoS One, 8, e63368. 
 
O'connell, T. X., Horita, T. J. and Kasravi, B. (2005) Understanding and 
interpreting serum protein electrophoresis. Am Fam Physician, 71, 105-12. 
 
________________________________________________________References 
274 
Oberyszyn, T. M. (2007) Inflammation and wound healing. Front Biosci, 12, 
2993-9. 
 
Oe, K., Miwa, M., Sakai, Y., Lee, S. Y., Kuroda, R. and Kurosaka, M. (2007) An 
in vitro study demonstrating that haematomas found at the site of human fractures 
contain progenitor cells with multilineage capacity. J Bone Joint Surg Br, 89, 133-
8. 
 
Oelgeschlager, M., Reversade, B., Larrain, J., Little, S., Mullins, M. C. and De 
Robertis, E. M. (2003) The pro-BMP activity of Twisted gastrulation is 
independent of BMP binding. Development, 130, 4047-56. 
 
Onichtchouk, D., Chen, Y. G., Dosch, R., Gawantka, V., Delius, H., Massague, J. 
and Niehrs, C. (1999) Silencing of TGF-beta signalling by the pseudoreceptor 
BAMBI. Nature, 401, 480-5. 
 
Oppmann, B., Lesley, R., Blom, B., Timans, J. C., Xu, Y., Hunte, B., Vega, F., 
Yu, N., Wang, J., Singh, K., Zonin, F., Vaisberg, E., Churakova, T., Liu, M., 
Gorman, D., Wagner, J., Zurawski, S., Liu, Y., Abrams, J. S., Moore, K. W., 
Rennick, D., De Waal-Malefyt, R., Hannum, C., Bazan, J. F. and Kastelein, R. A. 
(2000) Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with 
biological activities similar as well as distinct from IL-12. Immunity, 13, 715-25. 
 
________________________________________________________References 
275 
Otsuka, F., Moore, R. K., Iemura, S., Ueno, N. and Shimasaki, S. (2001) 
Follistatin inhibits the function of the oocyte-derived factor BMP-15. Biochem 
Biophys Res Commun, 289, 961-6. 
 
Padwal, R. S., Pajewski, N. M., Allison, D. B. and Sharma, A. M. (2011) Using 
the Edmonton obesity staging system to predict mortality in a population-
representative cohort of people with overweight and obesity. Cmaj, 183, E1059-
66. 
 
Pagliarulo, C., Salvatore, P. and Napoli, C. (2008) Targeting vascular niche by 
parathyroid hormone. Curr Med Chem, 15, 2984-90. 
 
Pankov, R. and Yamada, K. M. (2002) Fibronectin at a glance. J Cell Sci, 115, 
3861-3. 
 
Paskalev, M. and Goranov, N. (2012) Modulation Of Nitric Oxide Production by 
Therapeutic Pulsed Ultrasound in a Canine Tibia Fracture Model. Veterinarija ir 
Zootechnika  (Vet Med Zoot), T. 58 (80). 
 
Passing, H. and Bablok (1983) A new biometrical procedure for testing the 
equality of measurements from two different analytical methods. Application of 
linear regression procedures for method comparison studies in clinical chemistry, 
Part I. J Clin Chem Clin Biochem, 21, 709-20. 
 
________________________________________________________References 
276 
Patel, R. A., Wilson, R. F., Patel, P. A. and Palmer, R. M. (2013) The effect of 
smoking on bone healing: A systematic review. Bone Joint Res, 2, 102-11. 
 
Percival, T. J., White, J. M. and Ricci, M. A. (2011) Compartment syndrome in 
the setting of vascular injury. Perspect Vasc Surg Endovasc Ther, 23, 119-24. 
 
Petreaca, M. L., Yao, M., Ware, C. and Martins-Green, M. M. (2008) Vascular 
endothelial growth factor promotes macrophage apoptosis through stimulation of 
tumor necrosis factor superfamily member 14 (TNFSF14/LIGHT). Wound Repair 
Regen, 16, 602-14. 
 
Petryk, A., Shimmi, O., Jia, X., Carlson, A. E., Tervonen, L., Jarcho, M. P., 
O'connor M, B. and Gopalakrishnan, R. (2005) Twisted gastrulation and chordin 
inhibit differentiation and mineralization in MC3T3-E1 osteoblast-like cells. 
Bone, 36, 617-26. 
 
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, 
J. D., Moorman, M. A., Simonetti, D. W., Craig, S. and Marshak, D. R. (1999) 
Multilineage potential of adult human mesenchymal stem cells. Science, 284, 143-
7. 
 
Pitts, K. R., Yoon, Y., Krueger, E. W. and Mcniven, M. A. (1999) The dynamin-
like protein DLP1 is essential for normal distribution and morphology of the 
endoplasmic reticulum and mitochondria in mammalian cells. Mol Biol Cell, 10, 
4403-17. 
________________________________________________________References 
277 
Pohlman, T. H., Stanness, K. A., Beatty, P. G., Ochs, H. D. and Harlan, J. M. 
(1986) An endothelial cell surface factor(s) induced in vitro by 
lipopolysaccharide, interleukin 1, and tumor necrosis factor-alpha increases 
neutrophil adherence by a CDw18-dependent mechanism. J Immunol, 136, 4548-
53. 
 
Porter, S. E. and Hanley, E. N., Jr. (2001) The musculoskeletal effects of 
smoking. J Am Acad Orthop Surg, 9, 9-17. 
 
Prendergast, P. J. and Huiskes, R. (1995) The biomechanics of Wolff's law: recent 
advances. Ir J Med Sci, 164, 152-4. 
 
Prisell, P. T., Edwall, D., Lindblad, J. B., Levinovitz, A. and Norstedt, G. (1993) 
Expression of insulin-like growth factors during bone induction in rat. Calcif 
Tissue Int, 53, 201-5. 
 
Prockop, D. J. (1997) Marrow stromal cells as stem cells for nonhematopoietic 
tissues. Science, 276, 71-4. 
 
Pryor, W. A. (1997) Cigarette smoke radicals and the role of free radicals in 
chemical carcinogenicity. Environ Health Perspect, 105 Suppl 4, 875-82. 
 
Quaye, I. K. (2008) Haptoglobin, inflammation and disease. Trans R Soc Trop 
Med Hyg. 
 
________________________________________________________References 
278 
Raghow, R. (1994) The role of extracellular matrix in postinflammatory wound 
healing and fibrosis. Faseb J, 8, 823-31. 
 
Raikin, S. M., Landsman, J. C., Alexander, V. A., Froimson, M. I. and Plaxton, N. 
A. (1998) Effect of nicotine on the rate and strength of long bone fracture healing. 
Clin Orthop Relat Res, 231-7. 
 
Raisz, L. G. (2005) Pathogenesis of osteoporosis: concepts, conflicts, and 
prospects. J Clin Invest, 115, 3318-25. 
 
Ralston, S. H., Todd, D., Helfrich, M., Benjamin, N. and Grabowski, P. S. (1994) 
Human osteoblast-like cells produce nitric oxide and express inducible nitric 
oxide synthase. Endocrinology, 135, 330-6. 
 
Reddi, A. H. (2001) Interplay between bone morphogenetic proteins and cognate 
binding proteins in bone and cartilage development: noggin, chordin and DAN. 
Arthritis Res, 3, 1-5. 
 
Reddy, S. V. (2004) Regulatory mechanisms operative in osteoclasts. Crit Rev 
Eukaryot Gene Expr, 14, 255-70. 
 
Rees, T. D., Liverett, D. M. and Guy, C. L. (1984) The effect of cigarette smoking 
on skin-flap survival in the face lift patient. Plast Reconstr Surg, 73, 911-5. 
 
________________________________________________________References 
279 
Riancho, J. A., Salas, E., Zarrabeitia, M. T., Olmos, J. M., Amado, J. A., 
Fernandez-Luna, J. L. and Gonzalez-Macias, J. (1995) Expression and functional 
role of nitric oxide synthase in osteoblast-like cells. J Bone Miner Res, 10, 439-46. 
 
Riedel, G. E. and Valentin-Opran, A. (1999) Clinical evaluation of rhBMP-2/ACS 
in orthopedic trauma: a progress report. Orthopedics, 22, 663-5. 
 
Riefkohl, R., Wolfe, J. A., Cox, E. B. and Mccarty, K. S., Jr. (1986) Association 
between cutaneous occlusive vascular disease, cigarette smoking, and skin slough 
after rhytidectomy. Plast Reconstr Surg, 77, 592-5. 
 
Rinker, B. (2013) The evils of nicotine: an evidence-based guide to smoking and 
plastic surgery. Ann Plast Surg, 70, 599-605. 
 
Rivera, J. C., Strohbach, C. A., Wenke, J. C. and Rathbone, C. R. (2013) Beyond 
osteogenesis: an comparison of the potentials of six bone morphogenetic proteins. 
Front Pharmacol, 4, 125. 
 
Russell, M. A., Jarvis, M., Iyer, R. and Feyerabend, C. (1980) Relation of nicotine 
yield of cigarettes to blood nicotine concentrations in smokers. Br Med J, 280, 
972-6. 
 
Sacks, J. J. and Nelson, D. E. (1994) Smoking and injuries: an overview. Prev 
Med, 23, 515-20. 
 
________________________________________________________References 
280 
Sakou, T. (1998) Bone morphogenetic proteins: from basic studies to clinical 
approaches. Bone, 22, 591-603. 
 
Sakurai, H., Kohsaka, H., Liu, M. F., Higashiyama, H., Hirata, Y., Kanno, K., 
Saito, I. and Miyasaka, N. (1995) Nitric oxide production and inducible nitric 
oxide synthase expression in inflammatory arthritides. J Clin Invest, 96, 2357-63. 
 
Sammons, J., Ahmed, N., El-Sheemy, M. and Hassan, H. T. (2004) The role of 
BMP-6, IL-6, and BMP-4 in mesenchymal stem cell-dependent bone 
development: effects on osteoblastic differentiation induced by parathyroid 
hormone and vitamin D(3). Stem Cells Dev, 13, 273-80. 
 
Sandberg, M. M., Aro, H. T. and Vuorio, E. I. (1993) Gene expression during 
bone repair. Clin Orthop Relat Res, 292-312. 
 
Sato, Y., Kaji, M., Higuchi, F., Yanagida, I., Oishi, K. and Oizumi, K. (2001) 
Changes in bone and calcium metabolism following hip fracture in elderly 
patients. Osteoporos Int, 12, 445-9. 
 
Schagger, H. (2006) Tricine-SDS-PAGE. Nat Protoc, 1, 16-22. 
 
Schilling, J. A. (1976) Wound healing. Surg Clin North Am, 56, 859-74. 
 
________________________________________________________References 
281 
Schmid, G., Zilg, H. and Johannsen, R. (1992) Repeated batch cultivation of 
rBHK cells on Cytodex 3 microcarriers: antithrombin III, amino acid, and fatty 
acid metabolic quotients. Appl Microbiol Biotechnol, 38, 328-33. 
 
Schmidmaier, G., Wildemann, B., Bail, H., Lucke, M., Stemberger, A., Flyvbjerg, 
A. and Raschke, M. (2000) [Local liberation of IGF-I and TGF-beta 1 from a 
biodegradable poly(D,L-lactide) coating of implants accelerates fracture healing]. 
Chirurg, 71, 1016-22. 
 
Schmitt, J. M., Hwang, K., Winn, S. R. and Hollinger, J. O. (1999) Bone 
morphogenetic proteins: an update on basic biology and clinical relevance. J 
Orthop Res, 17, 269-78. 
 
Seibel, M. J. (2006) Biochemical markers of bone turnover part II: clinical 
applications in the management of osteoporosis. Clin Biochem Rev, 27, 123-38. 
 
Serhan, C. N. and Chiang, N. (2004) Novel endogenous small molecules as the 
checkpoint controllers in inflammation and resolution: entree for resoleomics. 
Rheum Dis Clin North Am, 30, 69-95. 
 
Serhan, C. N., Hamberg, M. and Samuelsson, B. (1984) Lipoxins: novel series of 
biologically active compounds formed from arachidonic acid in human 
leukocytes. Proc Natl Acad Sci U S A, 81, 5335-9. 
 
________________________________________________________References 
282 
Seshadri, T., Al-Farsi, K., Stakiw, J., Ma, C., Saragosa, R., Franke, N., Keating, 
A., Crump, M. and Kuruvilla, J. (2008) G-CSF-stimulated BM progenitor cells 
supplement suboptimal peripheral blood hematopoietic progenitor cell collections 
for auto transplantation. Bone Marrow Transplant, 42, 733-7. 
 
Seyler, L. E., Jr., Fertig, J., Pomerleau, O., Hunt, D. and Parker, K. (1984) The 
effects of smoking on ACTH and cortisol secretion. Life Sci, 34, 57-65. 
 
Seyler, L. E., Jr., Pomerleau, O. F., Fertig, J. B., Hunt, D. and Parker, K. (1986) 
Pituitary hormone response to cigarette smoking. Pharmacol Biochem Behav, 24, 
159-62. 
 
Shapiro, F. (2008) Bone development and its relation to fracture repair. The role 
of mesenchymal osteoblasts and surface osteoblasts. Eur Cell Mater, 15, 53-76. 
 
Sherwin, M. A. and Gastwirth, C. M. (1990) Detrimental effects of cigarette 
smoking on lower extremity wound healing. J Foot Surg, 29, 84-7. 
 
Shi, Y. and Massague, J. (2003) Mechanisms of TGF-beta signaling from cell 
membrane to the nucleus. Cell, 113, 685-700. 
 
Shimasaki, S. and Ling, N. (1991) Identification and molecular characterization of 
insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5 and -6). Prog 
Growth Factor Res, 3, 243-66. 
 
________________________________________________________References 
283 
Siana, J. E., Rex, S. and Gottrup, F. (1989) The effect of cigarette smoking on 
wound healing. Scand J Plast Reconstr Surg Hand Surg, 23, 207-9. 
 
Silcox, D. H., 3rd, Daftari, T., Boden, S. D., Schimandle, J. H., Hutton, W. C. and 
Whitesides, T. E., Jr. (1995) The effect of nicotine on spinal fusion. Spine, 20, 
1549-53. 
 
Silverstein, P. (1992) Smoking and wound healing. Am J Med, 93, 22S-24S. 
 
Simonsson, M., Heldin, C. H., Ericsson, J. and Gronroos, E. (2005) The balance 
between acetylation and deacetylation controls Smad7 stability. J Biol Chem, 280, 
21797-803. 
 
Skott, M., Andreassen, T. T., Ulrich-Vinther, M., Chen, X., Keyler, D. E., Lesage, 
M. G., Pentel, P. R., Bechtold, J. E. and Soballe, K. (2006) Tobacco extract but 
not nicotine impairs the mechanical strength of fracture healing in rats. J Orthop 
Res, 24, 1472-9. 
 
Sloan, A., Hussain, I., Maqsood, M., Eremin, O. and El-Sheemy, M. (2010) The 
effects of smoking on fracture healing. Surgeon, 8, 111-116. 
 
Smirnova, E., Shurland, D. L., Ryazantsev, S. N. and Van Der Bliek, A. M. 
(1998) A human dynamin-related protein controls the distribution of 
mitochondria. J Cell Biol, 143, 351-8. 
 
________________________________________________________References 
284 
Smith, S. (2013) Determining Sample Size:  How to Ensure You Get the Correct 
Sample Size. [Online].  Available from 
http://www.qualtrics.com/blog/determining-sample-size/.  Accessed 24.10.13 
 
Soberman, R. J. and Christmas, P. (2003) The organization and consequences of 
eicosanoid signaling. J Clin Invest, 111, 1107-13. 
 
Solheim, E. (1998) Growth factors in bone. Int Orthop, 22, 410-6. 
 
Sordi, V., Malosio, M. L., Marchesi, F., Mercalli, A., Melzi, R., Giordano, T., 
Belmonte, N., Ferrari, G., Leone, B. E., Bertuzzi, F., Zerbini, G., Allavena, P., 
Bonifacio, E. and Piemonti, L. (2005) Bone marrow mesenchymal stem cells 
express a restricted set of functionally active chemokine receptors capable of 
promoting migration to pancreatic islets. Blood, 106, 419-27. 
 
Sorensen, L. T., Friis, E., Jorgensen, T., Vennits, B., Andersen, B. R., Rasmussen, 
G. I. and Kjaergaard, J. (2002) Smoking is a risk factor for recurrence of groin 
hernia. World J Surg, 26, 397-400. 
 
Sorensen, L. T., Jorgensen, S., Petersen, L. J., Hemmingsen, U., Bulow, J., Loft, 
S. and Gottrup, F. (2009) Acute effects of nicotine and smoking on blood flow, 
tissue oxygen, and aerobe metabolism of the skin and subcutis. J Surg Res, 152, 
224-30. 
 
________________________________________________________References 
285 
Sorg, H., Krueger, C., Schulz, T., Menger, M. D., Schmitz, F. and Vollmar, B. 
(2009) Effects of erythropoietin in skin wound healing are dose related. Faseb J. 
 
Stefanovic-Racic, M., Meyers, K., Meschter, C., Coffey, J. W., Hoffman, R. A. 
and Evans, C. H. (1994) N-monomethyl arginine, an inhibitor of nitric oxide 
synthase, suppresses the development of adjuvant arthritis in rats. Arthritis 
Rheum, 37, 1062-9. 
 
Steigen, S. E., Schaeffer, D. F., West, R. B. and Nielsen, T. O. (2009) Expression 
of insulin-like growth factor 2 in mesenchymal neoplasms. Mod Pathol. 
 
Street, J., Bao, M., Deguzman, L., Bunting, S., Peale, F. V., Jr., Ferrara, N., 
Steinmetz, H., Hoeffel, J., Cleland, J. L., Daugherty, A., Van Bruggen, N., 
Redmond, H. P., Carano, R. A. and Filvaroff, E. H. (2002) Vascular endothelial 
growth factor stimulates bone repair by promoting angiogenesis and bone 
turnover. Proc Natl Acad Sci U S A, 99, 9656-61. 
 
Sugano, Y., Anzai, T., Yoshikawa, T., Maekawa, Y., Kohno, T., Mahara, K., 
Naito, K. and Ogawa, S. (2005) Granulocyte colony-stimulating factor attenuates 
early ventricular expansion after experimental myocardial infarction. Cardiovasc 
Res, 65, 446-56. 
 
 
 
 
________________________________________________________References 
286 
Sun, D., Bullock, M. R., Mcginn, M. J., Zhou, Z., Altememi, N., Hagood, S., 
Hamm, R. and Colello, R. J. (2009) Basic fibroblast growth factor-enhanced 
neurogenesis contributes to cognitive recovery in rats following traumatic brain 
injury. Exp Neurol, 216, 56-65. 
 
Sutherland, M. K., Geoghegan, J. C., Yu, C., Turcott, E., Skonier, J. E., Winkler, 
D. G. and Latham, J. A. (2004) Sclerostin promotes the apoptosis of human 
osteoblastic cells: a novel regulation of bone formation. Bone, 35, 828-35. 
 
Takamiya, A. S., Goiato, M. C. and Filho, H. G. (2013) Effect of smoking on the 
survival of dental implants. Biomed Pap Med Fac Univ Palacky Olomouc Czech 
Repub. 
 
Takayanagi, H. (2005) Mechanistic insight into osteoclast differentiation in 
osteoimmunology. J Mol Med, 83, 170-9. 
 
Tardif, G., Hum, D., Pelletier, J. P., Boileau, C., Ranger, P. and Martel-Pelletier, 
J. (2004) Differential gene expression and regulation of the bone morphogenetic 
protein antagonists follistatin and gremlin in normal and osteoarthritic human 
chondrocytes and synovial fibroblasts. Arthritis Rheum, 50, 2521-30. 
 
Thoroed, S. M., Lauritzen, L., Lambert, I. H., Hansen, H. S. and Hoffmann, E. K. 
(1997) Cell swelling activates phospholipase A2 in Ehrlich ascites tumor cells. J 
Membr Biol, 160, 47-58. 
 
________________________________________________________References 
287 
Tilley, S. L., Coffman, T. M. and Koller, B. H. (2001) Mixed messages: 
modulation of inflammation and immune responses by prostaglandins and 
thromboxanes. J Clin Invest, 108, 15-23. 
 
Tipton, D. A. and Dabbous, M. K. (1995) Effects of nicotine on proliferation and 
extracellular matrix production of human gingival fibroblasts in vitro. J 
Periodontol, 66, 1056-64. 
 
Tomek, R. J., Rimar, S. and Eghbali-Webb, M. (1994) Nicotine regulates collagen 
gene expression, collagenase activity, and DNA synthesis in cultured cardiac 
fibroblasts. Mol Cell Biochem, 136, 97-103. 
 
Tortora, G.J. and Grabowski, S.R. (2003) Principles of Anatomy and Physiology, 
10th Ed., New York, John Wiley & Sons, Inc. 
 
Toyooka, T. and Ibuki, Y. (2009) Cigarette sidestream smoke induces 
phosphorylated histone H2AX. Mutat Res, 676, 34-40. 
 
Tranquillo, R. T. and Murray, J. D. (1992) Continuum model of fibroblast-driven 
wound contraction: inflammation-mediation. J Theor Biol, 158, 135-72. 
 
Tsiridis, E., Upadhyay, N. and Giannoudis, P. (2007) Molecular aspects of 
fracture healing: which are the important molecules? Injury, 38 Suppl 1, S11-25. 
 
Tuck, S. P. and Francis, R. M. (2002) Osteoporosis. Postgrad Med J, 78, 526-32. 
________________________________________________________References 
288 
Turhani, D., Weissenbock, M., Stein, E., Wanschitz, F. and Ewers, R. (2007) 
Exogenous recombinant human BMP-2 has little initial effects on human 
osteoblastic cells cultured on collagen type I coated/noncoated hydroxyapatite 
ceramic granules. J Oral Maxillofac Surg, 65, 485-93. 
 
Uchida, S., Sakai, A., Kudo, H., Otomo, H., Watanuki, M., Tanaka, M., 
Nagashima, M. and Nakamura, T. (2003) Vascular endothelial growth factor is 
expressed along with its receptors during the healing process of bone and bone 
marrow after drill-hole injury in rats. Bone, 32, 491-501. 
 
Van Adrichem, L. N., Hovius, S. E., Van Strik, R. and Van Der Meulen, J. C. 
(1992) The acute effect of cigarette smoking on the microcirculation of a 
replanted digit. J Hand Surg [Am], 17, 230-4. 
 
Van Adrichem, L. N., Hovius, S. E., Van Strik, R. and Van Der Meulen, J. C. 
(1992) Acute effects of cigarette smoking on microcirculation of the thumb. Br J 
Plast Surg, 45, 9-11. 
 
Vazquez, M. A., Lopez, E., Montoya, M. J., Giner, M., Perez-Temprano, R. and 
Perez-Cano, R. (2012) Vertebral fractures in patients with inflammatory bowel 
disease compared with a healthy population: a prospective case-control study. 
BMC Gastroenterol, 12, 47. 
 
Villarreal, F. J., Hong, D. and Omens, J. (1999) Nicotine-modified postinfarction 
left ventricular remodeling. Am J Physiol, 276, H1103-6. 
________________________________________________________References 
289 
Waeber, B., Schaller, M. D., Nussberger, J., Bussien, J. P., Hofbauer, K. G. and 
Brunner, H. R. (1984) Skin blood flow reduction induced by cigarette smoking: 
role of vasopressin. Am J Physiol, 247, H895-901. 
 
Webb, A. R., Robertson, N. and Sparrow, M. (2013) Smokers know little of their 
increased surgical risks and may quit on surgical advice. ANZ J Surg, 83, 753-7. 
 
Wheater, G., Elshahaly, M., Tuck, S. P., Datta, H. K. and Van Laar, J. M. (2013) 
The clinical utility of bone marker measurements in osteoporosis. J Transl Med, 
11, 201. 
 
Whiteford, L. (2003) Nicotine, CO and HCN: the detrimental effects of smoking 
on wound healing. Br J Community Nurs, 8, S22-6. 
 
Whitesides, T. E., Jr., Hanley, E. N., Jr. and Fellrath, R. F., Jr. (1994) Smoking 
abstinence. Is it necessary before spinal fusion? Spine, 19, 2012-4. 
 
Whyte, D. A., Broton, C. E. and Shillitoe, E. J. (2002) The unexplained survival 
of cells in oral cancer: what is the role of p53? J Oral Pathol Med, 31, 125-33. 
 
Wikesjo, U. M., Qahash, M., Thomson, R. C., Cook, A. D., Rohrer, M. D., 
Wozney, J. M. and Hardwick, W. R. (2004) rhBMP-2 significantly enhances 
guided bone regeneration. Clin Oral Implants Res, 15, 194-204. 
 
________________________________________________________References 
290 
Wimalawansa, S. J., De Marco, G., Gangula, P. and Yallampalli, C. (1996) Nitric 
oxide donor alleviates ovariectomy-induced bone loss. Bone, 18, 301-4. 
 
Winniford, M. D., Wheelan, K. R., Kremers, M. S., Ugolini, V., Van Den Berg, 
E., Jr., Niggemann, E. H., Jansen, D. E. and Hillis, L. D. (1986) Smoking-induced 
coronary vasoconstriction in patients with atherosclerotic coronary artery disease: 
evidence for adrenergically mediated alterations in coronary artery tone. 
Circulation, 73, 662-7. 
 
Wipfli, H. and Samet, J. M. (2009) Global Economic and Health Benefits of 
Tobacco Control: Part 1. Clin Pharmacol Ther. 
 
Witte, M. B. and Barbul, A. (1997) General principles of wound healing. Surg 
Clin North Am, 77, 509-28. 
 
Witte, M. B. and Barbul, A. (2002) Role of nitric oxide in wound repair. Am J 
Surg, 183, 406-12. 
 
Wolff, J. (2010) The classic: on the theory of fracture healing. 1873. Clin Orthop 
Relat Res, 468, 1052-5. 
 
Wong, L. S. and Martins-Green, M. (2004) Firsthand cigarette smoke alters 
fibroblast migration and survival: implications for impaired healing. Wound 
Repair Regen, 12, 471-84. 
 
________________________________________________________References 
291 
Wozney, J. M. (2002) Overview of bone morphogenetic proteins. Spine (Phila Pa 
1976), 27, S2-8. 
 
Wright, V. J. (2006) Osteoporosis in men. J Am Acad Orthop Surg, 14, 347-53. 
 
Yager, D. R. and Nwomeh, B. C. (1999) The proteolytic environment of chronic 
wounds. Wound Repair Regen, 7, 433-41. 
 
Yang, L., Xu, M., Jin, X., Xu, J., Lu, J., Zhang, C., Tian, T. and Teng, L. (2013) 
Complications of absorbable fixation in maxillofacial surgery: a meta-analysis. 
PLoS One, 8, e67449. 
 
Yoshimura, Y., Nomura, S., Kawasaki, S., Tsutsumimoto, T., Shimizu, T. and 
Takaoka, K. (2001) Colocalization of noggin and bone morphogenetic protein-4 
during fracture healing. J Bone Miner Res, 16, 876-84. 
 
Yost, H. J. (1992) Regulation of vertebrate left-right asymmetries by extracellular 
matrix. Nature, 357, 158-61. 
 
Young, B. and Heath, J.W. (2003) Wheater's Functional Histology, a Text and 
Colour Atlas, 4th Ed., London, Elsevier. 
 
Yu, Y. Y., Lieu, S., Lu, C. and Colnot, C. (2010) Bone morphogenetic protein 2 
stimulates endochondral ossification by regulating periosteal cell fate during bone 
repair. Bone, 47, 65-73. 
________________________________________________________References 
292 
Yu, Y., Yang, J. L., Chapman-Sheath, P. J. and Walsh, W. R. (2002) TGF-beta, 
BMPS, and their signal transducing mediators, Smads, in rat fracture healing. J 
Biomed Mater Res, 60, 392-7. 
 
Yudell, R. M. and Block, M. S. (2000) Bone gap healing in the dog using 
recombinant human bone morphogenetic protein-2. J Oral Maxillofac Surg, 58, 
761-6. 
 
Zevin, S., Gourlay, S. G. and Benowitz, N. L. (1998) Clinical pharmacology of 
nicotine. Clin Dermatol, 16, 557-64. 
 
Zimmermann, G., Moghaddam, A., Reumann, M., Wangler, B., Breier, L., 
Wentzensen, A., Henle, P. and Weiss, S. (2007) [TGF-beta1 as a 
pathophysiological factor in fracture healing]. Unfallchirurg, 110, 130-6. 
 
Zuk, P. A., Zhu, M., Mizuno, H., Huang, J., Futrell, J. W., Katz, A. J., Benhaim, 
P., Lorenz, H. P. and Hedrick, M. H. (2001) Multilineage cells from human 
adipose tissue: implications for cell-based therapies. Tissue Eng, 7, 211-28. 
 
 
 
 
 
 
 293 
CHAPTER 7 
 
 APPENDICES 
________________________________________________________Appendices 
 
294 
7 APPENDICES 
________________________________________________________Appendices 
 
295 
7.1.1 Letter from Minister of Public Health 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
________________________________________________________Appendices 
 
296 
7.1.2 SICOT Conference Attendance 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
________________________________________________________Appendices 
 
297 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
________________________________________________________Appendices 
 
298 
 
7.1.3 Ethical Approval Documentation 
 
 
 
________________________________________________________Appendices 
 
299 
 
7.1.4 Copyright Permissions 
 
 
________________________________________________________Appendices 
 
300 
________________________________________________________Appendices 
 
301 
 
EA2 
 
Ethical Approval 
Form:  
Human Research 
Projects 
 
 
 
 
Please word-process this form, 
handwritten applications will 
not be accepted 
 
 
 
This form must be completed for each piece of research activity whether conducted by 
academic staff, research staff, graduate students or undergraduates. The completed form 
must be approved by the designated authority within the 
Faculty.mailto:jgreen@lincoln.ac.uk 
Please complete all sections.  If a section is not applicable, write N/A.  
 
1 Name of Applicant 
 
 
 
ANDREW STEPHEN SLOAN 
 
Department: 
NATURAL AND APPLIED 
SCIENCES 
Faculty: 
FACULTY OF HEALTH, 
LIFE AND SOCIAL 
SCIENCES     
 
 
2  Position in the 
University 
 
 
Postgraduate Researcher 
 
3 Role in relation to this 
research 
 
 
PhD Student 
 
4 Brief statement of  
 main Research 
Question 
 
The key question that is hoped to be answered is; what are the 
biological adverse effects of smoking on the microenvironment 
of healing bone fractures? 
 
 
5 Brief Description of 
Project 
 
 
 
 
The research will concentrate on the inhibition of healing of 
tibial fractures in smokers.  Smoking can delay the healing 
process of bone injuries and in some cases can account for 
the nonunion of a fracture. Extended healing times are a 
serious complication, resulting in adverse effects in quality of 
life and morbidity, leading to socio-economic problems.   
Approximate Start Date:   
 
April 2007 
Approximate End Date:    
 
July 2012 
 
6 Name of Principal 
Investigator 
 or Supervisor 
 
 
 
 Dr. Mohamed El-Sheemy 
 
Email address:  
Melsheemy@lincoln.ac.uk 
Telephone: 
Tel 01522 5733373 (dir) 
Fax 01522 573499 
 
7 Names of other 
researchers or 
 student investigators 
involved 
 
2.  Professor O Eremin 
3. Professor M Maqsood 
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9 Statement of the ethical 
issues  
 involved and how they are 
to 
 be addressed –including a 
risk  assessment of the project 
based on 
 the vulnerability of 
participants, the 
 extent to which it is likely to 
be  harmful and whether there 
will be 
 significant discomfort. 
  
 
 (This will normally cover 
such issues  as whether the 
risks/adverse effects 
 associated with the project 
have 
 been dealt with and whether 
the  benefits of research 
outweigh the 
 risks) 
 
 
 
The research will concentrate on the inhibition of 
healing of tibial fractures in smokers.  Smoking can 
delay the healing process of bone injuries and in 
some cases can account for the nonunion of 
fractures. Extended healing time is a serious 
complication, resulting in adverse effects in quality 
of life and morbidity, leading to socio-economic 
problems.     
 
In order to gain supporting data to confirm our 
hypothesis that smoking does cause delayed healing 
or nonunion of bone, a series of laboratory tests 
will be undertaken.  These may include; 
 
Specialised cell culturing 
Antibody testing techniques 
Protein analyses 
Assessment of in vitro growth factor inclusion in 
cell cultures (BMP-7, TGF-beta, VEGF) 
 
If we can understand the adverse effects at the 
molecular and cellular at the fracture site, then this 
can help the patient overcome the healing 
complications associated with smoking. 
 
 
This study hopes to provide an understanding of the 
deregulation and dysfunction of key cells and 
regulatory molecules at the time of traumatic 
haematoma formation in those patients who smoke.  
The research addresses an important clinical 
dilemma, which has been poorly studied at the 
biological level. 
 
Recent data show significant reduction rates in 
healing of bone fractures in smokers, which has 
been evident in both long bones and the bones of 
the vertebral column.  A previous study found a 
69% delay in radio-graphic union of tibial fractures 
 
8 Location(s) at which 
project 
 is to be carried out 
 
 
 
1.  Biomedical Research Laboratory, University of Lincoln 
2.  Lincoln County Hospital, Greetwell Road, Lincoln 
3.  Boston Pilgrim Hospital, Sibsey Road, Boston 
4.  Grantham & District  Hospital, Manthorpe Road, Grantham  
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in smokers compared with non-smokers.  Other 
research has shown a 60% increase in healing time 
to achieve stable clinical union following cast 
immobilisation of tibial fractures.  In smokers, 
there is a reduced bone mass density (BMD) 
throughout the skeleton, particularly affecting the 
hip.  Meta-analysis has demonstrated that those 
actively smoking are at increased risk of fractures  
 
Those patients taking anticoagulants, steroids or 
anti-inflammatory drugs in the three months prior 
to injury will be excluded from the trial.  The study 
will involve adult patients from each group (i.e., 
smokers and non-smokers).  The age of each 
patient, ethnic group and daily number of cigarettes 
smoked (where applicable) is to be noted and 
logged and will accompany each sample.  Informed 
consent from all patients, as well as ethical 
clearance from the NHS Research Ethics 
Committee has been granted.     
 
 
Main Ethical Risk: After exposure of the fracture 
site, the haematoma will be carefully removed 
manually and placed in a sterile polypropylene 
container by competent theatre staff at the Fracture 
Clinic, Lincoln County Hospital.  There will be no 
increased exposure to microbial pathogens or 
detrimental effect on the healing process as a result 
of sample excision.  Researchers are immunised 
against Hepatitis B. 
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Ethical Approval From Other Bodies 
 
 
10  Does this research require 
the 
 approval of an external 
body ? 
 
 
Yes      
 
 
If “Yes”, please state which body:-NHS RESEARCH 
ETHICS COMMITTEE  
 
 
 
 
11  Has ethical approval 
already been 
 obtained from that body ?  
 
 YES      Yes  -Please append documentary evidence to 
this form 
 
If “No”, please state why not:- 
 
 
 
 
 
Please note that any such approvals must be obtained and 
documented before the project begins. 
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APPLICANT SIGNATURE 
 
  
I hereby request ethical approval for the research as described above.  
I certify that I have read the University’s ETHICAL PRINCIPLES FOR CONDUCTING 
RESEARCH WITH HUMANS AND OTHER ANIMALS. 
 
16 SEP 2010 
_____________________________________  
Applicant Signature    
 
ANDREW STEPHEN SLOAN 
_____________________________________    
PRINT NAME 
 
 
 
 
FOR COMPLETION BY THE CHAIR OF THE FACULTY RESEARCH COMMITTEE 
 
Please select ONE of A, B, C or D below: 
 
 
 
  A. The Faculty Research Committee gives ethical approval to this research. 
 
 
 
  B. The Faculty Research Committee gives conditional ethical approval to this 
research. 
     
 
12  Please state the condition 
(inc. 
 date by which condition 
must be 
 satisfied if applicable) 
 
 
      
 
 
 
 
 
 
  C. The Faculty Research Committee can not give ethical approval to this 
research but refers the application 
to the University Research Ethics Committee for higher level consideration. 
     
 
13  Please state the reason 
 
 
      
 
 
 
 
 
 
  D. The Faculty Research Committee can not give ethical approval to this 
research and recommends that the research should not proceed. 
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Research Project:  The Inhibition of Fracture Healing in Smokers 
 
Tobacco smoking has been shown to have a detrimental impact on fracture 
healing and is often associated with poor bone repair.  Whilst a lot of research has 
concentrated on the clinical aspects of fracture healing and smoking, very few 
studies have been undertaken on human tissue.  The aims of this research project 
are to assess the impact of tobacco smoking on the biological aspects of bone 
healing.  This will be done by analysing tiny amounts of donated human blood 
from the site of the fracture (called a ‘haematoma’) using a variety of laboratory 
techniques at The University of Lincoln.  The information gained from the study 
is helping surgeons, scientists and patients to understand the impacts of smoking 
and how it affects the healing process.  
 
We are asking patients who have sustained a fractured tibia to take part in this 
study by consenting to donate a small amount of haematoma from the fracture 
site.  Your orthopaedic surgeon will collect this from you whilst you are 
undergoing your operation to reset your tibia, after you have been anaesthetised.  
This tissue is normally washed away during the operation, so your healing process 
will not be affected by its collection.   
 
The collected fracture haematoma will then be studied in a scientific research 
laboratory at The University of Lincoln and your personal details will not be 
known to anyone other than your orthopaedic surgeon.  You will not be contacted 
in the future regarding the study and you will remain anonymous throughout the 
research.  You are free to withdraw from the project at any time if you wish to do 
so. 
 
Many thanks indeed for your cooperation in this vital research. 
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Research Project:  The Inhibition of Fracture 
Healing in Smokers 
 
CONSENT FORM            Please initial box 
 
1. I can confirm that I have read and understand the 
information sheet for the above study.  I have had the 
opportunity to consider the information, ask questions and 
have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I 
am free to withdraw at any time without having to give 
reason and without my medical care and legal rights being 
affected. 
 
3. I understand that relevant sections of my medical notes and 
data collected during the study may be looked at by 
responsible individuals from regulatory authorities or from 
the NHS Trust, where it is relevant to my taking part in 
this research.  I give permission to for these individuals to 
have access to my records. 
 
4. I agree to my General Practitioner (GP) being informed of 
my participation in this study. 
 
5. I agree to take part in this study. 
 
Name of Patient:  Date:                Signature: 
      
Name of Person taking consent: Date:                Signature: 
 
Name of Researcher:  Date:                Signature: 
 
When completed 1 for patient, 1 for researcher site file, 1(original) to be kept in 
medical notes. 
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